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Abstract
Pharmacogenetic variations contribute to interindividual differences in drug response.
Advances in molecular techniques provided insights into interpopulation
pharmacogenomic variations. A limited number of pharmacogenetic studies were
conducted in the UAE population. The current study aims to explore the variation
landscape in important pharmacogenes in Emiratis. Furthermore, it investigates the
association between VKORC1 variants and warfarin dose in cardiovascular patients.
Finally, this study explores the applied/needed germline pharmacogenetic tests in
oncology in the UAE. In 100 healthy Emiratis, variants and star alleles in 100 relevant
pharmacogenes were defined by next-generation sequencing. 63% of detected variants
were rare, 30% were novel, and 141 variants were novel and damaging. By clinical
annotations, filtering variants resulted in 99 clinically actionable variants, from which
44 are highly significant alleles. Revising the results against the clinical
pharmacogenetics implementation consortium guidelines demonstrated that 93% of
participants have at least one actionable variant with a dosing recommendation. The
effect of VKORC1 on warfarin dose was explored in 90 patients. A model built from
two VKORC1 variants, rs9923231 and rs61742245, with age, significantly predicted
warfarin dose. High incidence rates of adverse chemotherapy effects were reported
from 66 pediatric acute lymphoblastic leukemia patients, which indicates the
plausibility of pharmacogenetic research to investigate toxicity biomarkers. Few cases
had a clinical pharmacogenetic test of TPMT and NUDT15 before starting oral 6mercaptopurine. Patients who received pharmacogenetic-guided doses suffered from
less adverse effects. Exploring the adverse drug effects in a group of 77 breast cancer
patients was faced by deficiencies in adverse effects reporting. The reported adverse
events suggested suitable candidates for future pharmacogenetic research. This
research highlighted population-specific variants, unexplored adverse drug events, and
possible pharmacogenomics applications in the UAE. Various research opportunities
were illustrated for the scientific community.

Keywords: Pharmacogenomics, United Arab Emirates population, cardiovascular
diseases, warfarin, cancer germline pharmacogenomics, drug adverse effects.
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)Title and Abstract (in Arabic

الوراثة الدوائية في المجتمع اإلماراتي :تطبيقات من األمراض القلبية الوعائية
والسرطان
الملخص

تساهم التنوعات الجينية في اختالف االستجابة لألدوية بين األفراد .قدم التطور في التقنيات
الجزيئية فهما ً أشمل لمدى التنوع الجيني بين المجتمعات في الجينات المؤثرة على األدوية ،أو ما
يعرف بعلم الوراثة الدوائية ( .)Pharmacogeneticsلم تجر من قبل سوى بضع دراسات في
مجال الوراثة الدوائية في اإلمارات العربية المتحدة .تهدف هذه الدراسة إلى استكشاف التنوع
الوراثية في مجموعة مؤثرة من الجينات الدوائية ،كما تعمل على دراسة وجود ارتباط بين
التنوعات الوراثية في جين ( )VKORC1وجرعة الوارفرين التي يحتاجها المريض .أخيراً،
يسعى هذا البحث للكشف عن مدى تطبيق فحوص الوراثة الدوائية في السرطان ،ومقدار الحاجة
لها في األمارات العربية المتحدة.
أظهرت النتائج مجموعة التبدالت الوراثية ،واألليالت النجمية ( ،)star allelesفي مئة جين
من الجينات الدوائية ،لدى مئة مواطن إماراتي سليم باستخدام تقنية تحديد التسلسل من الجيل التالي
( .)Next-generation sequencingكانت  %63من التبدالت الجينية نادرةً ،و %30منها
تبدل جيني جديد ،في حين أن  141تبدل جيني كان جديداً وباآلن ذاته ذو تأثير مخرب على
البروتين الناتج عن الجين .فيما أوضحت فلترة التبدالت الجينية بنا ًء على تأثيرها السريري أن
هناك  99تبدالً جينيا ً ذو داللة سريرية ،منها  44تبدالً مرتبطا ً بمالحظات سريرية ذات مصداقية
عالية .وفي خطوة فلترة أخرى للتبدالت الجينية ،تمت مراجعة توصيات لجنة تطبيق الوراثة
الدوائية سريريا ً ( )CPICليتضح أن  %93من المشاركين األصحاء في هذه المجموعة يحملون
تبدالً وراثيا ً واحداً على األقل ،يجعل حامله مؤهالً لتغيير جرعة دواء ما أو استبداله بدواء آخر.
في المجموعة الثانية ،تم استعراض تأثير التبدالت الجينية في جين ( )VKORC1على جرعة
الوارفرين لدى  90مريضا ً يتلقون الوارفرين .وقد أبدى نموذج إحصائي مرتكز على كل من
التبدل الوراثي  rs9923231و rs61742245وعمر المريض قدرةً على توقع جرعة الوارفرين
المناسبة للمريض ذات داللة إحصائية.
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في المجموعة الثالثة المؤلفة من  66طفالً مصابا ً بسرطان الدم اللمفاوي الحاد ،تم الكشف عن
معدالت مرتفعة لآلثار الجانبية لألدوية المستخدمة ،مما يشير إلى الفائدة الكامنة في بحوث الوراثة
الدوائية للكشف عن مسببات هذه اآلثار الجانبية .لم تجر على هذه المجموعة سوى بضعة فحوص
وراثية لكل من جين ( )TPMTو ( )NUDT15قبل البدء بتناول عقار الميركابتوبيورين 6-
( .)mercaptopurineأظهرت النتائج أن األطفال الذين تلقوا العالج بجرعات معدلة بنا ًء على
أنماطهم الجينية عانوا بشكل أقل من اآلثار الجانبية.
أخيراً ،تم استعراض اآلثار الجانبية الناتجة عن معالجة  77امرأة مصابة بسرطان الثدي .وقد
أوضحت هذه المجموعة بضعا ً من نقاط الضعف في تسجيل اآلثار الجانبية لألدوية ،وأظهرت
النتائج مجموعةً من اآلثار الجانبية المناسبة لدراستها في المستقبل.
سلطنا الضوء في هذا البحث على مجموعة التنوعات الجينية الخاصة بالمجتمع اإلماراتي في
الجينات المؤثرة على األدوية ،ومجموعةً من اآلثار الجانبية لألدوية غير المدروسة مسبقا ً في
اإلمارات العربية المتحدة .كما فتحت الدراسة آفاق جديدة نحو فرص البحوث المستقبلية أمام
الوسط العلمي.
مفاهيم البحث الرئيسية :الوراثة الدوائية ،مجتمع اإلمارات العربية المتحدة ،األمراض القلبية
الوعائية ،الوارفرين ،الوراثة الدوائية في السرطان ،اآلثار الجانبية لألدوية.
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Chapter 1: Introduction
1.1 Overview
The interindividual difference in drug response is a substantial challenge in
medical practice. Drug response ranges between 80% for commonly used drugs to
25% for cancer chemotherapeutics. Patients in the non-responder’s group will
consequently switch from one drug to another, looking for a better option, with a
resultant delay in achieving their treatment goals. Nevertheless, variation in drug
disposition can translate into differences in the associated adverse events, which might
be severe in many cases [1, 2].
Variance in drug response has been attributed to behavioral, biological, and
environmental factors, like smoking, physical activity, and body mass index [2, 3]. For
decades, genetic factors were proposed as contributors to drug response variation but
proved later to account for 20% to 90% of this variation, depending on drug class [2,
4].
Pharmacogenomics concentrates on the interaction of genomic components
with the pharmacological response. It aims at identifying the variation in the human
genome that can explain pharmacological interindividual differences [3].
Pharmacogenomic research resulted in a plethora of genomic variants-drug
pairs, some of which ended up into drug labels and clinical implications.
Pharmacogenes known to be active in the drug pharmacokinetics (PK) or
pharmacodynamics (PD) have been identified. These include genes encoding for drugmetabolizing enzymes, drug receptors, drug transporters, and drug binding proteins [57].
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Large differences in the pharmacogenes variations exist between populations,
even between the geographically neighboring ones [8]. It was also indicated that
pharmacogenes are rich with rare variants, and a significant proportion of these rare
variants have a sizeable effect on drug response [9]. Population studies also concluded
that rare variants tend to cluster or to become private to one population. Accordingly,
developing local catalogs of rare variants across the world was suggested [10].
Information about population pharmacogenomic biomarkers would positively
impact drug development, health-care cost-effectiveness, and public health [11]. The
importance of population pharmacogenomic studies becomes most evident when the
studied disease is of a significant burden on the community under investigation.
1.2 Statement of the Problem
Pharmacogenetic studies are scarce in the Middle East and for populations
originating from Arab countries. A handful of studies have covered a small number of
pharmacogenes in the United Arab Emirates (revised extensively in 2.1). Besides their
rarity, most of the previous pharmacogenetic studies applied in the UAE population
explored the frequencies of specific genetic variations in a few genes. There is a need
to evaluate the spectrum of variations in pharmacogenes in the UAE population and
compare their frequencies with worldwide populations.
Cardiovascular drugs are among the most studied drugs in the field of
pharmacogenetics. There are well established genetic associations for warfarin,
clopidogrel, simvastatin, and other agents. Cardiovascular pharmacogenetic
frequencies and associations have been studied and evaluated in different ethnicities.
Nevertheless, no studies have evaluated pharmacogenetic variation or drug-gene

3
associations in the Emirati population. Given the high prevalence of cardiovascular
diseases in the country, this knowledge gap is critical.
Chemotherapy and other agents used in cancer are known for their narrow
therapeutic index. Investigating germline pharmacogenetic biomarkers has the
potential of ameliorating these adverse events through pharmacogenetic-guided drug
selection and dosing. This approach was tested in several populations. The benefits of
germline pharmacogenetic studies demonstrated established progress in pediatric
acute lymphoblastic leukemia management worldwide.
In the UAE, cancer is the third cause of death. The use of chemotherapy is
projected to increase by almost 100% by the next two decades in the region. There has
never been any germline pharmacogenetic studies conducted in the UAE, including
the most well established and worldwide implemented pharmacogenetic test in
pediatric ALL. Moreover, none of the available reports describe the toxicity and
adverse events encountered in the UAE's oncology units. Real-life data from oncology
units in the country would emphasize the need for better toxicity and adverse events
controlling measures and would guide future research, particularly pharmacogenomic
research.
Herein, the current study aims to investigate the spectrum of variation in
important pharmacogenes among healthy Emiratis. This investigation is the first test
for the concept of “preemptive pharmacogenomic testing” in the Emirati, relatively
small population.
As a model of cardiovascular pharmacogenetic applications, the association
between the widely used anticoagulant, warfarin, and a single pharmacogene,
VKORC1, will be illustrated on a group of patients from the same population.
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Finally, clinical data from the national main oncology center will be revised to
evaluate the impact of chemotherapy adverse events on practice. Two types of tumors
have been chosen as prototypes. The first group includes pediatric acute lymphoblastic
leukemia, the best-studied germline pharmacogenetic implementation model in
cancer, while the second group includes females with breast cancer. Breast cancer is
the most common reason for female deaths worldwide. However, germline
pharmacogenetic toxicity biomarkers are poorly studied. Nevertheless, breast cancer
is the most common type of tumor in UAE, and optimizing its management has great
potential.
Pharmacogenomics implementation is evolving worldwide and is still in its
infancy in the Gulf region’s health care systems. Studies highlighting the differences
between the Emirati population and other populations in terms of drug response, the
associated adverse events, and the genomic components of pharmacological diversity
are immensely needed.
1.3 Pharmacogenomics: A General Background
To introduce the main concepts of pharmacogenetics, a historical review of
pharmacogenetics evolution, the chief definitions, and concepts, and the different
pharmacogenetic studies designs are illustrated.
1.3.1 Historical Perspective
The first recognition of pharmacogenomics could be traced back to Pythagoras
in 510 BC, who noticed that some individuals show intolerance to fava beans, later
explained by an inherited glucose-6-phosphate-dehydrogenase (G6PD) deficiency
[12]. The replication of this environmental-genetic interaction was not clearly reported
with drugs until the early nineteenth century. Sir Archibald Garrod, in 1909,
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documented a vital observation; the same doses of medicines that heal some patients
can be poisonous to others, which was considered an insightful early vision of the basic
tenets of pharmacogenomics [13].
More than two decades later, in 1932, Larry Synder established the first link
between drug response and genetics when his work illustrated that the inability of
tasting phenylthiourea is a recessively inherited trait [3]. Papers appeared to link
between inherited traits, namely cholinesterase deficiency, G6PD deficiency, and Nacetyl transferase deficiency, and the development of toxicity with succinylcholine,
primaquine, and isoniazid, respectively. These were considered among the first reports
that suggested genetic factors in drug response [6, 13]. While the first mention of the
term “pharmacogenetics” to define the science that merges genetics with
pharmacology and their interaction is attributed to Friederich Vogel in 1959 [3].
Subsequent twin studies relied on using a drug probe followed by phenotyping
monozygotic and heterozygotic twins. These studies provided the genetic contribution
in drug response with concrete evidence. One of the earliest pieces of evidence of the
CYP2D6 polymorphisms as an inherited effector on nortriptyline metabolism and
response originated from an experiment on twins done by Folke Sjoqvist and
collaborators in the late sixties. Numerous twin studies followed Sjoqvist’s work
during the seventies and eighties, which compared the relative impact of genetic
factors and environmental factors on drug PK. Twin studies proved that genetic factors
were a significant contributor to the interindividual variability of the studied drugs’
metabolism [14].
Successively, a continuous stream of reports orig

inating

from

family

studies illustrated the early models of gene-drug interactions. Most of these early
studies were concentrating on the PK pathways and specifically on the metabolic
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enzymes. Inherited variation cytochrome p-450 (CYP) enzymes and N-thiopurine
methyltransferase (TPMT) were reported, although none of the enzyme-coding genes
were cloned or sequenced yet [15].
In the late eighties, concurrently with the strides in molecular biology brought
by the polymerase chain reaction (PCR) invention, drug response inheritance’s
molecular basis started to be elucidated. CYP2D6, which encodes a key CYP enzyme,
was cloned and characterized, and its polymorphisms proved to cause the variable
enzyme activity. In the following decades, more genes known to be active in the
metabolic pathways were described, including CYP2C9, which was found to affect
warfarin and phenytoin metabolism [16]. During the nineties, many of the drugs PK
active enzymes were under investigation, owing to their convenient metabolic
phenotypes that can be easily measured. These included more CYP members and
enzymes

from

other

families

like

the

UDP-glycosyltransferases

(UGT),

sulfotransferases (SULT), and methyltransferases such as TPMT [15].
In the 21st century, the accumulated outcomes of the preceding body of
research fueled a rapid adoption of the Human-Genome project outcomes into
pharmacogenomics. Since then, pharmacogenomics discovery rates have increased
dramatically in parallel with other genomic sciences [15]. The slow, but steady,
pharmacogenomics timeline across the twentieth century, barely displays the
prominent historical landmarks [17]. While most of the pharmacogenomic research
outcomes, including those found following the completion of the human genome
project, are still protracted in the discovery phase, calling for further work.
1.3.2 Pharmacogenomics-Related Definitions and Terminology
Pharmacogenomics in practice has been conventionally defined as delivering
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“the right drug to the right patient at the right dose”. While pharmacogenetics’ research
involves exploring genetic variation role in drug response [18, 19].
The term “pharmacogenetics” has been historically used when a single or a few
genes were examined against a defined pharmacological phenotype. Later, with the
shift from candidate gene studies into genome-wide association studies, researchers
tended to use the term “pharmacogenomics” instead. The latter usually refers to the
effect of multiple genes and their interaction with drug response. However, both terms
are frequently used interchangeably. The main goal of pharmacogenomic research is
to identify genetic biomarkers that can be used to optimize drug selection, dose
justification, and avoidance of adverse drug effects [19]. At the same time, the ultimate
outcomes of pharmacogenomic research contribute to the implementation of
personalized medicine.
Personalized medicine is the practice of implementing genetic data to develop
targeted therapies and to choose the right candidates for these therapies [20]. In the
late nineties, few articles started to use the term “personalized medicine” to describe
the use of predictive efficacy and safety biomarkers for treatment adjustment instead
of the classical practice of “one size fits all.” Given the high cost and impracticality of
tailoring drugs to individual patients, “stratified medicine” and “precision medicine”
became more preferred terms. Nevertheless, the three terms are used interchangeably
[21, 22]. Alfirevec and Pirmohamed revised the number of hits in PubMed that used
the previously mentioned five standard terms (pharmacogenetics, pharmacogenomics,
personalized medicine, stratified medicine, and precision medicine). Figure 1 displays
the results of this review and depicts the increment of publications with time. A
significant increase in the usage of pharmacogenomics-related terms occurred
following the completion of the first human genome draft.
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Figure 1: Number of publications using pharmacogenomics terms over 25 years.
The figure illustrates the rising tendency to use the term “pharmacogenomics” versus
“pharmacogenetics” in publications, and the striking rise in number of publications concerned with
personalized, stratified and precision medicine. Source [21].

Another novel term that appeared and been in use is “pharmacogenes.” Genes
involved in drug pharmacology pathways are described as pharmacogenes. This
includes genes active in drug PK or PD pathways. The PK pathways comprise genes
involved in the absorption, distribution, metabolism, and excretion (ADME) of drugs.
In comparison, the PD pathways enclose genes coding for drug receptors and drug
targets, whether these targets are ion channels, receptors, enzymes, or nucleic acids
[23, 24]. Figure 2 illustrates the different classes of pharmacogenes with few examples.

9

Examples of Pharmacogenes in Drug Pathways
Pharmacokinetics
pathways
Absorption

Distribution

Metabolism

Phase I
Oxidases
Reductases
Hydrolases

ABC
transporters
SLC
transporters

Pharmacodynamics
Pathways
Excretion

Phase II
Conjugation
enzymes

CYP-450
POR
FMO

Receptors

Ion channels

EGFR
VDR

KCNH2

Targets

VKORC1

UGT
GST
NAT
TPMT

Figure 2: Pharmacogenes in drug pathways: classes and examples.
ABC; ATP-binding cassette, SLC; solute carriers, CYP-450; cytochrome 450 dependent enzymes, POR;
cytochrome P-450 oxidoreductase, FMO; flavin containing dimethylaniline monooxygenases, TPMT;
thiopurine S-methyltransferases, EGFR; epidermal growth factor receptor, VDR; vitamin D receptor,
KCNH2; potassium voltage-gated channel subfamily H member 2, VKORC1; vitamin K epoxide
reductase complex subunit 1.

From another perspective, to label a gene as a pharmacogene, it should play a
role in one of the following ways:
1- Genes associated with drugs mechanism of action (e.g., VKORC1 involved in
warfarin mechanism)
2- Genes associated with drug metabolic transformation (e.g., CYP2D6 which
catalyzes the metabolism of 20-25% of prescribed drugs)
3- Genes associated with drugs transportation (e.g., ABCB1 which encodes an ATPbinding cassette transporter active in the transport of xenobiotics and other
substrates)
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Moreover, some authors tend to classify genes involved in disease
pathogenesis, which makes them suitable targets for drug design as pharmacogenes
[25].
At the molecular level, the most common form of variation in pharmacogenes
is single nucleotide variants (SNVs), which are, in general, the most common genetic
variation in the human genome. These are single base-pair changes in DNA. Variants
occurring at a high frequency are usually called single nucleotide polymorphisms
(SNPs) [26]. Historically, variation’s minimum frequency has been set at 1% in the
population, to be considered as a polymorphism [3]. Other types of variations include
copy number variants (CNVs), deletions, insertions, and variants affecting splicing
sites [27].
An actionable variant in a pharmacogene could be any of the previously
mentioned types of variants, though it should show penetrance on a drug effect or a
relevant endophenotype, such as metabolizing enzyme activity, or a pharmacological
property [28].
After discovering a specific variant, the first identified allele in the human
reference genome is named as the major allele. The other alternative alleles are
recognized as minor alleles. However, the words “major” and “minor” do not
necessarily reflect each allele’s actual frequency in a specific population as these
frequencies tend to vary between populations. A haplotype describes the combination
of alleles that are inherited together due to their proximity on a chromosome. This
correlation between adjacent variants that enable their co-inheritance is usually known
as linkage disequilibrium (LD) [29]. While a diplotype is used to describe the
haplotype pair on homologous chromosomes [30].
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With the increasing number of alleles found to be in association with drug
response, there was a need to unify the nomenclature system for these alleles. Hence,
the star allele nomenclature evolved as a unique way of conveying information related
to pharmacogenomic alleles [27]. In the star allele nomenclature, *1 is given to the
reference allele, which is usually the first described, and it codes the functional protein.
It might be the most common allele in some populations but not for other populations.
Subsequently, each identified novel variant’s allele will get a unique number (e.g.,
CYP2B6*2, CYP2B6*3, etc.). Novel alleles inherited in conjunction with an already
named allele are given an additional letter, rather than a new number (e.g.,
CYP2B6*2A, CYP2B6*2B) where usually the principle allele is designated with an A
[31].
At the phenotype level, a pharmacogenomic measurable phenotype would be
an individual’s metabolic status or his vulnerability to adverse drug effects.
Conventionally, individuals with normal levels of the metabolizing enzyme were
described as extensive metabolizers. Recently, the term “normal metabolizer” has been
chosen as a preferable expression. In contrast, individuals with little or no enzyme
activity are described as poor metabolizers. In between the two types, individuals with
decreased metabolic activity are referred to as intermediate metabolizers. Finally,
some individuals might have an increased enzymatic activity than the normal
metabolizers, which makes them rapid metabolizers, or in some cases, ultra-rapid
metabolizers [32].
Regarding adverse drug effects, which are other significant phenotypes
motivating pharmacogenomics research, multiple terms are used to describe them.
These terms include, but are not limited to, adverse events, side effects, adverse
reactions, adverse drug effects, and others. An adverse event is an undesirable outcome
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occurring during or following the use of a drug or intervention, without being
necessarily attributed to it. These include signs, symptoms, laboratory tests, a
combination of these abnormalities, or unexpected deterioration of the concurrent
illness. In comparison, drugs’ adverse effects describe these undesirable events that
can be attributed to a drug, by some degree of probability. An adverse event will be
known as an adverse drug effect when it can predict the hazards of future
administration of the drug or warrant dose adjustment or drug withdrawal [33].
In comparison, “side effect” is a general term used to describe a collateral drug
effect at therapeutic drug doses. These effects originate mostly from the
pharmacological characteristics of the drug. Nevertheless, some side effects might be
desirable. For example, the antidepressant mirtazapine is used in anorexia patients for
its weight gaining side effect. Accordingly, adverse drug effect is the preferred term
to use as it encompasses the deleterious effects without making any assumptions on
the mechanism of this effect [33]. Adverse drug effects might be an extension of the
drug’s pharmacological action (e.g., bleeding from the blood-thinning agent warfarin)
or off-target effects, which are hard to predict or interpret [27].
One of the contemporary concepts in pharmacogenomics is pre-emptive
testing. In this approach, the pharmacogenetic test is done before the actual need for a
medication prescription. In contrast, a reactive or gene-drug approach describes testing
the patient at the point of prescribing a drug that has pharmacogenomic guidelines.
Randomized controlled trails provided supporting evidence for single gene-drug tests
to guide dosing of specific drugs like warfarin, 6-mercaptopurine and others. On the
other hand, few studies were designed to examine the utility of pre-emptive testing of
multiple genes across different ethnicities in a pre-emptive approach. Examples of
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these studies include the PREPARE study, a part of the Ubiquitous Pharmacogenomics
Project (U-Pgx) in Europe [34].
To conclude, the emergence of pharmacogenomics dictated not only the
introduction of new terms but also redefining old ones. Pharmacogenomics-related
terms and definitions (summarized in Table 1) are based on the basic concepts of
genomics and pharmacology.

Table 1: Pharmacogenomics-related definitions
Term

Definition

References

Pharmacogenetics

The study of the role of genetic variation in drug response

[19]

Pharmacogenomics

The expansion of pharmacogenetics to the genomic level

[19]

Personalized
medicine

The practice of genomic data implementation in therapies’
introduction and optimization.

[20]

Stratified medicine

[35]

Pharmacogene

The implication of pharmacogenomic data in stratifying
patients’ populations according to response. A term that is
more preferred than personalized medicine.
A more reliable term than personalized medicine, to describe
the practice of genomic data implementation in medicine.
A gene involved in a drug pharmacology pathway.

Star alleles
nomenclature

a unique way for describing pharmacogenomic alleles and
haplotypes.

[27]

Normal
metabolizers
(extensive
metabolizer)

individuals with normal levels of metabolizing enzyme.

[32]

Poor metabolizers

individuals with a little or no enzyme activity.

[32]

Intermediate
metabolizers

individuals with a decreased metabolic activity.

[32]

Rapid metabolizers

individuals with an increased enzymatic activity than the
normal metabolizers.

[32]

Ultra-rapid
metabolizers

individuals with an increased enzymatic activity than the rapid
metabolizers.

[32]

Precision medicine

[21]
[24]
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Table 1: Pharmacogenomics-related definitions (continued)
Term

Definition

References

Adverse event

undesirable outcome occurring during or following the use of
a drug or intervention, without being necessarily attributed to
it, including signs, symptoms, laboratory test, a combination
of these abnormalities, or unexpected deterioration of the
concurrent illness.
The undesirable or adverse events that can be attributed to the
drug, by some degree of probability.
Testing healthy individuals and making the results available in
the health system for future use.

[33]

Testing a specific gene or variants before an associated drug is
prescribed.

[34]

Adverse drug effect
Pre-emptive
pharmacogenetic
testing
Reactive
pharmacogenetic
testing

[33]
[34]

1.3.3 Pharmacogenomic Information Resources
The leading drug regulators usually revise the information about genomic
biomarkers associated with drug responses like the Food and Drug Administration
(FDA) in the United States, European Medicines Agency (EMA) in Europe, and the
Pharmaceutical and Medical Device Agency in Japan. The drug labels are then
updated, and warnings of adverse effects are issued [21].
Despite the accumulated evidence of pharmacogenomic testing impact in
improving medication usage, slow adoption into clinical practice has been hindering
implementation. Various consortia were established to bridge the gap between
research and clinic by issuing clinical guidelines that clinicians can implement easily.
Among these, the Clinical Pharmacogenetics Implementation Consortium (CPIC) and
the Dutch Pharmacogenetics Working Group (DPWG) have been working for the last
15 years. These groups regularly publish systematic analysis of genetic variants and
drug response phenotypes, the severity of adverse events, the available lab tests, and
the dose adjustments or alternative drugs when needed [21, 36].
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Pharmacogenomics Knowledgebase (PharmGKB) is a National Institutes of
Health (NIH)-funded resource that collects, curates, and disseminates knowledge
about clinically actionable gene-drug associations and genotype-phenotype
relationships. It curates and updates the drug labels annotations approved by the drug
regulators like FDA and EMA. Besides, curating the guidelines published by CPIC,
DPWG, and others. Nevertheless, evidence-based diagrams of drugs PK and PD can
be found in this repertoire with the relevant or potential pharmacogenomic
associations. Accordingly, it forms a comprehensive resource for practitioners and
researchers [37].
The clinical annotations section in PharmGKB summarizes all annotations
derived from published research for the associations between genetic variants and
medications. They are given a PharmGKB rating depending on the quality and
quantity of the available published evidence.
The evidence rating is leveled into six levels; level 1A indicates associations
with the most robust evidence with an approved clinical implementation or a medical
regulator endorsed guideline. Level 1B includes high evidence associations that have
been replicated in more than one cohort with significant p-values. Level 2 contains
variants with moderate evidence, replicated in several cohorts, but some of these
studies were not with a significant p-value. This level is further subdivided into 2A
and 2B, in which the former includes variants in one of the very important
pharmacogenes (VIP, i.e., genes that have a large number of drug associations with
sever effects). Level 3 includes significant associations that were reported in a single
significant study without replication. Level 4 contains annotations based on a case
report, insignificant study, in vitro study, and associations depending on functional
assays only without clinical data.
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Traditionally, germ-line DNA sequence and genetic variations were compiled
in repositories to makes them available for the scientific community. dbSNP database
serves as a central repository for SNPs and short indels that contains the largest
collection of human variants. The dbSNP assigns colocalizing submitted variants from
the same type a reference SNP identifier, also known as “rs ID”, or “rs number” [38].
The phenotypes and functional interpretations of variants are not part of the
information provided by dbSNP. In contrast, ClinVar is the largest archive for
genotype-phenotype data and their supporting evidence. One of the clinical
interpretation categories in ClinVar is “drug response”; however, no further details are
provided about this response' nature [39].
Due to the high pharmacogenes variability, databases curating variants and
alleles information exclusively for pharmacogenes have been developed. The oldest
and best-established one was the Human Cytochrome P450 Allele Nomenclature
(CYP-allele) website, which transitioned into PharmVar in 2017. While the former
served as an assembly for the published information about CYP-alleles and NADPHCYP Oxidoreductase (POR) alleles exclusively, the latter started introducing
information from other pharmacogenes in 2018. These databases’ primary objective is
to facilitate allele definitions, which researchers use consistently and can be utilized
by PharmGKB, CPIC, and other committees [40, 41].
The mentioned resources are just a few examples, while an increasing number
of resources are continuously evolving. Some old resources have expanded in response
to the increasing

need for pharmacogenetic information like DrugBank

(www.drugbank.ca), which started to add pharmacogenomic information from its
second version, and further expanded its related content in its 4th version [42]. Another
example is FINDbase (www.findbase.org), which is a database documenting the
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frequency of clinically relevant variants in various populations. Since 2010, FINDbase
also included pharmacogenomic biomarkers in records, including the population,
geographic region, and ethnic group along with the rare alleles frequencies and
population-specific information [43].
1.3.4 Pharmacogenomic Studies Design
Most of the study designs used in disease-genomic research apply to
pharmacogenomics. However, some differences exist. For example, family studies are
central to the genetics of rare diseases’ discoveries. In contrast, it is not usual to have
multiple family members exposed to the same drug. Hence, the utilization of family
studies in pharmacogenomics is minimal [27]. In the following paragraphs, the
standard designs used in pharmacogenomic studies are described.
a. Candidate gene approach: Genes active in the pharmacodynamic or
pharmacokinetic pathways of the drug of interest are selected. These genes are studied
either extensively (e.g., by sequencing) or genotyped for the known variants (e.g., PCR
based SNP genotyping) to look for significant associations with inter-individual
differences in drug response.
Advantages: Candidate gene studies are relatively inexpensive and fast. They
have had many successes, like discovering of the association between TPMT genotype
and bone marrow suppression with 6-mercaptopurine [44].
Disadvantages: Candidate gene approaches suffer from being hypothesisdriven, which usually yields a high percentage of false-positive associations [44].
Many findings were not replicated or remained in the discovery phase because of many
reasons. Concentrating on a few variants rather than the whole gene, and the limited
knowledge of some drugs’ mechanisms or pathways, are among these reasons [23].
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b. Genome-wide association studies (GWAS): these are hypothesis-generating
rather than hypothesis-driven studies. Most GWAS are designed as case-control
studies where patients treated for the same indication with similar treatment regimens
are recruited. The case arm includes patients with a response of interest (e.g., patients
suffering from a defined adverse effect) in comparison to the control arm that includes
patients that do not develop the same response. The aim is to explore which of the
SNPs, which might reach in the count to one million SNPs, distributed genome-wide
are significantly associated with developing the studied response [44, 45].
Advantages: High confidence associations are usually generated. Associations
with SNPs in genes that were not considered in the previous candidate gene studies
could be delineated. GWAS identified multiple loci associated with a drug response
that can elucidate the new drug’s mode of action [23].
Disadvantages: Rare, novel, and population-specific SNPs are missed. The
total number of pharmacogenomic biomarkers identified, using even the most
comprehensive (microarray-based) genetic screening assay, is significantly less
compared to the number of variants identified using next-generation sequencing
(NGS) based approach. Large sample sizes are usually needed to reach the required
power of association while attaining the required sample size is typically tricky with
rare pharmacological responses [44].
c. Whole Exome/Genome Sequencing (WES/WGS): In this case, associations
are searched by linking the whole exome or genome data derived from NGS with the
PK/PD data or drug response.
Advantages: NGS approaches combine the benefits of the two previous
methodologies. It is hypothesis-generating, and it can detect rare and populationspecific polymorphisms. In their extensive study that analyzed rare variants in 208
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pharmacogenes from 60,706 individuals, Ingelman-Sundberg and colleagues
concluded that rare variants substantially contribute to interindividual differences in
medication metabolism phenotypes. In the same study, the authors advocated for
leveraging WES and WGS data at a population scale as a significant approach in
pharmacogenetic studies [46].
Disadvantages: High cost and needs burdensome computer analysis. Although
NGS will detect many novel variants, most of these will not be characterized
functionally due to many functional experiments' infeasibility. The available
alternative, in this case, is relying on in silico tools predictions. Nevertheless, in silico
tools have proved a low efficacy in predicting variant effects in ADME genes. The low
evolutionary conservation of ADME genes is one suggested reason for the in-silico
tools' insufficiency. Another justification lies in the design of these tools built and
trained on disease-causing variants [47]. As a result, most of the NGS-detected novel
variants will be unusable. One recent study highlighted that genotyping array
performance was on par with WGS and better than WES [48], making the costeffectiveness of choosing the expensive NGS-approaches questionable.
d. Targeted NGS of a selected panel of genes: Although this approach shares
the same technique as the previous one, it adds some benefits in the context of
pharmacogenomics. Lately, targeted NGS capture panels became a reasonable choice
for pharmacogenomic research, specifically at population scale and clinical
implementation studies [49].
Advantages: the costs are lower than WES and WGS, and the speed is higher,
besides preserving the ability to detect the rare and population private variants.
Disadvantages: The choice of the panel’s genes and its coverage is critical, and
panel design limitations can underpower the sequencing results.
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Despite the increasing use of NGS techniques, slower techniques are still
needed and used. Indeed, these approaches should be viewed as complementary rather
than competitive [23]. Figure 3 depicts the common pharmacogenomic studies’
designs and their differences.

Figure 3: Comparison of the standard approaches in pharmacogenomic studies
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Chapter 2: Landscape of Pharmacogenomic Variation in UAE
2.1 Populations Pharmacogenetics: Literature Review
In the following paragraphs the concept of population pharmacogenetics are
discussed briefly with an emphasize on its potential application in the UAE population.
2.1.1 Interpopulation Differences in Pharmacogenes
High throughput sequencing enabled identifying genetic variation at an
unprecedented pace and exceeded all the earlier used technologies by detecting rare
variants at a fast and precise scale. During the last two decades, several big projects
aimed to better understand human variation by utilizing NGS. The 1000 genome
project (1000 GP) was a seven-year project that ended its final phase in 2015. In its
final phase, the 1000 GP consortia openly released the sequences of 2,504 human
genomes from 26 populations, which contained over 88 million variants. The included
populations were originating from Africa, East Asia, Europe, South Asia, and the
Americas [50, 51]. In comparison, the Exome Aggregation Consortium (ExAC)
compiled the whole-exome sequencing data from 60,706 individuals of European,
South Asian, East Asian, African, Latino ancestries [52].
The field of pharmacogenomics was no exception in embracing the benefits of
NGS in genomic medicine. A considerable number of studies have already utilized the
publicly available data repertoires, like 1000 GP and the ExAC dataset, to extract the
common and rare variants in pharmacogenes identified in earlier association studies
[9, 46, 53]. Such studies indicated that pharmacogenes are highly variable, and the
variability extent differs between populations [7, 53, 54].
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Following these findings, a new concept of population pharmacogenomics has
emerged. Population pharmacogenomics aims to identify the population-specific
actionable variants and utilize this knowledge in precision public health [55, 56]. Such
studies are needed to infer rates and risks at the population level and guide
pharmacogenomic implementation [35]. A precision public health can contribute to
crucial inputs into the healthcare system. In this approach, health care will be
customized at the population level by selecting genes or variants that should be tested,
and the right time to test them. This paradigm will enable medication prioritization
guidelines, reduce possible adverse events, improve patients’ quality of life, and
reduce the national health expenditure [55].
Numerous studies have compared pharmacogenomic biomarkers frequencies
and prevalent alleles in populations from North America [57], Europe [8, 58], Latin
America [56, 59], Africa [60, 61], Oceania [62, 63], South Asia [64, 65], and East Asia
[66, 67]. In comparison, very few pharmacogenomic studies have been applied in West
Asia, specifically the Arabian Peninsula, and in other Arab countries in the
Mediterranean east and south coasts. The under-representation of Arabs in the
pharmacogenomic data is proportional to the rare genomics data originating from this
region. Approximately 0.08% of the genomic data available in public domains is from
Arab populations [68].
2.1.2 Pharmacogenetic Studies in the United Arab Emirates:
In the east of the Arab Peninsula, UAE is situated central to the old-world, in
a location that made it a vital nexus in modern-human dispersal and migration waves
[69]. Indigenous UAE citizens are constituted of an admixture population that
preferably practice consanguineous marriages [70]. In parallel to the country’s
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economic growth, a rapid improvement in the healthcare system has been witnessed
in the UAE [71]. However, non-communicable diseases and their associated mortality
are still challenging, specifically, cardiovascular diseases and cancer [72].
A limited number of pharmacogenetic studies have been applied in the UAE.
The first research, conducted in 1996, examined G6PD. In their work, Bayoumi and
colleagues tested the G6PD enzyme activity in healthy Emirati children and
determined the genotypes in G6PD deficit individuals. Soon, another study
considering the acetylation status of healthy Emiratis was conducted [73]. Woolhouse
and coworkers demonstrated the high percentage of slow acetylators in Emiratis and
detected two NAT2 novel alleles in their study published in 1997 [74]. Quite a long
gap existed before the next pharmacogenetics related paper was published. In 2011,
Qumseieh and coworkers reported the results of CYP2D6 genotyping by direct
sequencing and TaqMan real-time quantitative PCR in 151 Emiratis. In the same study,
the authors reported four novel CYP2D6 variants [75].
The first study about VKORC1 was published in 2016, in which AlJaibeji and
coworkers examined the genotypes at two VKORC1 variants (rs9923231 and rs7294)
and compared the interpopulation allele frequencies [76]. In the following year, two
pharmacogenetic studies from the Emirati population were published. In the first
study, Al-Ahmad and colleagues genotyped NAT2 in 576 Emiratis. They also
determined the acetylation phenotype by examining caffeine metabolites following
caffeine consumption containing soft drinks. The authors reported a 96.2%
phenotype/genotype concordance in NAT2 and displayed the predominance of slow
acetylator phenotype among Emiratis [77].

Similarly, CYP1A2 phenotype and

genotype were examined. In contrast to the high prevalence of NAT2 alternative
alleles, the major CYP1A2 allele (*1/*1) was predominant in the studied cohort [78].
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In a recent study, Saber-Ayad and coworkers described the genotypes at
two SLCO1B1 SNPs (rs4149056 and rs2306283). The prevalence of statin-induced
myopathy was not evaluated in patients, and pharmacogenetic associations were not
examined. However, the authors highlighted the low prevalence of the rs4149056-C
allele, the allele associated with statin-induced myopathy, compared to two other
populations and conclude that statins' use should be encouraged in the UAE [79].
In summary, scant pharmacogenetic studies were conducted in the Emirati
population. Each of the previous studies was limited to a single gene, in which the
focus was on comparing frequencies with other few populations. However, most of the
outcomes were not projected back to their potential impact on the population health
issues. With the described deficiency in pharmacogenetic data, there are no
possibilities for the commencement of precision medicine approaches in UAE.
2.1.3 Study Questions and Objectives (100 Pharmacogenes Resequencing)
1- To explore the variation landscape in important pharmacogenes and
actionable alleles in the native UAE population (Emiratis).
2- To infer the potential candidates for future pharmacogenetic research and
applications in the country.
2.1.4 Hypothesis (100 Pharmacogenes Resequencing)
Rare and novel variants could be detected, and actionable pharmacogenetic
variants will probably be found in healthy individuals.
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2.1.5 Primary and Secondary Outcomes (100 Pharmacogenes Resequencing)
Primary outcomes: Determining important pharmacogenes allele frequencies
and genotypes and comparing these to global frequencies in genomic databases.
Secondary outcome: To indicate the actionable variants and potential
pharmacogenetic population-specific targets.
2.2 Methods (100 Pharmacogenes Resequencing)
2.2.1 Participants
Participants were recruited from Tawam hospital, Al-Ain city, Emirate of Abu
Dhabi, UAE. All the participants signed an informed consent form to participate in
this study. This study was conducted following the approval of the Tawam Human
Research Ethics Committee (THREC#552).
2.2.2 Samples Collection and Preparation
Whole blood samples were collected from the participants on EDTA tubes. 3
to 5 ml were collected from each individual. DNA was extracted from the fresh blood
samples using FlexiGene® DNA Kit (Qiagen®, Germany), according to the
manufacturer’s procedure. The extracted DNA was kept in a sterile plastic vial at 4°C
until analysis or stored at −20°C for future research.
2.2.3 DNA Quality and Quantity Check
The

quality

and

quantity

of

extracted

DNA

were

checked

spectrophotometry using Nanodrop® (Thermo Fischer Scientific®, US).

by
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2.2.4 Resequencing and Raw Data Manipulation
Resequencing of the coding regions of 100 pharmacogenes included in the 100
PKSeq panel, described elsewhere [80]. Table 2 lists the targeted genes classified
according to their functions and gene-families.

Table 2: Pharmacogenes included in the 100 PKSeq panel
Gene
function

Gene class

Gene
family

Genes

Transportati
on

solute carriers

SLC

Transportati
on

solute carriers

SLCO

SLC16A7, SLC19A1, SLC22A1, SLC22A2,
SLC22A3, SLC22A4, SLC22A5, SLC22A6,
SLC22A8, SLC22A9, SLC22A11, SLC22A12,
SLC28A1, SLC28A2, SLC28A3, SLC29A1,
SLC29A2, SLC29A3, SLC31A1, SLC46A1,
SLC47A1, SLC47A2
SLCO1B1, SLCO1B3, SLCO2B1

Transportati
on

ATP-binding cassette
transporters

ABC

ABCB1, ABCB4, ABCB11, ABCC1,
ABCC2, ABCC3, ABCC4, ABCG2

Metabolism

Cytochrome P-450
metabolizers

CYP

CYP1A1, CYP1A2, CYP1B1, CYP2A6,
CYP2A13, CYP2B6, CYP2C8, CYP2C9,
CYP2C18, CYP2C19, CYP2D6, CYP2E1,
CYP2J2, CYP2S1, CYP2W1, CYP3A4,
CYP3A5, CYP3A7, CYP3A43, CYP4A11,
CYP4B1, CYP4F2, CYP4F3, CYP4F8,
CYP4F12, CYP4Z1, CYP11A1, CYP17A1,
CYP19A1, CYP26A1

Metabolism

Flavin monooxygenase

FMO

FMO1, FMO2, FMO3, FMO4, FMO5

Metabolism

Carboxylases

CES

CES1, CES2

Metabolism

Glutathione Stransferases

GST

GSTA1, GSTM1, GSTP1, GSTT1

Metabolism

N-acetyltransferases

NAT

NAT1, NAT2

Metabolism

Uridine diphosphate
glucuronosyltransferase

UGT

UGT1A1, UGT1A3, UGT1A4, UGT1A5,
UGT1A6, UGT1A7, UGT1A8, UGT1A9,
UGT1A10, UGT2B7

Metabolism

Sulfonyl transferases

SULT

SLUT1A1, SULT1A2, SULT1E1, SULT2B1

Metabolism

Miscellaneous

-

DPYD, TPMT, NUDT1, NUDT15, POR

Drug target

Reductases

VKORC

VKORC1
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The targeted coding regions (159 kilo base pairs) were sequenced using 1,102
gene-specific primers and dual barcodes to the PCR products to differentiate each
sample. After purification and quantification of the PCR products, the pooled libraries
were sequenced using the MiSeq Reagent Kit v2 (Illumina, USA) with an output of 2
× 250 bp. Raw fastq files were processed using a standard analysis pipeline.
Trimmomatic [81] tool to trim the leading and trailing bases if quality < 20. Then reads
shorter than 200 bp or having an average quality below 20 were removed. Reads
passing through the quality filtering were retained and aligned to the human reference
genome (GRCh37/hg19) by Burrows-Wheeler Aligner (BWA 0.7.17). Variants were
called by the Genome Analysis Toolkit (GATK, v3.5) [82] including SNPs and
insertions and deletions (indels).
Variant quality score recalibration (VQSR) was applied on the retrieved
variants using GATK, v3.5, as a refinement to reduce the false-negative calls.
Minimum sequencing depth was set at 30X, with over 98% of targets covered.
2.2.5 Annotation and Effect Prediction
Annotating the variants and effect prediction was achieved using three different
tools: ANNOVAR [83], snpEff [84], and dbNSFP v4.0 [85, 86].
ANNOVAR and snpEff annotate and provide the in-silico effect predictions
and frequencies of all types of variants. While and dbNSFP v4.0 annotates and provide
the functional predictions for the non-synonymous variants only. The function
prediction scores are compiled from more than 30 prediction algorithms, including
SIFT, Polyphen2, LRT, MutationTaster2, Mutation Assessor, FATHMM, MetaLR,
CADD, and others. The used tools enabled a comparison of minor allele frequencies
(MAF) with the frequencies reported from populations in several databases, including
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1000 Gp3 (phase 3 of 1000 GP), UK10K, ExAC, and the genome aggregation database
(gnomAD exome and gnomAD genome). Moreover, the splicing site predictions were
filtered against the splicing site variants database (dbscSNV) [87].
ANNOVAR gives an “unknown” annotation of function when an exon open
reading frame is not correct. In the cases of “unknown” annotations, these variants
were tracked manually using other tools and by revising literature to assign the
appropriate annotation.
2.2.6 Haplotypes and Star Alleles Calling
Stargazer_v1.0.8 [88] to extract the common haplotypes from phased
genotypes and call the star alleles. Stargazer is a bioinformatic tool that uses the NGS
resequencing produced files in the format of BAM or VCF files to extract the star
alleles from 51 pharmacogenes. The shared genes between the tool and the targeted
genes were 41 genes. Accordingly, these 41 genes were genotyped individually in the
whole sample using the “Genotype” tool provided with the Stargazer package.
Stargazer's input file was the (combined VCF) file, which resulted from combining
calibrated individual VCF files of the study participants. Stargazer uses the phasing
algorithm Beagle (v4.1) [89] and matches the phased haplotypes to star alleles
employing a built-in translation Table depending on Pharmvar [90] star alleles
definitions.
2.2.7 Statistical Methods for Targeted Sequencing Data
Statistical tests of this part of the study were processed using the freely
available statistical software R (RStudio, US) using the appropriate tests and their
compatible R packages.
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Alleles and genotypes frequencies were extracted during the variant calling
process using. Actionable variants were checked for Hardy-Weinberg equilibrium. For
interpopulation MAFs comparisons, Chi-square test, Fishers’ exact tests were used. P
values were obtained two-sided and significance was selected at p < 0.05.
2.2.8 Bioinformatics Tools
The used bioinformatics tools for data analysis are listed in Table 3.

Table 3: Bioinformatic tools used for data analysis
Tool common
name
Trimmomatic
GATK
ANNOVAR

SnpEff

DbNSFP

SIFT
Polyphen-2

LRT
MutationTast
er-2
Mutation
Assessor
FATHHMM

Tool full name

Description

References

Trimmomatic
Genome analysis tool
kit
ANNOVAR

A trimmer for Illumina sequence data
A set of tools for variant discovery and
genotyping from NGS data
Annotation of single nucleotide variants,
deletions, and insertions from highthroughput sequencing
annotates and predicts the effects of genetic
variants on genes and proteins

[81]

database for functional prediction and
annotation of non-synonymous singlenucleotide variants (nsSNVs) in the human
genome
Prediction of amino acid changes effect on
protein function
Prediction of amino acid changes effect on
protein function

[85, 86]

Prediction of amino acid changes effect on
protein function
Prediction of amino acid changes effect on
protein function
Prediction of amino acid changes effect on
protein function
Predicting functional consequences of both
coding variants and non-coding variants in
the human genome

[93]

Genetic variant
annotation and
functional effect
prediction toolbox
dbNSFP

Sorting intolerant fro
m tolerant
Polymorphism
phenotyping-version
2
Likelihood ratio test
Mutation taster
version 2
Mutation assessor
Functional Analysis
through Hidden
Markov Models

[82]
[83]

[84]

[91]
[92]

[94]
[95]
[96]
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Table 3: Bioinformatic tools used for data analysis (continued)
Tool common
name
MetaLR

Tool full name

Description

References

Meta logistic
regression

[97]

CADD

Combined annotation
dependent depletion

Stargazer

Stargazer

R studio

R studio

Logistic regression tool to integrate nine
independent variant deleteriousness scores
and allele frequency information to predict
the deleteriousness of missense variants.
An integrative annotation tool for scoring the
deleteriousness of variants in the human
genome.
Tool for calling star alleles from sequencing
data
Free and open source for R tools for data
science

[98]

[88]
[99]

2.2.9 Contributions
Targeted gene panel sequencing (NGS) wet lab work was performed, as part
of the South East Asia Pharmacogenomics Association (SEAPharm) collaborative
project, in the Laboratory for Pharmacogenomics, RIKEN Center for Integrative
Medical Sciences, Japan. Raw NGS data processing was performed in the Center for
Medical Genomics, Faculty of Medicine Ramathibodi Hospital, Mahidol University,
Thailand.

2.3 Results (100 PGx Resequencing)
2.3.1 Sample Descriptive
One hundred healthy Emirati volunteers participated in this group. The
participants were 48 males and 52 females with an age range of 18-60 years.
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2.3.2 Variants Call Quality
Following sequence alignment and variant calling, 1282 single nucleotide
variants and indels were retrieved. VQSR applied to reduce the number of falsepositive calls filtered out 39 variants. Accordingly, 1243 high-quality variants resulted
from the targeted sequencing of the coding regions of 100 pharmacogenes (157 Kbp).
2.3.3 Minor Alleles Frequencies
Approximately 63% (778) of the 1243 variants were detected in a minor allele
frequency (MAF) of ≤ 0.01, and the majority (656 variants) were found as singletons
(i.e., in a heterozygous individual carrying one minor allele with a MAF of ≈ 0.005).
The distribution of detected variants according to their MAF is illustrated in Figure 4.
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Figure 4: Distribution of variants according to their MAF
MAF: minor allele frequency

The MAF of variants annotated through dbNSFP-v4 were compared to the
following public databases: 1000Gp3, UK10K, ExAC, gnomAD exome and gnomAD
genome (sample counts = 1000; 10,000; 60,706; 125,748 and 15,708; respectively). In
the current Emirati group, 30% of the detected variants were novel, i.e., were not found
in any of the public databases (total populations count = 213,162).
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Moreover, the current group’s MAFs were compared to the same variants’
frequencies in gnomAD exome and genome populations. 41.7% (n = 537) of the
retrieved variants from the current population had MAF ≤ 0.01 worldwide, and out of
these globally rare variants, 154 variants showed MAF > 0.01 in the current group. In
other words, 154 variants were more common in UAE population than the compared
ones.
2.3.4 Functional Classes of Variants and Effect Predictions
Out of the detected variants, 56% were classified as non-synonymous single
nucleotide variants (SNVs), followed by 36% of synonymous variants, then other
classes of variants, as illustrated in Table 4 and Figure 5.

Table 4: Functional classes of the detected variants
Variant Class
Synonymous
Non-Synonymous SNV
Frameshift deletion
Frameshift insertion
Non-frameshift deletion
Non-frameshift insertion
Start-loss
Stop-gain
SNP; Single nucleotide variant

Count
456
722
25
12
4
1
2
21

Frequency
0.362646
0.561089
0.019455
0.007782
0.003113
0.000778
0.000778
0.016342
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Synonymous
Non-Synonymous SNV
Frameshift deletion

Frameshift insertion
Non-frameshift deletion
Non-frameshift insertion
Start-loss
Stop-gain

Figure5: Distribution of the detected variants according to their functional implication
Loss of function variants (LOF): Four participants carried 4 different LOF
variants as single alleles in 4 different genes. These included rs1034422305 in ABCC3,
rs2020866 in FMO2, G>A at Chr19:15770170 in CYP4F3, and G>A at
Chr10:104590479 in CYP17A1. While 24 other detected variants were at splice sites
as indicated through filtering the variants against the (dbscSNV) database.
Variable in silico predictions of the variants’ effects were obtained from the
different tools used. SIFT predicted 301 variants as deleterious/damaging variants,
which was the highest amongst all other tools, followed by Mutation Taster with 296
variants, Polyphen2_HDIV with 239 variants, LRT with 233, Polyphen2_HVAR with
197, FATHM with 131 variants, and MetaLR with 130 variants. The latter, MetaLR,
is a prediction tool that incorporates scores from 10 prediction tools with allele
frequencies in the 1K genome populations, in a logistic regression-based design.
Accordingly, the variants predicted to be “damaging” by MetaLR can be considered
as the consensus in silico predicted damaging variants. In the current populationunique variants, 61 of them had a consensus-damaging prediction by MetaLR.
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Although most of these variants were occurring in an individual heterozygous carrier,
six variants were carried as single alleles by two individuals, while two populationunique variants in SLC29A3 were carried in 26 heterozygous carriers from the current
sample.
According to their CADD scores, filtration of the novel variants revealed that
the current sequencing detected 141 novel variants with CADD Phred scores ≥ 20.
Accordingly, these 141 novel variants can be considered the most likely damaging
variants. These variants appeared in different frequencies among different gene
families, as described later.
2.3.5 Haplotypes and Star Alleles
Stargazer genotyping generated files were analyzed to extract the star alleles,
diplotypes, their frequencies, and the associated phenotype predictions. Later,
PharmGKB and PharmVar databases were manually searched to confirm the
predictions and to conclude the clinical significance of the annotated haplotypes and
diplotypes.
Some genes presented with numerous diplotypes among the participants; these
include CYP2D6, CYP2B6, DPYD, CYP1B1, CYP4B1, and NAT2. Most of the
diplotypes were previously reported in association with normal enzymatic activity.
However, 24 diplotypes in 11 important pharmacogenes with a PharmGKB clinical
annotation of a high significance were found among the study participants. Significant
diplotypes are listed in Table 5.
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Table 5: Detected diplotypes with evident clinical significance in PharmGKB
Diplotype

Freq

Drug Affected by the Diplotype according to PharmGKB Clinical
annotations (level of evidence)1
Nicotine (2A)
Hydroxybupropion (2A)

CYP2A6*2/*18
CYP2B6*1/*18

0.05
0.01

CYP2B6*4/*6
CYP2B6*6/*6
CYP2C8*3/*3
CYP2C9*1/*2
CYP2C9*1/*3
CYP2C9*2/*2
CYP2C9*2/*3

0.01
0.03
0.02
0.17
0.13
0.02
0.01

CYP2C19*1/*2
CYP2C19*2/*2

0.28
0.01

CYP2D6*1/*10
CYP2D6*2/*10
CYP2D6*10/*10

0.1
0.09
0.02

NAT2*5/*5
NAT2*6/*6
NAT2*6/*7
NAT2*5/*6

0.19
0.08
0.01
0.18

NAT2*5/*7
NUDT15*1/*3

0.02
0.005

6-MP (2B)

SLCO1B1*1B/*1B
UGT1A1*1/*6
UGT1A4*1/*3B

0.07
0.01
0.21

Pravastatin (2A)
Irinotecan (2A)
Lamotrigine (2B)

Bupropion, hydroxybupropion (2A)
Efavirenz (1A)
Ibuprofen (2A)
Phenytoin(1A), Warfarin (1A) Acenocoumarol (2A)
Tenoxicam (1A), Flurbiprofen (1A), Ibuprofen (1A)
Phenytoin(1A), Warfarin (1A) Acenocoumarol (2A)
Tenoxicam (1A), Flurbiprofen (1A), Ibuprofen (1A), Meloxicam
(1A)
Clopidogrel (1A), Citalopram, escitalopram (1A) Amitriptyline
(1A) Sertraline (1A) Doxepin (1A) Clomipramine (1A)
Trimipramine (1A) Clobazam (2A) Voriconazole (1A)
Lansoprazole (1A) Pantoprazole (1A) Dexlansoprazole (1A)
Omeprazole (1A), Rabeprazole (2A) Aspirin (2A)
Paroxetine (1A) , Fluvoxamine (1A)
Paroxetine (1A)
Paroxetine (1A), Nortriptyline (1A), Fluvoxamine (1A)
Tamoxifen (1A), Atomoxetine (1A), Tramadol (1A)
Propafenone (2A), Desipramine (2A), Venlafaxine (2A)
Tolterodine (2A), Metoprolol (2A), Flecainide (2A), Risperidone
(2A)
Isoniazid (2A)
Hydralazine (2A)

UGT1A4*3B/*3B
0.01
Freq; frequency in the current study, 6-MP; 6-mercaptopurine. 1 Clinical associations with the highest
level of evidence (level 1 and 2) are only listed here

2.3.6 ClinVar and PharmGKB Clinical Annotations
Thorough filtration of the retrieved variants based on ClinVar database
significance annotations highlighted 28 SNPs designated with a “drug response”
annotation. These include four NAT2 SNPs, three in CYP2C9 and CYP2B6, two
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in ABCB1 and CYP2C19, and one SNP in each of ABCC4, ABCG2, CES1, CYP2C8,
CYP4F2, CYP2A6, DPYD, GSTP1, NUDT15, SLCO1B1, TPMT, UGT1A1, UGT1A4,
and VKORC1.
Next, all the variants were filtered according to their clinical annotation in
PharmGKB clinical annotations, in which only annotations with a level of evidence ≥
level 3 were considered. The filtration resulted in 99 SNPs with a minimum of one
significant clinical annotation. Amongst these, 20 variants (besides the haplotypes
critical variants in the previous section) had annotations within the four highest levels
of evidence 1A, 1B, 2A, and 2B. Table 6 lists these SNPs, their associated drugs and
type of association in PharmGKB, and their frequencies in the current sample.

Table 6: Detected SNPs with significant PharmGKB annotations
Gene

Variant

Type of interaction

Drug

SLCO1B1
NUDT15

rs4149056
rs116855232

DPYD
CYP2C9

rs115232898
rs1799853

Toxicity, ADR
Dosage
Toxicity/ADR
Toxicity/ADR
Dosage

Simvastatin
Azathioprine,
6-Mercaptopurine
Fluorouracil
Warfarin

CYP4F2

rs1057910
rs2108622

Dosage
Dosage

CYP2B6
ABCB1

rs3745274
rs1045642

Dosage
Toxicity/ADR

rs2032582

Efficacy
Dosage
Other
Efficacy

ABCC4
ABCG2

rs1751034
rs2231142

CES1
CYP2C8

rs71647871
rs10509681

CYP4F2

rs2108622

Metabolism/PK
Efficacy
Dosage, Efficacy
Efficacy
Efficacy, Toxicity/ADR,
Metabolism/PK
Dosage
Dosage

Evidence
level
1A
1A

AF
0.187
0.005

1A
1A

0.005
0.11

Warfarin
Warfarin

1A
1A

0.07
0.46

Efavirenz
Methotrexate,
Nevirapine
Ondansetron
Fentanyl
Digoxin
Simvastatin,
Ondansetron
Tenofovir
Rosuvastatin
Allopurinol
Clopidogrel
Rosiglitazone

1B
2A

0.31
0.6

2A

0.6

2A
2A

0.83
0.061

2A
2A

0.02
0.14

Phenprocoumon
Acenocoumarol

2A

0.46
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Table 6: Detected SNPs with significant PharmGKB annotations (Continued)
Gene

Variant

Type of interaction

Drug

CYP2B6

rs2279343
rs3745274

Metabolism/PK
Other

Efavirenz
Nevirapine

Toxicity/ADR
Dosage
Other
Metabolism/PK
Toxicity/ADR
Dosage, Toxicity/ADR
Toxicity/ADR

Efavirenz
Methadone
Nevirapine
Efavirenz
Nevirapine
Warfarin
NSAIDs, Celecoxib,
Diclofenac
Celecoxib
Acenocoumarol,
Warfarin
Acenocoumarol

rs28399499

CYP2C9

rs7900194
rs1057910

Dosage
Toxicity/ADR
Dosage, Toxicity/ADR
CYP2C19

rs4244285

Other
Metabolism/PK

UGT1A1

rs4148323

SLCO1B1

rs4149056

NAT2

GSTP1

rs1799930

Efficacy /Toxicity/ADR
Other
Other
Toxicity/ADR
Other
Metabolism/PK
Toxicity/ADR,
Metabolism/PK

rs1041983

Toxicity/ADR

rs1695

Toxicity/ADR
Efficacy
Efficacy, Toxicity/ADR

VKORC1
CES1
SLC28A3

rs61742245
rs71647871
rs7853758

Toxicity/ADR
Dosage
Efficacy
Toxicity/ADR

Imipramine,
Clomipramine
Citalopram,
Escitalopram
Aspirin, Clopidogrel
SN-38
Irinotecan
Cerivastatin
Rosuvastatin
Simvastatin acid
Ethambutol,
Isoniazid,
Pyrazinamide,
Rifampin
Ethambutol,
Isoniazid,
Pyrazinamide,
Rifampin
Platinum
compounds
Fluorouracil,
Oxaliplatin
Cyclophosphamide,
Epirubicin
Cisplatin
Warfarin
Clopidogrel
Anthracyclines

Evidence
level
2A
2A

AF
0.059
0.31

2A
2A
2B
2A
2A

0.01

2A

0.15

2A

0.005

2A

0.187

2B
2A

0.32

0.02
0.07

0.33

2A

0.316

2B
2A
2B
2B

0.005
0.02
0.11

UGT1A4
rs2011425
Other
Lamotrigine
2B
0.12
AF; allele frequency, ADR; adverse drug reaction, NSAIDs; non-steroidal anti-inflammatory agents
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2.3.7 Summary of the Retrieved Variants in Different Gene Families
To summarize the findings, the counts of retrieved variants, their distribution
on functional classes, the counts of clinically significant variants, and the counts of
novel variants are summarized under each gene group in Table 7.

Table 7: Summary of the retrieved variants
Gene
family
(no. of
genes)

Total
SNPs
count

ABC (8)
CYP (30)
SLC (29)
UGT
(10)
SULT (4)
FMO (5)
CES (2)
NAT (2)
GST (4)
DPYD
(1)
NUDT
(2)
POR (1)
VKORC1
(1)
TPMT
(1)
Total

192
417
324
130

Functional Classes

Syn.

SNPs with a
PharmGKB significant
annotations
Total L1 L2 L3

Novel SNPs

D

I

SL

SG

76
141
138
49

Nonsyn.
110
252
166
81

3
11
8
-

6
4
-

6
-

3
1
8
-

9
29
27
13

0
6
1
0

4
6
1
2

5
17
25
11

48
107
87
43

Delt
.
26
46
34
10

37
59
38
24
15
14

16
14
12
9
2
2

20
37
26
13
11
11

3
1
1
-

1
-

1
-

1
4
1

2
3
2
4
2
3

0
0
0
0
0
1

0
1
1
1
1
0

2
2
1
3
1
2

6
12
8
8
5
4

1
4
5
2
2
4

9

4

5

-

-

-

-

1

1

3

2

6
2

1

3
1

2
-

1
-

-

-

1
2

0
0

0
1

1
1

6
2

2
1

2

-

1

-

-

-

1

1

1

0

0

2

2

341

141

1243

99

Total

ABC; ATP-Binding Cassette transporters, CYP; Cytochrome P450, SLC; Solute Carriers, UGT; uridine
diphosphate glucuronosyltransferase, SULT; Human cytosolic sulfotransferase, FMO; Flavin
monooxygenase, CES; Carboxylases, NAT; N-acetyl Transferases, GST; Glutathione transferases,
DPYD; Dihydropyrimidine dehydrogenase, NUDT; Nucleoside diphosphate-linked moiety, POR;
Cytochrome P-450 reductase, VKORC1; Vitamin K epoxide reductase, TPMT; Thiopurine Smethyltransferase, Syn; synonymous, Non-Syn; non-synonymous, D; deletion, I; insertion, SL; startloss, SG; stop gain, L1, L2, L3 =levels of evidence according to the PharmGKB clinical annotations.
CADD; Combined Annotation Dependent Depletion, Delt; deleterious.
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2.3.8 In-silico Predictions of Clinically Actionable Pharmacogenetic Variants
To demonstrate the inconsistencies between in silico tools predictions and the
reported effects of actionable variants, the in silico effect predictions of 18 nonsynonymous variants with significant PharmGKB annotations were compared. Table
8 illustrates the in silico predictions of the selected variants form different tools, and
the CADD scores. The percentage of tolerated or neutral variants from the total
predictions of each tool is shown. All in silico tools classified almost 50% of these
variants as tolerated or of low effect. The CADD_phred scores below 20, which refer
to the low probability of variant effect on the protein, was given to 8 variants (42%).

Table 8: Demonstration of the in-silico tools predictions inconsistencies
Gene

Rs_id
dbSNP-147

SIFT

Polyphen

In Silico-tools predictions
LRT MA PROVEAN

SLCO1B1
NUDT15
CYP2C9
CYP2C9
CYP4F2
CYP2B6

rs4149056
rs116855232
rs1799853
rs1057910
rs2108622
rs3745274

D
T
D
D
D
T

D
P
D
B
D
B

N
D
U
U
U
N

M
L
M
L
M
N

MetaLR

CADD

D
N
D
N
D
N

T
T
T
T
T
T

22.9
22.2
29.1
20.4
26.1
0.001

ABCB1

rs2032582

T

B

N

N

N

T

9.437

ABCG2
CES1
CYP2B6

rs2231142
rs71647871
rs2279343

T
D
T

B
D
B

D
D
N

N
H
N

N
D
N

T
T
T

18.2
23.9
0.001

CYP2B6
CYP2B6
CYP2C8

rs3745274
rs28399499
rs10509681

T
D
T

B
D
B

N
D
U

N
H
M

N
D
N

T
T
T

0.001
25.1
0.532

UGT1A1
rs4148323
D
D
.
N
N
T
23.7
NAT2
rs1799930
T
D
D
M
D
T
25.5
GSTP1
rs1695
T
B
N
N
N
T
0.001
VKORC1
rs61742245
T
D
N
M
D
D
25.1
UGT1A4
rs2011425
T
B
.
N
N
T
0.001
Tolerated (%)
57%
47%
47% 52%
57%
89%
42%
SIFT (D; damaging, T; tolerated), Polyphen2 (B; benign, P; probably damaging, D; damaging), LRT
(N; neutral, D; damaging, U; unknown), MA; mutation assessor (L; low impact, N; neutral, M; medium
impact; H; high impact), PROVEAN (D; damaging, N; neutral), Meta_LR (T; tolerated, D; damaging).
In silico tools tolerated, or benign, or neutral predictions of the functionally proven damaging variants
are shaded.
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2.3.9 Comparing Allele Frequencies to Other Populations
Chi-square and Fisher Exact tests were used to compare the MAF of variants
of the highest level of evidence with other populations. The comparison included
variants MAF in the current sample and their MAF in gnomAD eight subpopulations:
African (Af), South Asians (SA), East Asians (ES), Europeans non-Finnish (EnF),
Europeans-Finnish (EF), Ashkenazi Jewish (AJ), Latin and Others. The allele counts
and numbers were retrieved from the gnomAD browser (last accessed 14 Jun 2020).
The allele frequencies were significantly different in some cases and
insignificantly different in others, revealing a unique allelic architecture in the current
population. The statistical test results and p-values are listed in Table 9.

Table 9: Interpopulation comparison of allele frequencies
Gene and
variant ID
ABCB1
rs1045642
ABCB1
rs2032582
ABCC4
rs1751034
ABCG2
rs2231142
CES1
rs71647871
CYP2B6
rs2279343
CYP2B6
rs28399499
CYP2B6
rs3745274
CYP2C19
rs3758581
CYP2C19
rs4244285
CYP2C8
rs10509681
CYP2C9
rs1057910
CYP2C9
rs1799853

UA
E
0.6
0.6
0.8
0.06
0.02
0.06
0.01
0.3
0.08
0.15
0.14
0.07
0.11

Af
0.799
(< 10-5)
0.916
(< 10-5)
0.74
(0.007)
0.027
(0.007)
0.002
(8*10-3)
0.24
(< 10-5)
0.07
(1*10-4)
0.370
(0.088)
0.012
(< 10-5)
0.178
(0.388)
0.02
(< 10-5)
0.012
(< 10-5)
0.022
(< 10-5)

MAF in GnomAD populations (p-values from Chi2 tests)
SA
EA
EnF
EF
AJ
Latin
0.3952
0.6321
0.4663
0.386
0.6441
0.548
(< 10-5) (0.3468)
(0.003) (< 10-5) (0.197)
(0.193)
0.3494
0.4765
0.547
0.469
0.6247
0.548
(< 10-5)
(0 .001)
(0.195)
(0.06)
(0.477)
(0.201)
0.9062
0.787
0.817
0.843
0.743
0.74
(0.002)
(0.208)
(0.82)
(0.571) (0.011)
(0.009)
0.093
0.307
0.1036
0.073
0.0653
0.224
(0.157)
(< 10-5)
(0.067)
(0.630) (0.933)
(< 10-5)
0.0061
0.0001
0.015
0.012
0.026
0.007
(0.034)
(< 10-5)
(0.54)
(0.299) (0.821)
(0.052)
0.2516
0.155
0.107
0.101
0.1536
0.170
(< 10-5)
(4*10-4)
(0.046)
(0.075) (5*10-4) (8*10-6)
0.0001
0
0.0001
0
0
0.003
(0.008)
(NA)
(0.0005)
(NA)
(NA)
(0.156)
0.3894
0.1908
0.240
0.191
0.2684
0.31
(0.026)
(3*10-5)
(0.025)
(0.003) (0.218)
(0.96)
0.11
0.037
0.065
0.0559
0.0822
0.037
(0.141)
(0.009)
(0.69)
(0.313) (0.811)
(0.007)
0.324
0.3075
0.146
0.175
0.132
0.101
(< 10-5)
(< 10-5)
(0.93)
(0.440) (0.488)
(0.027)
0.0408
0.0003
0.1134
0.1107
0.0992
0.068
(< 10-5)
(< 10-5)
(0.3656)
(0.30)
(0.108) (2*10-3)
0.109
0.033
0.068
0.063
0.084 (
0.038
(0.103)
(0.007)
(0.99)
(0.747)
0.58)
(0.029)
0.047
0.0004
0.126
0.114
0.135 (
0.068
(5*10-5)
(< 10-5)
(0.561)
(0.933)
0.348)
(0.029)

Other
0.5127
(0.024)
0.5512
(0.23)
0.7974
(0.362)
0.1084
(0.046)
0.0156
(0.553)
0.165
(0.008)
0.0015
(0.046)
0.2607
(0.138)
0.0609
(0.502)
0.1595
(0.842)
0.0993
(0.112)
0.063
(0.751)
0.1035
(0.857)
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Table 9: Interpopulation comparison of allele frequencies (continued)
Gene and
variant ID
CYP4F2
rs2108622
DPYD
rs115232898
GSTP1
rs1695
NAT2
rs1041983
NAT2
rs1799930
NUDT15
rs116855232
SLC28A3
rs7853758
SLCO1B1
rs4149056
UGT1A1
rs4148323
UGT1A4
rs2011425

UA
E
0.46
0.00
5
0.31
6
0.33
3
0.31
5
0.00
5
0.11
1
0.18
7
0.00
5
0.11
7

Af
0.09
(< 10-5)
0.02
(0.137)
0.448
(3*10-4)
0.451
(0.001)
0.257
(0.077)
0.001
(0.512)
0.311
(< 10-5)
0.03
(< 10-5)
7*10-4
(0.14)
0.099
(0.482)

MAF in GnomAD populations (p-values from Chi2 tests)
SA
EA
EnF
EF
AJ
Latin
0.398
0.249
0.287
0.196
0.346
0.229
(0.093)
(< 10-5)
(< 10-5) (< 10-5) (0.001)
(< 10-5)
-6
-4
3*10
0.00005
4*10
0
0
0.0008
(0.013)
(0.02)
(0.01)
(NA)
(NA)
(0.146)
0.287
0.177
0.333
0.27
0.2143
0.5175
(0.411)
(< 10-5)
(0.681)
(0.177) (0.008)
(< 10-5)
0.428
0.419
0.314
0.27
0.37
0.304
(0.009)
(0.02)
(0.607)
(0.07)
(0.29)
(0.414)
0.362
0.258
0.288
0.238
0.35
0.156
(0.189)
(0.08)
(0.45)
(0.013) (0.278)
(< 10-5)
0.067
0.1048
0.0035
0.023
0.004
0.06
(0.009)
(< 10-5)
(0.8)
(0.15)
(0.772)
(0.002)
0.127
0.151
0.137
0.07
0.2132
0.1995
(0.59)
(0.145)
(0.341)
(0.02)
(0.006)
(0.003)
0.05
0.13
0.159
0.21
0.179
0.112
(< 10-5)
(0.01)
(0.327)
(0.43)
(0.87)
(0.001)
0.02
0.153
0.002
0.05
0.005
0.024
(0.193)
(< 10-5)
(0.33)
(< 10-5)
(1)
(0.098)
0.1955
0.208
0.088
0.053
0.1045
0.1243
(0.008)
(0.002)
(0.18)
(10-4)
(0.641)
(0.852)

Other
0.29
(< 10-5)
0.002
(0.299)
0.3348
(0.643)
0.328
(0.940)
0.276
(0.252)
0.021
(0.202)
0.156
(0.101)
0.165
(0.471)
0.012
(0.732)
0.1024
(0.576)

Af;African, AJ; Ashkenazi Jewish, EA; East Asians, EnF; European non-Finnish, EF; European
Finnish, SA; South Asia, UAE; Frequencies in the current study, MAf; minor allele frequencies. Cells
with significant p-value are shaded.

Additionally, the MAF of the 99 PharmGKB clinically annotated variants,
were plotted against the MAF in the same eight gnomAD subpopulations and against
frequencies in the “Greater Middle East Genome” (GME) project [100] (last accessed
14 Jun 2020), referred here as GME_all (n=2497). The results are depicted in a
heatmap with a dendrogram (Figure 6).
The clustering through the dendrogram illustrates that the current sample
(UAE) clustered closest to gnomAD South Asia (Sou_As), and the GME (GME_all)
populations.
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Figure 6: Heatmap for comparison of MAF in UAE to 10 other populations.
Top right: color scale according to allele frequency. Afr; African, Eas_As; East Asians, GME-all; Greater
Middle East whole sample, UAE; Frequencies in the current study. Sou_As; South Asia,
Eur_Fin=European Finnish, Ash_Jew; Ashkenazi Jewish, GnomAD_All; Frequencies from GnomAD
whole samples
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2.3.10 Evaluation of the Generated Recommendations from CPIC guidelines
A thorough revision of CPIC guidelines with the 100 healthy individuals’
sequencing results revealed that 93% of the assessed individuals had at least one
genotype or haplotype that affects at least one medication. Although the limitation in
panel design excluded some pharmacogenes and excluded the non-coding regions of
the sequenced genes, the applied approach for testing healthy individuals from this
population has the power to detect significant and clinically relevant dosing
recommendations. The affected drug classes and the number of individuals with
pharmacogenomic-guided recommendations are listed in Table 10.

Table 10: Drug classes affected by the detected variants
Drug Class

Drug name

Number of individuals with
a pharmacogenomic-based
dosing recommendation

Cardiovascular
Drugs

Clopidogrel
Simvastatin
Warfarin
5-Fluro uracil, Capecitabine
Tamoxifen
6-Mercaptopurine, Thioguanine
Amitriptyline, Nortriptyline, Clomipramine,
Imipramine, Trimipramine, Desipramine,
Doxepin
Escitalopram, Citalopram, Sertraline,
Fluvoxamine, Paroxetine
Codeine
Phenytoin
Atomoxetine
Tacrolimus
Azathioprine
Voriconazole
Atazanavir
Celecoxib, Flurbiprofen, Ibuprofen,
Lornoxicam, Meloxicam, Piroxicam,
Tenoxicam

29
34
85
1
6
2
5

Cancer Drugs

Psychotropic
drugs
(Antidepressants)
Narcotics
Anticonvulsants
Anti ADHD
Immunosuppressants
Anti-fungals
Anti-viral agents
NSAIDs/
Analgesics

1
5
36
7
6
1
1
1
17

ADHD; Attention deficit hyperactivity disorder, NSAIDs; non-steroidal anti-inflammatory drugs.
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2.4. Discussion (100 PGx Resequencing)
2.4.1 General Overview of the Results
The current study is one of the very few pharmacogenomics studies from the
Middle East region, covering this number of pharmacogenes at several analytical
levels. The clinical actionability of the variants and the probable clinical implications
have been emphasized. The applied analysis covered the MAFs, the star alleles, and
the common diplotypes and compared these with other populations. Herein, the
spectrum of variation in pharmacogenes has been illustrated for the first time in a
sample from the UAE.
The analysis showed that more than 60% of the detected variants were rare,
which is an observation repeatedly reported from population studies examining
pharmacogenes through NGS [58, 59]. Prominently, a high percentage of these rare
variants were novel and not reported in the public databases. Rare variants are known
to be abundant (one variant every 17 bases) and tend to become private to one
population [10]. One recent study found that 30% to 40% of drug response variation
can be attributed to rare variants [7]. Moreover, delineating the rare and populationspecific pharmacogenomic polymorphisms would underscore the deficiencies in the
popular genotyping platforms originating from disparities in the coverage of global
populations [101].
Besides extracting data related to single variants, haplotypes composed of
multiple variants have been analyzed through the novel bioinformatics tool, Stargazer.
Released in 2018, Stargazer has been one of the few available tools dedicated to
pharmacogenes and their important, though complex, star alleles nomenclature [88].
Due to the limited number of publications, the Stargazer called haplotypes were
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reviewed manually for confirmation. The called alleles were in concordance with the
star alleles annotations in PharmGKB and PharmVar. A limited number of significant
star alleles were not called correctly. However, these errors originate mainly from
excluding genomic regions with key variants from the targeted sequences. For
example, CYP2C19*17 is determined by two SNPs; rs3758581, reported with MAF=
0.075, and rs12248560, which locates in the 5’-flanking region of the gene and is not
targeted by the used panel here. Accordingly, carriers of rs3758581 might be carriers
of the non-functional haplotype CYP2C19*17, though this needs further testing of the
other variant. Indeed, a considerable number of actionable pharmacogenomic
haplotypes are determined by SNPs in the intronic and gene flanking regions.
Accordingly, covering these variants should be considered during the early stages of
the pharmacogenomics study design. Despite this limitation, a list of star alleles has
been curated and become available for future research.
The variability in the in silico tools’ predictions of variants’ effects is not
surprising. It can be partially explained by the fact that many pharmacogenomic
actionable SNPs are classified as synonymous variants, which are usually assumed to
have minimal effects, and their consequences are not detected by the standard
prediction tools [102]. Indeed, the interpretation of any novel variant requires
functional studies in expression systems. However, this is not feasible with the
overwhelming number of variants detected through NGS [103]. Thus, computational
methods are necessary, but their limitations should be kept in mind. Prediction tools
depend on algorithms that utilize proteins’ secondary structures, proteins’ stability, or
the sequence conservation across species. Pharmacogenes were found to be under
lower evolutionary conservation, making the sequence conservation a piece of
unreliable information for pharmacogenomic variants’ predictions. Moreover,
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computerized tools are trained on disease-causing variants, and they are not ideally
calibrated for pharmacogenomic variation [104].
Zhou and colleagues have recently compared the performance of different in
silico algorithms for pharmacogenomics variants’ effect prediction. CADD scores
were amongst the best tools to predict pathogenicity [104]. Accordingly, the detected
novel variants with the CADD scores > 20 were denoted as likely pathogenic novel
variants. However, in the same paper the authors described the need to develop
methods optimized for detecting pharmacogenetic variants functionality rather than
pathogenicity [104]. Meanwhile, pharmacogenomic studies outcomes should be
compared to the latest evidence curated in public archives and databases such as
ClinVar and PharmGKB.
ClinVar is a database that archives human variants and annotates a ClinVar
class or category [39]. ClinVar uses the general term “drug response” to describe
variants proven to affect drug response, although adding more specific
pharmacogenomic terms is anticipated based on the CPIC recommendations. All the
SNPs reported to be in the Clinvar drug response class from the current group were
further retrieved in PharmGKB clinical annotations.
PharmGKB, curates knowledge about pharmacogenetic variation and its
impact on drug response. In its clinical annotations, PharmGKB classifies variant-drug
pairs according to the supporting evidence strength into levels, as described earlier. In
the current group, the retrieved variants were filtered for the first three levels only. The
outcomes of this analysis are discussed in the following sections classified according
to genes groups.
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2.4.2 Findings in Each Gene Family
ABC genes
ATP-binding cassette (ABC) transporter genes function in the transportation
of endogenous and exogenous molecules, including drugs. The ABC genes variants’
associations with drugs’ PK and PD resulted in some PharmGKB level-2 clinical
annotations. Even though the accumulated evidence was not strong enough to lead to
any regulatory body dosing recommendations [105].
ABCB1 harbors most of the PharmGKB clinical annotations from the ABC
group of genes. In the current Emirati group, the minor alleles at the three most studied
SNPs in ABCB1, rs1045642, rs2032582, and rs1128503, were detected with high
frequencies (MAF = 0.596, 0.597, 0.566 respectively). A haplotype comprised of the
three SNPs has been defined and studied in different ethnicities, given the high LD
between them [106]. In the current group, a haplotype consisted of the alternative allele
at the three SNPs was the haplotype, with the highest frequency of 52.3%. Recurrent
studies reported ABCB1 haplotypes’ association with simvastatin toxicity. However,
this data is not significant enough to support clinical utilization [105]. Meanwhile,
association studies categorized rs1045642 and rs2032582 in a level-2 clinical
association with five important agents: methotrexate, ondansetron, fentanyl, digoxin,
and nevirapine. As 80% of the participants’ group were carriers of one of these alleles,
this gene can be an important candidate for association studies in the Emirati
population.
Detected variants in other genes from the ABC family include rs2231142
in ABCG2 and rs1751034 in ABCC4. While the former (rs2231142) has a
contradictory data supporting its association with allopurinol and rosuvastatin’s
concentration and response [107], the latter (rs1751034) has moderate evidence
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supporting its association with the anti-HIV drug, tenofovir, clearance. Both are
classified as PharmGKB level-2 clinical annotations.
CYP genes
Cytochrome p-450 (CYP) enzymes catalyze the oxidation reactions of a wide
range of drugs. This group is composed of fifty-seven members. Twelve CYP enzymes
are considered responsible for almost 75% of drugs’ oxidation reaction [108].
In the present study, CYP4F12 carried the largest number of variants in
comparison to other CYP genes. CYP4F12 has been previously described as the most
variable CYP gene [53]. CYP2D6 was the second most polymorphic gene, and eleven
of its SNPs were key markers in clinically actionable haplotypes.
Significantly, the highest number of clinically actionable variants in the current
Emirati individuals are located in CYP genes group. Low or non-functional alleles with
level-1 clinical evidence were reported at the important pharmacogenes CYP2A6,
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP4F2.
Seventy-two individuals carried an alternative allele at rs2108622, also known
as CYP4F2*3. Out of these, 18 individuals were homozygous to the alternative allele.
The resulting MAF (0.459) is significantly higher than all other gnomAD populations
except for south Asia (as illustrated in Table 9). Individuals carrying this variant
require higher warfarin doses to achieve the target international normalized ratio (INR)
in comparison to wild type carriers.
CYP2C9 is another CYP gene known to affect warfarin dose. In the current
group, 30 individuals carried one of its low-function alleles (CYP2C9*2 or *3), while
three other individuals were homozygous carriers of these alleles. CYP2C9*2 or *3
carriers are vulnerable to an increased risk of warfarin-induced bleeding.
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Indeed, as described elsewhere, the three genes, CYP4F2, CYP2C9,
and VKORC1, have well-studied genetic biomarkers of warfarin dose and wellestablished dose adjustment algorithms. However, these algorithms showed unequal
performance for different races, suggesting the need to re-evaluate these algorithms in
diverse populations [109].
CYP2D6 is one of the most important pharmacogenes metabolizing around
25% of the commonly prescribed drugs [110]. Two intermediate function alleles were
detected in the current group; CYP2D6*2 and CYP2D6*10. The latter is known to
interact with many medications, including antidepressants, breast cancer drug
tamoxifen, and to form a contraindication of tramadol use. Two individuals carry
the CYP2D6*10/*10 diplotype, making them vulnerable to its various drug
interactions. Despite the numerous studies published about CYP2D6, few of these
originated from Arab populations. In the UAE, a single study examined the alleles and
haplotypes of CYP2D6 in 151 UAE citizens [75]. Comparison of the CYP2D6 alleles
frequencies between the two Emirati groups, there was no significant difference
(p=0.72) between the reference CYP2D6*1 allele count in this group (37.5%) and the
previous one (39.1%). However, in contrast to Qumsieh and colleagues’
findings, CYP2D6*41, was not detected in the current group while it was the most
common low-function allele (15.2%) in the older Emirati group. CYP2D6*41 is
comprised of three SNPs; two exonic (rs16947 and rs1135840) and one intronic
(rs28371725). The alternative alleles at the former SNPs were present in this sample
(MAF = 0.57 and 0.45, respectively). However, the latter intronic SNP was not covered
in the panel design. Hence, it is not possible to exclude the existence of CYP2D6*41
allele carriers among the current group. One recent review of CYP2D6 alleles in
different Middle Eastern populations from Saudi Arabia, UAE, Egypt, Iran, Jordan,
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Syria and Turkey, CYP2D6*41 and CYP2D6*4 were the most common reduced and
no-function function allele, respectively [111].
In contrast to the heterogeneity of CYP2D6, all participants in the current study
carried the ancestral allele of CYP1A2 (i.e., CYP1A2*2), in concordance with a
previous study on Emirati volunteers, where CYP1A2*2 allele was present in 90.5%
of the participants [78].
CYP2C19 metabolizes a wide range of drugs, including clopidogrel,
imipramine, and phenytoin [112]. In the current group, CYP2C19*2 allele was highly
prevalent as it was carried by 28 individuals, which is consistent with its high
prevalence in Middle Eastern populations [113]. Clopidogrel-CYP2C19*2 association
has been demonstrated in several studies and prompted a CPIC recommendation of
replacing clopidogrel by an alternative agent for CYP2C19*2 carriers. The same allele
interacts with many antidepressants, of which some are substrates to CYP2D6 at the
same time. The effect of carrying the no-activity alleles at both genes on
antidepressants warrants further evaluation. There are a limited number of studies that
evaluated CYP2C19 impaired activity alleles in participants other than Caucasians
[112, 113, 114, 115].
Another critical interaction of CYP2C19 alleles is with proton pump inhibitors
(PPIs). Individuals with intermediate or no-function CYP2C19 alleles are
recommended to start with a normal dose of the first generation PPIs to achieve the
highest concentration of the active PPIs, though the dose should be decreased later by
50% to avoid the probable long PPI’s toxic effects [116].
SLC and SLCO genes
Solute carriers (SLC) are membrane transporters that carry a plethora of
organic

and

inorganic

substrates

across

the

cell

membrane,

including
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drugs. SLC variants of pharmacogenomic significance are highly differentiated
between populations, with some interpopulation differences reaching up to five folds
[54]. A single actionable variant was detected from this family, which is rs7853758 in
SLC28A3. The alternative allele, occurring at MAF=0.11 in the current group, is
associated with anthracycline-induced cardiotoxicity, a severe adverse event that
limits anthracyclines' use and results in substantial morbidities and mortalities among
cancer survivors [117]
SLCO is a closely related family of organic anion transporter proteins, with 11
members. In the current panel, SLCO1B1, SLCO1B3, and SLCO2B1 were targeted.
Among pharmacogenomic variants, rs4149056 in SLCO1B1 is an extensively studied
SNP, specifically in relation to simvastatin clearance and induced myopathy [118].
This variant was present in the current group with a significantly higher (p<0.05)
frequency than South Asians, East Asians, Latino, and African populations.
Rs2306283, also known as SLCO1B1*1B, is another variant in the same gene that was
carried by seven homozygous individuals. Earlier studies have shown that both
variants can partially explain the inter-ethnic differences in statin exposure and adverse
effects [118]. The high frequencies of these variants in the current population suggests
SLCO1B1 as a strong candidate for association studies in UAE.
UGT genes
The uridine diphosphate glucuronosyltransferase (UGT) enzymes catalyze the
glucuronidation of various compounds, preparing them for elimination. The numerous
substrates of UGT enzymes made them the subject of several pharmacogenetic studies
[119]. Two variants in UGT genes with a level-2 evidence clinical annotation were
detected in the current group. These are rs4148323 in UGT1A1 and rs2011425
in UGT1A4, also known as UGT1A4*3B. The first SNP has shown an association with
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irinotecan-induced toxicities with conflicting evidence [119]. Similarly, inconsistent
evidence supports an association between UGTA4 and lamotrigine, requiring further
confirmatory studies [120].
SULT genes
Human cytosolic sulfotransferase (SULT) enzymes act on the sulfate
conjugation of multiple compounds [121]. Two PhramGKB annotated variants were
detected in the four SULT genes targeted in the current study. Rs1042028 in SULT1A1,
detected in a relatively high frequency (MAF=0.199) in the current group, is known to
be active in the biotransformation of procarcinogens [121]. Due to its suggested
importance in carcinogenesis, SULT1A1 forms a probable candidate for studying in
UAE population were escalating rates of cancer are reported [122].
FMO genes
Flavin monooxygenase (FMO) oxidizes morphine, tamoxifen, imipramine, and
many drugs. The FMO enzymes activity resembles CYP-450s’ activity. However, it is
a smaller group of enzymes with only five members, rarely studied [123]. Three
variants (rs2266780, rs1736557, and rs2266782) were detected in FMO3, the most
important and studied member of this family [123] but has never been studied before
in any Arab population.
CES genes
Carboxylesterases (CES) are involved in the metabolic transformation of
essential drugs such as anticoagulants, antihyperlipidemic, chemotherapeutics, and
others. CES are highly polymorphic genes with variable SNPs frequencies among
different ethnicities [124]. Rs71647871 in CES1 was the single variant with a clinical
annotation in PharmGKB in the current group. It is known to be associated with
clopidogrel efficacy and other drugs, but with lower significance. This variant’s
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frequency (MAF=0.02) was significantly higher than its frequency in South and East
Asians and Africans. CES1 is relatively understudied compared to CYP genes, despite
its contribution to multiple drugs’ metabolism [125]. CES1:rs71647871 can be a
suitable candidate for pharmacogenomic studies in the UAE population, given its
relatively high frequency.
NAT genes
N-acetyl transferases (NAT) are key conjugation enzymes for multiple
pharmacological and environmental compounds. The acetylation phenotype (i.e.,
slow, intermediate, and fast acetylators) were among the

first studied

pharmacogenomic traits that showed later high variability among different populations
[126]. NAT2 is the most studied pharmacogene in Emiratis, among the handful of
pharmacogenetic studies conducted in this population [74, 77]. 81% of the current
participants were carriers of either one or two of the slow-acetylator alleles (*5,*6 or
*7), an observation which was not significantly different (p=0.506) from a previous
Emirati group results of 74.4% slow-metabolizer alleles rates [77]. Earlier studies have
indicated the high frequency of slow metabolizers amongst different Arab populations
[127, 128]. The predominance of slow acetylators in Arabs is similar to Europeans and
in contrast to East Asian and African populations [129]. There is a strong evidence
supporting the association between NAT2 and isoniazid-induced liver injury during
tuberculosis treatment [126]. However, none of these studies were applied in Arab
populations, despite the fact that tuberculosis is still a significant health problem in
some of these countries [130].
Other than the mentioned alleles, two SNPs in NAT2 were detected; rs1208
and rs1041983 at MAF= 0.526 and 0.33, respectively. Both have been reported to
affect isoniazid and phenytoin metabolism but with level-3 evidence level. The
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relatively high frequency of these alleles and little data about their effect highlights the
importance of studying the whole gene rather than genotyping the common alleles for
future studies in UAE population.
GST genes
Glutathione transferases (GSTs) are multifunctional proteins of three families,
from which the cytosolic family is the most studied in human health and disease.
GSTM1, GSTT1, GSTP1, and GSTA1

are

extensively

studied

polymorphic

pharmacogenes [131]. Only one SNP, rs1695 in GSTP1, was of clinical significance
with multiple level-2 and level-3 annotations, in the current group. The most common
polymorphism in both GSTM1 and GSTT1 is the complete deletion of these genes, i.e.,
null allele [131], which would not be detected through the currently used method.
Rs1695 has been frequently studied as an affecter on multiple tumors’ responses and
outcomes with inconsistent findings [132]. It was detected in a relatively high
frequency (MAF=0.316), suggesting it as a suitable candidate for population studies.
DPYD
Dihydropyrimidine dehydrogenase (DPYD) is the rate-limiting enzyme in the
pyrimidine pathway. It is encoded by the large DPYD gene, known to have around 160
variant alleles described in the literature [133]. There are ten different DPYD variants
annotated in PharmGKB clinical annotations, all with level-1 significant associations
with fluorouracil or/and capecitabin. Indeed, fluorouracil and capecitabine prescribing
guidelines based on DPYD activity have been issued by several societies [133]. One
of these level-1 actionable DPYD variants, rs115232898, was detected in a single
heterozygous carrier in the current group. Four other variants, with level-3 clinical
annotations, were detected in the same gene. These variants are the determining
variants of DPYD*4, DPYD*5, and DPYD*6, besides rs2297595. Interestingly, these
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alleles were detected at similar frequencies in Tunisian and Egyptian populations [134,
135]. The few DPYD studies in Arabs, given its importance, emphasize it for further
sequencing and association studies.
TPMT
Thiopurine S-methyltransferase (TPMT) catalyzes the metabolism of
thiopurines, including 6-MP and azathioprine. None of the TPMT low activity alleles
were detected in the current group. At the same time, two individuals carried one copy
of the intermediate activity alleles, TPMT*8, and TPMT*16, which have a moderate
significance [136]. Some studies have evaluated the frequencies of TPMT star alleles
(mainly *3A and*3B, with *3C in some cases) among Arabs. The participants were
either healthy or pediatric leukemia patients from Egypt, Tunisia, Morocco, Jordan,
and Lebanon [137-141]. The frequencies of low function star alleles were ranging from
zero to 0.0089. However, these studies examined the common TPMT star alleles rather
than the whole gene variants. The utilization of TPMT star alleles suffers from
ignoring rare and novel variants’ impact. In a recent study, Park and colleagues
illustrated that the integration of NGS-resulting common, rare, and novel variants from
both TPMT and NUDT15 is a more reliable predictor of 6-MP dose than the star allele
haplotypes [142].
NUDT
Nucleoside diphosphate-linked moiety X motif 15 (NUDT15) dephosphorylates an active metabolite of thiopurines. The association between NUDT15
variants and 6-MP was found through GWAS studies. Functional and confirmatory
studies proved this association and illustrated an inter-population variability
in NUDT15 variants [143, 144]. Two NUDT15 variants were detected in the current
group, and each was present as a heterozygous allele (MAF=0.005). In contrast to
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rs533746264, the unstudied missense variant, rs116855232 is the key variant of the
low-functional allele NUDT15*3. This allele has a level-1 clinical annotation in
PharmGKB, and a CPIC thiopurine dosing recommendations [145]. Since NUDT15*3
association with 6-MP toxicity was proved, it has been repeatedly investigated and
showed higher frequencies among Asians compared to Europeans [142]. It has been
reported in two studies from the middle east with frequencies of 0.006 and 0.004 [146,
147], which were not significantly different (p>0.05) from the current population.
Given the significance of NUDT15 as a 6-MP dose predictor, it should be considered
for further exploration.
Nudix hydrolase 1 (NUDT1) hydrolyzes oxidized purines and is known for its
important roles in cancer and aging [148]. In the current group, seven SNPs were
detected, but none of them has any published significance.
POR
Cytochrome P-450 reductase (POR) affects the microsomal CYP-450
enzymes’ activities. Many POR polymorphisms have been identified, of which
rs1057868 is the most common one with a frequency of 25% in different populations
[149]. The frequency of the minor allele in the current group was not different from
the global frequency (MAF=0.25). Multiple probable associations of rs1057868 with
numerous drugs have been reported, without enough evidence yet for any clinical
annotation above level 3.
VKORC1
Vitamin K epoxide reductase (VKORC1) is a vital enzyme in the vitamin K
cycle and the known target of warfarin, as discussed earlier. Several studies have
explored variations in VKORC1 in independent populations. This gene has been
studied extensively in the second group in the current study. Here only the coding
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region of the gene was sequenced, and the important promoter SNP, rs9923231, was
not covered. One rare variant, rs61742245, reported in Ashkenazi Jewish, Ethiopians,
and in the Emirati warfarin-users group (i.e. the second group) was also detected in the
current group. rs61742245 has a very low minor allele frequency worldwide and it can
be considered a population-specific variant [150].
2.4.3 Interpopulation Comparisons
The interpopulation comparison of minor alleles frequencies (Table 9),
illustrates that the frequencies were significantly different compared to other
populations. These differences are predictable given the heterogeneity of the UAE
population and its underrepresentation in the global genomic data.
The heatmap, which included more variants than the previously described
comparison, illustrated that the studied population clustered closest to the South Asia
population and furthest from Africans, which is consistent with a previous
phylogenetic study on 109 Emirati individuals [69]. The country's geographical spot,
its substructure, and its high consanguinity rates can partially explain these findings
[69, 70].
The heatmap also illustrated that frequencies from the current UAE sample
were closer to the South East populations than frequencies from the Greater Middle
East (GME) variome project. GME includes populations from the Arabian peninsula,
South and East costs of the Mediterranean, Turkey, Iran, and Pakistan [100]. The
populations included in the GME database illustrate a variegated genetic architecture
owing to their substantial diversity, presence of several ancient founder populations,
high consanguinity rates, and increased runs of homozygosity [151]. Accordingly, any
detected deviations between the current group of Emiratis and the GME is not
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surprising, despite the fact that the UAE population is represented in the GME
database.
Finally, revising the CPIC recommendations revealed that 93% of the
participants would receive at least one genetic-guided dosing guideline, interacting
with 34 drugs from various classes. In one extensive study implementing whole exome
and whole genome data from the 44,000 samples from the Estonian biobank, 99.8%
of all tested individuals had a genotype with a pharmacogenetic recommendation [48].
In comparison, another group used the PGxSeq exome panel in 235 subjects, and 78%
of those received a pharmacogenomic guided dosing guideline [49]. Accordingly, the
detection power of the currently used panel is comparable to other populations and
other panels. Nevertheless, adding few more non-coding regions which harbor
actionable variants, like VKORC1 promotor, would have increased the detection power
of the used panel.
2.4.4 Study Limitations (100 Pharmacogenes Resequencing)
1. In the current study subset, a relatively small number of genomes were
sequenced.
2. Although the samples were collected from Emiratis originating from
different emirates, most of the participants were from the Emirate of Abu Dhabi.
3. The genetic sub-structure was not accounted for in the current study. The
Emirati population is described as highly admixed. Nevertheless, the population's
genetic sub-structure was never described comprehensively in the literature.
4. The sequencing panel targeted the coding regions of pharmacogenes. Some
of the actionable variants lay in the intronic or untranslated regions. This limitation
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has affected the number of inferred haplotypes and alleles in some genes. Adding a
few more regions would have increased the detected actionable variants.
5. Copy number variation was not assessed in the current analysis which
banned inferring relevant alleles in CYP2D6.
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Chapter 3: Pharmacogenetics Application in Cardiovascular Diseases
3.1 Cardiovascular Diseases Pharmacogenetics: Literature Review
Pharmacogenetics research has invested heavily in drugs used for
cardiovascular diseases (CVDs). In the following paragraphs, the pharmacogenetic
research contribution in the management of these diseases are described briefly and
illustrated by examples.
3.1.1 Pharmacogenomics in Cardiovascular Diseases
CVDs are the leading cause of death globally. Coronary heart diseases,
peripheral arterial diseases, rheumatic heart diseases, and other CVDs take almost 17.9
million lives annually [152].
In the UAE, CVDs risk factors including obesity, dyslipidemia, smoking, type
2 diabetes, and others are all reported at higher rates than developed countries. As a
result, the CVDs-associated death rates among the UAE nationals are higher than the
global average. The age-standardized death rates from cardiovascular diseases were
found to exceed 350 cases per 100,000 in 2002, compared to rates ranging between
170 to 210 cases per 100,000 in Germany, Thailand, the US, UK, and Singapore the
same year [153]. More recent data show that the cumulative incidence of acute
congestive heart diseases (CHDs) over nine years in men from the UAE was 8.9%
compared to 4.7% of the crude incidence of acute CHDs over ten years in Europeans.
Accordingly, CVDs can be considered as a significant health threat in UAE [154].
Despite the established benefits of cardiovascular drugs, their narrow
therapeutic indexes and response interindividual differences made them suitable
candidates for pharmacogenomic studies. Pharmacogenomic literature is available for
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a wide range of CVD drugs, though the detected pharmacogenetic evidence is not
equal for different agents. At the top of the list, warfarin and clopidogrel are two
commonly used drugs with recognized benefits but with strictly narrow therapeutic
indexes. Both drugs have been extensively studied pharmacogenetically [19, 21]. A
recent systematic review of pharmacogenetic implementation in cardiovascular care,
warfarin with VKORC1/CYP2C9, and clopidogrel with CYP2C19, were the only genedrug pairs among cardiovascular drugs with a significantly evident cost-effectiveness
proof [155].
In the following sections, the anticoagulant warfarin pharmacogenomics will
be briefly reviewed as a pharmacogenomic implementation model in cardiovascular
diseases.
3.1.2 Warfarin: An Overview
Warfarin remained the mainstay anticoagulant worldwide for more than 60
years. Despite the development of new classes of anticoagulants, warfarin is still the
most popular anticoagulant [24, 156]. Warfarin indications include atrial fibrillation,
deep vein thrombosis, pulmonary embolism, cardiac valve prosthesis, and other
morbidities for prophylaxis and thromboembolism management [157].
Warfarin has a narrow therapeutic window and a wide interindividual
variability. Achieving warfarin maintenance dose is challenging, as low doses will not
be effective in preventing thromboembolism, and high doses will increase bleeding
risk [158]. Conventionally, warfarin dose is titrated through international normalized
ratio (INR) monitoring [159]. However, the process of defining the right warfarin dose
can take weeks [158]. Severe adverse effects of high warfarin doses include bleeding
and hospitalization. Warfarin related adverse events are among the leading causes of
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emergency department visits and emergency hospital admissions in the USA and UK
[27, 160, 161].
New direct oral anticoagulants (DOACs), which do not exhibit a similar
challenging optimization, were developed. These agents with a superior safety profile
have gradually replaced warfarin in many indications [162, 163]. Nevertheless,
warfarin is still used worldwide, which might be due to its lower cost compared to
DOACs, making it the preferred anticoagulant in developing countries. Moreover,
DOACs are contraindicated in some cases like mechanical valve replacement and
kidney failure patients [164].
In one observational study from UAE atrial fibrillation patients prescriptions
from three major hospitals were analyzed, and 60% of patients were found to receive
warfarin as a monotherapy [165]. In contrast, a more recent study found that among
468 newly diagnosed non-valvular atrial fibrillation patients in Dubai (UAE) private
sector hospitals, 14% only received a warfarin prescription [166]. However, no recent
and official data reflects warfarin's actual use versus DOACs in the UAE healthcare
system. The closest estimates could be inferred from a study conducted in a
neighboring country, Qatar. The authors concluded that over five years span following
DOACs introduction to the healthcare system, practitioners showed an increasing
tendency to switch from warfarin into DOACs. Nevertheless, warfarin remained the
most prescribed anticoagulant during the study period [167].
Many factors contribute to interindividual differences in warfarin response.
Drug-drug interactions, food supplements, alcohol consumption, age, and weight can
affect warfarin maintenance doses [168]. In the 1990s, the first reports of genetic
variations affecting warfarin dose emerged [169]. In the following years, genetic
variations proved to explain between 40% to 50% of warfarin dose variability [170].
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Warfarin's initial pharmacogenomics studies assessed genes in the drug
metabolic pathway. CYP2C9, which encodes a major metabolizing enzyme in the
warfarin pathway, was pointed out as a strong candidate. Warfarin is composed of a
racemic mixture of S and R enantiomers, of which the former is the more potent
anticoagulant, and the one mainly metabolized by CYP2C9 [19]. Individuals carrying
the impaired functional CYP2C9 alleles, such as CYP2C9*2 (rs1799853) and
CYP2C9*3 (rs1057910), can be intermediate to poor metabolizers; hence they will
show increased risk of bleeding, and need lower warfarin doses [157]. Nevertheless,
CYP2C9 genotypes were not able to explain all the observed variation in warfarin
maintenance dose. Substantial understanding of warfarin pharmacogenomics was not
attained until 2004, the year in which Vitamin K epoxide reductase, warfarin’s
molecular target, was spotted [19, 169].
Vitamin K epoxide reductase complex subunit 1 (VKORC1) is an enzyme that
catalyzes vitamin K epoxide conversion into a reduced vitamin K, active in clotting
factors formation. Warfarin targets the enzyme encoded by the VKORC1 gene and
exerts its anticoagulant effect in a mechanism that remained ununderstood for decades
[157, 171].
Variations in VKORC1 were investigated and demonstrated an effect on the
enzyme’s availability and activity. Soon, the association between warfarin response
and these SNPs was validated [172], and some variants were associated with partial or
complete warfarin resistance [173]. VKORC1 variants alone were able to explain
approximately 20% to 30% of the variation in warfarin dosing [174]. Rs9923231, also
known as -1639G>A, is the most studied VKORC1 variant. This promotor SNV
abolishes the enzyme activity through interference with the transcription factor binding
site [175].
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Further research, mostly in Caucasians, enabled establishing haplotype maps.
There are two conventional approaches in VKORC1 haplotypes reporting: The H
system [176], and the star system [177]. The H haplotypes are determined by 10 SNPs
(rs9923231,

rs2884737,

rs7196161,

rs2359612,

rs17880887,

rs17881535,

rs17708472, rs9934438, rs8050894, rs7294). H haplotypes are further grouped into
low dose haplotypes (group A), including H1 and H2, and the high dose haplotypes
(group B), including H7, H8, H9 [176]. Alternatively, the star haplotypes are
determined by genotypes at five SNPs (rs9923231, rs9934438, rs7294, rs17708472,
rs2359612,). In the star system, *2 haplotype is associated with low dose warfarin,
while both *3 and *4 alleles are associated with high dose warfarin [177].
Later pharmacogenomic studies utilizing GWAS pointed out CYP4F2 as
another pharmacogene active in warfarin pathways by catalyzing vitamin K
metabolism. [19, 44]. Extensive GWAS indicated another variant located near the
CYP2C gene cluster, rs12777823. However, association studies concluded that the
latter variant associates with warfarin dose variation in African Americans, exclusively
[178].
The contribution of the three genes, CYP2C9, VKORC1, and CYP4F2, in the
genetic components of warfarin dose is unequal. The highest contribution is for
VKORC1, which can maximumly reach 78% of genotype-based dose change, and the
least is for CYP4F2 which reaches a maximum of 11.1%, while CYP2C9 lies inbetween the two percentages [163, 179].
In total, the known and employed genetic variants in the three genes are
recently thought to predict little more than 40% of warfarin dose variability, and more
factors are yet to be uncovered [178]. Figure 7 illustrates the interaction of the three
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genes with warfarin’s mechanism and the effect of genetic, non-genetic, and other
proposed factors on warfarin.

Figure 7: Genetic and non-genetic factors affecting warfarin response.
Reproduced from [178].

3.1.3 Warfarin pharmacogenetic studies
Replication of the preliminary association studies in different ethnicities
suggested that despite some SNPs differ in their ethnic frequencies, they exhibit a
constant effect on warfarin. For example, rs9923231 with a MAF ranging from 0.1 in
African Americans to 0.86 in Asian, is constantly associated with almost two-fold
lower VKORC1 expression. In contrast, the variant rs12777823, which is common in
different ethnicities (MAF = 0.14, 0.25, 0.32, in Europeans, African Americans, and
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Asians, respectively), has an evident impact on warfarin response in African
Americans only [180].
The FDA introduction of a CYP2C9 and VKORC1-guided dosing table in the
warfarin label motivated the warfarin dosing algorithms research. The proposed
algorithms build a regression equation that can calculate warfarin dose individually
depending on clinical factors besides genetic factors. In a large retrospective study
(N=1378), Finkelman and colleagues found that dosing algorithms were significantly
more accurate than the FDA labels [181].
Gage algorithm is a universally used algorithm developed from a derivation
cohort of 1,015 individuals of mixed ethnicities, though 83% were Caucasians. Since
it was introduced and validated in 2008, the Gage algorithm has been freely accessible
online (www.warfarindoising.com) [182]. Soon, the International Warfarin
Pharmacogenetics Consortium introduced its dosing algorithm, IWPC, derived from a
larger cohort of 4,043 individuals (55.5% White, 30.4% Asian, 8,7% black, and 5.6%
mixed) and validated on another cohort of 1009 individuals [183].
At least 19 randomized controlled trials (RCTs) were conducted to evaluate the
benefit of genotype-guided dosing algorithms. The largest two RCTs, the European
Pharmacogenetics of Anticoagulant Therapy EU-PACT [184] and the Clarification of
Optimal Anticoagulation through Genetics (COAG) [185], reported their outcomes in
2013 and displayed contradictory results. While the former identified a significant
benefit of pharmacogenetic-guided dosing on the percent time in the target INR range
(PTTR), the latter found no difference between the two study arms for the same
outcome. However, different dosing algorithms, control arms, blinding protocol, and
patients’ ethnicities were used in both RCTs [178].

67
In 2017, the Genetics Informatics Trial (GIFT) was conducted in a
methodology remarkably similar to COAG; however, it illustrated an improved
pharmacogenetic-guided dosing impact on PTTR, in contrast to COAG [186]. Li and
colleagues compared the three RCTs and listed five key differences that can explain
their contradictory outcomes. Firstly, diverse dosing strategies were used for the
control group (clinical algorithm in GIFT and COAG versus traditional dosing in EUPACT). Secondly, the pharmacogenetic dosing algorithm used in the patients’ arm was
different (Gage algorithm for GIFT and COAG versus IWPC for EU-PACT). Third
factor was the inclusion of CYP4F2*3 in the pharmacogenetic algorithm used for
patients in GIFT only. Fourthly, patients in GIFT had a longer genotype-guided dosing
duration than their counterparts in COAG, which might explain the PTTR
improvement in GIFT but not in COAG. Finally, the less diverse ethnicity in the GIFT
cohort versus COAG cohort (91% Caucasians versus 73% Caucasians and 27%
African American) might explain the algorithm’s better performance when it was
challenged in a population similar to its derivation cohort [178].
Diverse populations exhibit different allele frequencies and genetic variant
effects. As described earlier, most of the literature on genotype-guided warfarin dosing
algorithms and RCTs is from Caucasians. Studies in diverse populations showed a
limited benefit from using these algorithms. One suggested refinement of dosing
algorithms was to add variants that are important across the study population to the
algorithm’s genetic variables. Such an approach was tested in African Americans,
Latino, and Asian populations. Despite the limited studies, race-specific algorithms
improved pharmacogenetic guided warfarin dosing in some populations beyond what
is seen in populations of European ancestry [187].
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3.1.4 Warfarin Pharmacogenetics in UAE and Arab Populations
A limited number of warfarin pharmacogenetics studies were conducted in
Arab populations. In Saudi Arabia, three studies reported the frequencies of rs9923231
in VKORC1, and CYP2C9*2 and *3 alleles and their significant association with
warfarin dose [188-190]. In Kuwait, the same variants were evaluated besides three
additional variants in VKORC1; rs9934438, rs7294 and rs2884737. In the latter study
all studied variants, except rs7294, were associated with warfarin dose [191].
In two separate studies, the whole exome/genome data from Kuwaiti and Qatari
healthy individuals were revisited to extract the frequencies of warfarin interacting
variants. Both studies demonstrated high frequencies of rs2108622 in CYP4F2 and
characterized the allelic distribution of other variants known to interact with warfarin
[191, 192].
One more recent study from Qatar evaluated the effect of CYP2C9*2/*3,
VKORC1 rs9923231, CYP4F2*3, and clinical factors on warfarin dose. Variant in the
first two genes were significant predictors of warfarin dose, in contrast to CYP4F2*3
[193].
The single warfarin-dosing algorithm study in the gulf region comes from
Oman. In their study, Pathare and colleagues included functional variants in VKORC1,
CYP2C9, and CYP4F2, with demographic and clinical variable in a locally developed
model. The algorithm developed from a derivation cohort of 142 patients, and a
validation cohort of 70 patients, performed better than IWPC in predicting warfarin
dose in the study patients. The authors reported that CYP4F2*3 did not show a
significant association with warfarin dose despite its high frequency in the study
population [194].
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One study from UAE reported the genotypes and allele frequencies at VKORC1
rs9923231 and rs7294 in Emiratis [76]. No further data regarding the allele frequencies
or genotypes at any other warfarin related genetic variants are available. Moreover, no
association studies between any genetic or non-genetic factors were conducted in
UAE.
3.1.5 Study Questions and Objectives (Warfarin Group)
To explore the allele frequencies of some actionable variants in VKORC1 and
the common haplotypes, and to investigate if these variables contribute to warfarin
dose.
3.1.6 Hypothesis (Warfarin Group)
Actionable variants in VKORC1 might show frequencies different than global
frequencies. Some variants might explain variability in warfarin maintenance dose.
3.1.7 Primary and Secondary Outcomes (Warfarin Group)
Primary outcomes: VKORC1 variants allele frequencies and genotypes in
comparison to the global genomic databases.
Secondary outcomes: Probable associations between the detected variants and
warfarin maintenance dose.
3.2 Methods (Warfarin Group)
3.2.1 Participants
Participants were recruited from the INR clinic, Tawam hospital, Al-Ain city,
Emirate of Abu Dhabi, UAE. All the participants signed an informed consent form to
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participate in this study. This study was conducted following the ethical approval
(CRD 261-Protocol No. 13/38) granted by Al-Ain medical district social research
ethics committee.
Inclusion criteria: Emirati patients treated with warfarin for more than 2
months and have reached a stabilized dose (dose not varied by more than 10%) for
three consecutive visits.
Exclusion criteria: severe hepatic impairment or malignancy.
3.2.2 Clinical Data
The following data was collected retrospectively from the files of patients
treated with warfarin (n=90):
1- Warfarin stabilized dose: the last dose of warfarin that achieved maintain the
INR within the target range and was consistent for three consecutive clinic
visits.
2- Clinical indication for warfarin.
3- Target INR: as stated by the treating physician.
4- Demographic characters: age and gender.
5- Concomitant medication: patients taking other medications with remarkable
interactions with warfarin (e.g. Amiodaron) were excluded from this study
sample (n = 6).
3.2.3 VKORC1 Genotyping
Genotyping was performed by Sanger sequencing. First, a polymerase chain
reaction (PCR) was used to amplify most of the VKORC1 gene sequence and its
promoter. PCR primers were designed using (https://primer3.ut.ee/), and were custom
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made by Metabion Inc (http://www.metabion.com/). PCR primers sequences and
reaction conditions are listed in Table 11.

Table 11: Primers and PCR conditions used to amplify and sequence most of
VKORC1 sequence
Forward Primer

Reverse Primer

F1GCCAGCAGGAGAGGGAAAT
A
F2GCAGGCACCTGTAGTCCAA
F3TGATCCGCTGGTCTCTAGGT
F5- GTCTGGCTGTGCGTGATG

R1AGTTTGGACTACAGGTGCCT

R2CGCTTACCCTATGCCAAGTC
R3GAGAGCACTAAGCCCGTCAG
R5GCCATAGCGCCCGATTAATT
F6R6AGGCGTTAGCATAATGACGG
GGGTGGAACCAGGTTAGGA
C
F7R7GTCCTAACCTGGTTCCACCC
CCCTCCAAGGGACTGGTCT
F9R9GAATACGTGCGTAAGCCACC
GGTTCAGACTTGGCTGATTG
Ann. Temp; annealing temperature, Ann. Time; annealing time.

Ann.
Temp
(°C)
58

Ann.
Time
(m)
60

Product
Size
(bp)
290

58

60

842

58

60

786

58

45

313

60

60

725

60

60

995

60

45

659

The quality of PCR amplification was checked by electrophoresis on 0.6%
agarose gel before Sanger sequencing. For sequencing, the PCR products were purified
using ExoSAP-IT® (Applied Biosystems, USA) according to the manufacturer’s
protocol, followed by cycle sequencing using the BigDye Terminator kit v3.1 (Applied
Biosystems, USA) under standard conditions. Capillary electrophoresis was
performed in 3130xl Genetic Analyzer (Applied Biosystems, USA).
3.2.4 Sequencing Results Interpretation and Genotype Calling
Chromas (v.2.6.5) program was used for the alignment of resulting
chromtaograms to the reference VKORC1 sequence (ENST00000394975) and for
genotype calling. The chosen variants for genotyping were included SNPs in the star
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system (five SNPs) and three more SNPs that were found to be actionable in some
populations.
3.2.5 Statistical Methods
For descriptive statistics frequencies and percentages were used to describe
categorical data and means with standard deviations for numerical data. Hardy
Weinberg equilibrium was tested by Chi-square test. Minor allele frequencies were
compared to the MAFs for each variant in different populations in the GnomAD
database by Chi-square test.
Analysis of variance (ANOVA) was applied to evaluate the effect of each
VKORC1 polymorphism on the warfarin maintenance dose for variants with normally
distributed genotypes.
Patients were assigned into three groups depending on their warfarin dose;
group 1 included patients with doses ≤ 3 mg/day and (i.e., designated as a low-dose
group). Group 2 comprised patients with doses between 3.1 to 5.9 mg/day (i.e.,
intermediate-dose group), and group 3 included patients with doses ≥ 6 mg/day (i.e.,
high-dose group). Cross-tabulation and Chi-square tests (nonparametric test for
discrete variables) were performed to describe the relation between genotypes and
dose-dependent groups.
Pairwise linkage disequilibrium between the selected SNPs was assessed by
calculating D' and r2. Then haplotypes were constructed based on the selected SNPs
using the SNPStats [195] software.
Multivariant linear regression was used to determine the ability of genetic
factors (VKORC1 genotypes) and non-genetic factors (i.e., age and gender) to predict
warfarin dose.
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All Statistical tests, except linkage disequilibrium and haplotype analysis, were
performed using the statistical software SPSS version 24 (SPSS Inc, US). The
significance level of a two-sided p-value was fixed at p < 0.05.
3.2.6 Contributions
Samples collection, clinical data curation, and DNA extraction were done by
H. AlJaibeji. Sanger sequencing was done by H. AlJaibeji and Z. Almahairi.
3.3 Results (Warfarin Group)
3.3.1 Warfarin Group’s Sample Descriptive
Ninety unrelated patients treated with warfarin with a dose ranged from 0.5 to
15 mg per day (mean 4.7±2.48) to reach a target INR of 2–3. Participants in this group
were 45 females and 45 males with an age range of 21-98 years. The full descriptive
statistics of this group are illustrated in Table 12. Additional 107 samples from healthy
non-warfarin using Emiratis were collected and used as controls for this group.

Table 12: Description of the warfarin group participants
Variable
Gender (%)
Female
Male
Age in year
Mean (SD)
Indication for warfarin therapy
Atrial Fibrillation
Prosthetic heart valve
Deep vein thrombosis
Cardiomyopathy
Hypercoagulable state
Stroke
Pulmonary Embolism
Left ventricular thrombosis
Valve Disease

Value
45 (50)
45 (50)
21-98
60.54 (17.8)
38
26
16
3
2
2
1
1
1
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3.3.2 VKORC1 Genotypes Frequencies
Frequencies of genotypes at the selected genotyped variants in both patients
and control groups were calculated. A Chi-square test to test for differences in
genotypes counts in both groups. There were no significant differences in genotypes
at the selected VKORC1 variants between the patients and control groups at
significance level 0.05. The counts of some genotypes at 3 SNPs were less than 5,
accordingly, the Chi-square test was not feasible at these three SNPs. The genotypes
and Chi-square p-values are listed in Table 13, which illustrates also that there were
no significant differences in genotype frequencies between both groups.

Table 13: Retrieved genotypes from warfarin-patient and control groups
VKORC1 SNP

Genotype

Patients count (%)

Controls count (%)

X2 p-value

rs9923231

GG
GA
AA
GG
GT
TT
AA
AG
CC
CT
TT
CC
CT
TT
GG
GC
CC
CC
CT
TT
GG
GA
AA

22 (24.4%)
43 (47.8%)
25 (27.8%)
86 (95.6%)
2 (2.2%)
2 (2.2%)
89 (98.9%)
1 (1.0%)
76 (84.4%)
13 (14.4%)
1 (1.1%)
22 (24.4%)
43 (47.8%)
25 (27.8%)
21 (26.7%)
45 (50.0%)
24 (23.3%)
19 (21.1%)
47 (52.2%)
24 (26.7%)
39 (43.3%)
43 (47.8%)
8 (8.9%)

30 (25.6%)
58 (49.6%)
29 (24.8%)
114 (97.4%)
3 (2.6%)
0
115 (98.3%)
2 (1.7%)
117 (100%)
0
0
30 (25.6%)
56 (47.9%)
31 (26.5%)
29 (24.8%)
55 (47.0%)
33 (28.2%)
27 (23.1%)
59 (50.4%)
31 (26.5%)
54 (46.2%)
46 (39.3%)
17 (14.5%)

0.8882

rs61742245

rs188009042
rs17708472

rs9934438

rs8050894

rs2359612

rs7294

NA

NA
NA

0.9704

0.9128

0.9413

0.3202
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Allele frequencies at five SNPs (rs9923231, rs9934438, rs8050894,
rs2359612, rs7294) were consistent with Hardy Weinberg equilibrium. The minor
allele frequencies at (rs61742245, rs188009042, rs17708472) were too small; hence,
HW equilibrium at these variants could not be assessed.
3.3.3 VKORC1 Variants Frequencies Compared to Other Populations
The total frequencies (patients and controls) of minor alleles at the selected
SNPs were calculated and compared to the MAF in gnomAD populations (Table 14).
The MAFs in this population were not consistent with the reported frequencies from
any other gnomAD population. However, the frequencies were comparable at some
variants to their reported frequencies in Ashkenazi Jewish. Noteworthy, the
frequencies of South Asian populations were missing for most of the studied SNPs.

Table 14: Comparison of VKORC1 SNPs frequencies to other populations
Variant

UAE

GnomAD

MAF at gnomAD subpopulations
p-value from Chi-square test
AJ
Lat
EF
EnF
0.48
0.44
0.39
0.37
0.49
0.05
<10-5
<10-5
0.03
0.002 0.0001 0.0006
0.108 <10-5 <10-5
<10-5
0
0
0
0

SA
EA
Afr
0.326c
NA
0.89
0.1
<10-5
<10-5
<10-5
rs61742245 0.022
0.002
0.001
0
0.00005
<10-5
<10-5
<10-5
rs188009042 0.01
0.0009
NA
0.017
0
0.0069
0.175
rs17708472 0.083
0.168
NA
0.001
0.15
0.127 0.229
0.023
0.06
-5
-5
-5
-5
-5
-5
<10
<10
<10
<10
<10
<10
<10-5
rs9934438
0.52
0.326
NA
0.899 0.475
0.44
0.39
0.37
0.1
<10-5
<10-5 0.496 0.050 <10-5
<10-5
<10-5
rs8050894
0.52
0.37
NA
0.897 0.472 0.466
0.39
0.37
0.39
0.525
<10-5 o.278 0.099 <10-5
<10-5
<10-5
rs2359612
0.53
0.643
NA
0.1
0.52
0.54
0.61
0.63
0.79
-5
-5
-5
-5
<10
<10
0.967 0.452 <10
<10
<10-5
rs7294
0.328
0.39
NA
0.101 0.328 0.393 0.381
0.394
0.4554
0.016
<10-5
0.88
0.053 0.078
0.013
<10-5
UAE; MAF in the current study (Patients & controls), GnomAD; MAF in all GnomAD populations and
in each sub-population. c. The upper number represents the MAF d. The lower number represents pvalue. Cells with significant p-values (<0.05) are shaded. NA=data not available. GnomAD; The
Genome Aggregation Database, SA; South Asia, EA; East Asia, AS; Ashkenazi Jewish, Lat; Latino,
EF; Europe (Finnish), EnF; Europe (non-Finnish), Afr; African.
rs9923231

0.53
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3.3.4 VKORC1 Variants Genotypes Against Warfarin Dose
Analysis of variance (ANOVA) was used to examine the effect of patients’
genotypes on their warfarin dose. A significant difference (P<0.05) in average doses
of warfarin between genotype groups was found at six variants: rs9923231, rs9934438,
rs8050894, rs2359612, rs7294, and rs61742245 (Table 15).

Table 15: Analysis of variance in warfarin dose between genotypes groups
VKORC1 SNP

rs9923231
GG
GA
AA
rs61742245
GG
GT
TT
rs9934438
CC
CT
TT
rs8050894
GG
GC
CC
rs2359612
CC
CT
TT
rs7294
GG
GA
AA
* Statistically significant

Genotypes
Frequencies (%)

Average dose
±SD

22 (24.4%)
43 (47.8%)
25 (27.8%)

7.05 ± 2.89
4.73 ± 1.63
2.56 ± 1.00

86 (95.6%)
2 (2.2%)
2 (2.2%)

4.53 ± 2.22
7.50 ± 2.12
9.25 ± 8.13

22 (24.4%)
43 (47.8%)
25 (27.8%)

7.05 ± 2.89
4.73 ± 1.63
2.56 ± 1.00

21 (26.7%)
45 (50.0%)
24 (23.3%)

7.03 ± 2.94
4.73 ± 1.71
2.58 ± 1.01

19 (21.1%)
47 (52.2%)
24 (26.7%)

7.09 ± 3.04
4.81 ± 1.76
2.58 ± 1.01

39 (43.3%)
43 (47.8%)
8 (8.9%)

ANOVA
F (2,87)

P value

32.955

0.00*

5.3.5

0.007*

32.955

0.00*

29.541

0.00*

28.37

0.00*

9.23

0.00*

3.60 ± 2.48
5.32 ± 1.99
6.71 ± 2.63

3.3.5 Stratifying Patients According to Warfarin Dose and Crosstabulation
Analysis
Individuals in the patients’ group were classified into three groups according
to their warfarin dose; high, intermediate, and low. Crosstabulation of genotypes
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against maintenance dose groups revealed that all the patients who were minor allele
carriers at rs9923231, rs9934438, rs8050894, and rs2359612 required warfarin doses
lower than 6 mg/day, which puts them in the low or intermediate dose group. 70% of
these patients were in the warfarin low dose group (≤3 mg/day). In contrast, patients
that carry the wild-type at the same variants clustered in the high-dose group (≥6
mg/day), and only very few were in the intermediate or low-dose groups. A similar
observation was reported at rs7294, but it was inverted. For this variant, minor allele
carriers clustered in the high-dose group, and most of the wild-type carriers were in
the low-dose group. Figure 8 illustrates the crosstabulation results.
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Figure 8: Crosstabulation of warfarin dose versus genotypes at the studied SNPs
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3.3.6 Linkage Disequilibrium Analysis
For linkage disequilibrium (LD) analysis, five SNPs were found to have
significant pairwise r2, indicating high LD. Moreover, two SNPs, rs9923231 and
rs9934438, were in complete linkage disequilibrium (pairwise r 2=1). Figure 9
illustrates the pairwise LD statistics of the linked markers. These markers were suitable
for further haplotype analysis.

Figure 9: Linkage disequilibrium analysis of VKORC1 SNPs
A schematic presentation of VKORC1 showing the locations of the selected SNPs (Transcript:
VKORC1-205 ENST00000394975.2). Black and blue boxes represent exons (E) and
untranslated regions (UTR), respectively. Blocks with dark red color represent stronger LD
than the lighter ones. Values inside red blocks represent pairwise r 2.

3.3.7 Haplotypes Association with Warfarin Dose
Haplotypes were extracted according to the star system annotation.
VKORC1*2 haplotype was the most frequent haplotype with a frequency of 50%. The
next most frequent alleles combination was VKORC1 *3 with 32% frequency,
followed by VKORC1*4 with a 7% frequency, followed by the reference allele
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VKORC1*1 with a 6% frequency. The rest (5%) were rare haplotypes. A global test
for the star haplotypes statistical association with dose did not show any significance
(P=0.62). Results of this analysis are illustrated in Table 16.
Table 16: Association between star system haplotypes and warfarin dose
Haplotype

SNP1

SNP2

SNP3

SNP4

SNP5

F
(%)

Difference in mean
(CI)*

P

*1

A

C

T

T

G

0.5053

0.00

---

*2

G

C

C

C

A

0.3278

2.23 (1.57 - 2.89)

<0.0001

*3

G

T

C

C

G

0.0775

1.94 (0.89 - 2.98)

0.00046

*4

G

C

C

C

G

0.0613

2.66 (1.68 - 3.64)

<0.0001

*5

G

C

C

T

G

0.0167

2.08 (-0.14 - 4.3)

0.069

rare

*

*

*

*

*

0.0114

0.69 (-2 - 3.38)

0.62

* Difference in means measures the difference between the mean of dose among each haplotype and
the most common haplotype (haplo-1). F; frequency, CI; confidence interval, SNP1; rs9923231, SNP2;
rs17708472, SNP3; rs9934438, SNP4; rs2359612, SNP5; rs7294. ** Significant association.

Accordingly, haplotypes were reextracted depending on the genotyped variants
in the studied population, excluding two variants, rs188009042, and rs17708472, as
both variants did not show significant genotypes variation.
Haplotypes extracted from the six remaining variants (rs9923231, rs61742245,
rs9934438, rs8050894, rs2359612, rs7294) have given a significant global haplotype
association with dose (P=0.009) in linear regression after adjusting for age and gender
(Table 17). The most frequent haplotype, AGTCTG at the six variants, respectively,
was denoted by haplo-1, and it had a 50% frequency. The next most common
haplotype, denoted as haplo-2, (GGCGCA) appeared in 32% frequency. These
haplotypes were followed by haplo-3 (GGCGCG) with 11% frequency, then haplo-4
(GTCGCG) with a 2% frequency. The rare haplotypes which occurred in ≤ 2
individuals were combined in one group denoted as “rare.”
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Table 17: Haplotypes built on the six significant SNPs and their association with
warfarin dose
Haplotype

SNP1

SNP2

SNP3

SNP4

SNP5

SNP6

F
(%)

Difference in
mean
(CI)*
0.00

P

Haplo-1

A

G

T

C

T

G

50

Haplo-2

G

G

C

G

C

A

32

2.29
(1.6 - 2.95)

<0.0001**

Haplo-3

G

G

C

G

C

G

11

1.87
(0.93 - 2.81)

0.00015**

Haplo-4

G

T

C

G

C

G

2

3.18
(1.9 - 4.46)

<0.0001**

Haplo-5

G

G

C

G

T

G

1.2

1.02
(-1.61 - 3.65)

0.45

Rare

*

*

*

*

*

*

2.8

2.36
(0.62 – 4.1)

0.0089**

---

* Difference in means measures the difference between the mean of dose among each haplotype and
the most common haplotype (haplo-1). F; frequency, CI; confidence interval, SNP1; rs9923231, SNP2;
rs61742245, SNP3; rs9934438, SNP4; rs8050894, SNP5; rs2359612, SNP6; rs7294. ** Significant

association

3.3.8 Multivariate Linear Regression
The final analysis was to examine the effect of all genetic and non-genetic
variables on warfarin dose. A stepwise multivariate regression, including genotypes at
all VKORC1 variants with age and gender (the non-genetic factors), was applied to
achieve this goal. The results show that the main predictors for warfarin dose were
rs9923231, age, and rs61742245. The most potent indicator (indicated by adjusted r 2
value) was rs9923231, which solely explained 0.424 of the dose variability. Adding
age increased the prediction power of the model to 0.482, adding rs61742245 made r2
reach 0.507, which indicates that 50.7% of the average warfarin dose in the current
sample was explained by genotype at rs9923231 and rs61742245 and age (P <0.05).
Table 20 lists predictors of the model, and Table 18 lists the coefficients.
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Table 18: Model summary and Predictors of multivariate logistic regression
Std.
R2
F
df2
Sig. F
Error of
Change
Change
change
the
Estimate
1
0.656a
0.431
0.424
1.88
0.431
66.6
88
0.00
b
2
0.702
0.493
0.482
1.79
0.063
10.7
87
0.002
3
0.724c
0.524
0.507
1.74
0.030
5.44
86
0.022
1. Predictors (constant), rs9923231, Standarized B .644 (p = 0)
2. Predictors (constant), rs9923231, Age, Standarized B .598, -.249 (p = 0, .002)
3. Predictors (constant), rs9923231. Age, rs61742245, Standarized B .542, -.274, .185 (p = 0, 0, .018)
Dependent variable: Dose
Model

R

R2

Adjusted
R2

3.4 Discussion (Warfarin Group)
This study aimed to explore the allele frequencies of eight VKORC1 SNPs and
their effect on warfarin dose in a group of Emirati patients. The main findings were
determining the allele frequencies, genotypes, haplotypes, and obtaining a significant
effect of these variants on warfarin dose in a group of Emirati patients.
Comparing allele frequencies between populations revealed a statistically
significant differences (P < 0.05) in the allele frequencies at the studied SNPs and most
of gnomAd populations frequencies. Notably, the data from South Asian populations
was missing for most of the studied SNPs from the database. As indicated by the
resequencing of 100 pharmacogenes group-results, the allele frequencies could have
been closer to south Asians than other populations.
Analysis of warfarin dose variance between the genotypes illustrated
significant differences. Rs9923231 was a leading contributor that remained a
significant predictor in the multivariate linear regression analysis. This association is
a well-established pharmacogenomic association that has been demonstrated in
different populations and ethnicities. Indeed, the CPIC warfarin dosing
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recommendations include this variant alone from VKORC1, besides two CYP2C9
alleles and clinical factors, to determine the starting warfarin dose [157].
Rs9923231, commonly referred to as −1639G>A, is located to the transcription
factor binding site in the VKORC1 promotor. The alternative allele presence reduces
gene expression and leads to a decrease in vitamin K carboxylation, which is
postulated to reduce the required warfarin dose [110, 176, 177].
As such, the clustering of more than 70% of rs9923231 alternative allele
carriers in the low-warfarin dose group is reasonable. Similarly, the wild type carriers
clustered in the high-dose group. These findings are consistent with previous reports
[177, 196].
Rs9934438 is an intronic variant reported to be in a near-perfect LD with
rs9923231 [197, 198], a finding that was replicated in the current group. Accordingly,
an identical distribution of genotypes on dosing groups was seen. Cavallari and
colleagues reported that variation in any of the two variants could explain 18% and
5% of warfarin dose variability in Caucasians and African Americans, respectively
[199]. In comparison, either of the two variants’ prediction power was 42.4%, which
is higher than the previous figures and higher than the Chinese and Iranian patients
(31% and 20.3%, respectively) [200, 201]. However, it was close to Omani patients
(45%) [194]. Nevertheless, the aforementioned studies’ associations considered
CYP2C9*2 and *3 alleles beside VKORC1 variants, besides more non-genetic factors.
Accordingly, the current results are probably overestimating the predictability of this
variant.
Two other variants, rs8050894 and rs2359612, had similar dose variance. None
of the patients who carried the two alternative alleles were in the high-warfarin dose
group, and 70% of these were in the low-warfarin dose. Both SNPs are located in an
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intronic region and presumed to affect a transcription factor binding site. Several
studies demonstrated a similar observation regarding the two SNPs’ effect on warfarin
dose [176, 177].
The fifth significant variant is rs7294, in which its alternative allele is known
to correlate with a significantly higher warfarin dose than the wild allele [199, 202].
In the current group, significant differences were reported between the wild and
alternative allele carriers in ANOVA and cross-tabulation. However, the genotypes at
this SNP were not significant predictors through the multivariate analysis model.
These findings were consistent with previous reports from European populations [196,
203], but unlike those reported from a group of patients from Sudan [204].
Importantly, rs61742245 was carried by four individuals in the current group.
This variant, identified in Ashkenazi Jews and Ethiopians (MAF=0.04 and 0.15,
respectively) [205, 206], has also been found in the 100 pharmacogenes-resequencing
group. It has been reported that the carriers of one minor allele at this SNP will need
to, at least, double their warfarin dose [207]. Three from the alternative allele carriers
in the current group required high warfarin doses (6, 9, and 15 mg/day), in concordance
to other populations [206].
Although only a few patients carried the rs61742245 variant, it was a
significant predictor in the regression model. The current observation was the first
from any Arab population as no studies have considered this variant in Arabs. The two
remaining SNPs, rs188009042, rs17708472, showed low variability, and analyzing
them was not plausible.
In the LD analysis, five SNPs were in strong LD: rs9923231, rs9934438,
rs8050894, rs235961, and rs7294, strongest at the first four (r 2 ≥0.93) but moderated
at the fifth (r2≈0.7). A similar observation is reported in other populations [176, 188].
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The high LD observed might indicate the un-necessity of genotyping the five variants
as this will lead to redundant information [208]. One patient who represented an outlier
(warfarin dose 8 mg/day) carried one minor allele at rs188009042 and two minor
alleles at rs17708472, while all other SNPs were wild type.
Haplotype analysis using the star system did not show a significant association
with dose. In contrast, haplotypes composed of the six significant variants resulted in
a significant association with warfarin dose. This finding highlights the importance of
reconsidering haplotype reanalysis in small populations rather than adopting the
haplotypes based on Caucasians.
The non-genetic factors evaluated included age and gender. Age was a
significant variable in the dose-prediction model. Older patients are usually treated
with more conservative warfarin doses due to their higher risk of bleeding,
polypharmacy use, and comorbidities [209].
3.5 Limitations (Warfarin Group)
1. The current study subset included a small number of samples due to the
limited number of patients consistent with the inclusion criteria (Emirati nationality,
treated with warfarin stabilized dose for at least two months without interacting
medications).
2. Few non-genetic data were collected. The smoking status, height, weight,
and body mass index were not collected, although they are believed to affect warfarin
dose requirement, and the model should have been adjusted for these variables.
3. The concomitant interacting medication was one of the exclusion criteria;
however, a uniform description of all dietary supplements and over-the-counter

86
medications was missing from the collected data. The numerous Warfarin drug-drug
and drug-food interactions may have affected the accuracy of the current model.
4. Comorbidities were not uniformly reported. The main comorbidities that
were considered an exclusion-criteria were oncology and liver diseases, which adds to
the current study's limitations.
5. Genotyping of the two other warfarin pharmacogenes, CYP2C9 and
CYP4F2, would have better demonstrated the genetic variability in the Emirati
population related to warfarin dose variability.
3.6 Projections of the 100-Pharmacogenes Re-sequencing Results to the
Cardiovascular Subset
1- The significant VKORC1 variant, rs61742245, was also detected with a
MAF= 0.05 in the sequencing of 100 pharmacogenes in 100 healthy Emiratis group.
Accordingly, this variant is an important rare variant that should be considered in
future warfarin pharmacogenetic studies in the UAE. It is a strong candidate for
potential efforts to build national dosing algorithms.
2- CYP2C9 actionable alleles distribution from the first research group were as
following: CYP2C9*1/*2 (17%), CYP2C9*1/*3 (13%), CYP2C9*2/*2 (2%), and
CYP2C9*2/*3 (1%). Accordingly, 35% of the UAE's current sample has an actionable
CYP2C9 allele and is eligible for pharmacogenetic-guided warfarin dosing. If this
percentage is projected to the warfarin group, 38 individuals would have been eligible
for a warfarin dose modification.
3- CYP4F3: 18% were homozygous to the *3 allele and will require a higher
warfarin dose. Accordingly, if this allele occurred in a similar frequency in warfarin
groups, 5 individuals would need an increment in their warfarin dose.
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Chapter 4: Pharmacogenomic Application in Oncology
4.1 Pharmacogenomics in Cancer: Background
Cancer incidence rates are rapidly increasing worldwide. The World Health
Organization (WHO) has estimated that 29.5 million new cancer cases will be
diagnosed by 2040, with an overall increase of 63.4% compared to 2018 cancer
incidence rates [210]. The postulated growth rates in cancer incidence per country have
been made publicly available by the WHO. Figure 10 illustrates these estimates in the
UAE. Undoubtedly, these numbers make cancer one of the major health crises today

Number of cancer cases

and make its safe treatment a global health priority [211].

United Arab Emirates, Both Sexes

Figure 10: Estimated growth of cancer incidence rates from 2018 to 2040, all
cancers, both sexes, all ages. Source [210]

The primary modalities in cancer treatments include surgery, radiotherapy, and
systemic therapy. A notable increase in new cancer systemic therapies has been
witnessed in the last three decades. The new agents include new cytotoxic agents,
targeted therapy, biological therapy, and immunotherapy. However, chemotherapy,
which started in the ’40s of the last century, remains a vital option for almost all cancer
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management plans, which might be explained by the fact that all novel agents
introduced are usually suitable for a percentage of patients, in contrast to the broadspectrum chemotherapeutics [211, 212].
The 2018 estimates show that the global use of chemotherapy will increase by
53% by 2040; approximately 15 million people will be using chemotherapy at that
time. Regionally, the proportional growth of chemotherapy utilization from 2018 to
2040 in western Asia (including the Arabian Peninsula) is projected to reach 99%
growth, which is amongst the highest predicted chemotherapy usage growth rates
globally [211].
Chemotherapy is delivered either for its potential curative effect or within the
palliative care of cancer patients. In the curative context, treatment is used with the
highest tolerated doses, in contrast to palliative care, where the target is delaying
progression. As such, palliative chemotherapy doses are adjusted to minimize toxicity
[213]. In both scenarios, four criteria are used to measure treatment effectiveness:
tumor response, time to remission, survival, and toxicity [214].
Chemotherapies are designed to be cytotoxic, which means that toxicity and
adverse effects are predictable with their use [215]. Toxicity signs can occur
immediately or later to therapy. The toxicity intensity can range from mild or moderate
(grade 1 and 2) to severe, life-threatening, or disabling (grade 3 and 4). All the body
organs are vulnerable to toxicity, including the vital organs like the heart and brain.
Grade 3 and 4 toxicities can lead to paralysis, spasms, and coma [214].
As such, the reduction of treatment-associated adverse effects is increasingly a
vital topic. There have been many pharmacological attempts to control chemotherapy
toxicity, like introducing the granulocyte colony-stimulating factor (G-CSF) to counter
chemotherapy’s myelosuppressive effect or using laxatives to reduce chemotherapy-
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induced constipation. However, these attempts suffered from being costly, fit one type
of toxicity, and can cause drug-drug interactions or new adverse events [216, 217].
Importantly, focusing on chemotherapy high toxicity does not imply that other
agents used in cancer treatment are free of toxic effects. Small molecules inhibitors
such as imatinib, monoclonal antibodies, such as trastuzumab, angiogenesis inhibitors,
such as bevacizumab, and agents targeting cytotoxic -T lymphocytes (CAR-T cells),
all are associated with adverse events that can reach in severity to grade 3 or grade 4
in some cases [214].
In this context, pharmacogenomics can provide promising input. Indeed,
oncology is considered the field of medicine in which pharmacogenomics and
personalized medicine are most established. About 39% of FDA pharmacogenomic
label warnings are in the oncology drugs’ labels. However, the majority of these are
related to the tumor tissue (somatic) variants. Only 20% of oncology FDA
pharmacogenomics labels are linked to germline variants, i.e., host variants affecting
oncology drugs’ response [12]. Somatic pharmacogenetic variants are beyond the
current research scope, and all the following demonstrated oncology pharmacogenetic
research will only describe germline DNA pharmacogenetics.
Germline pharmacogenomic associations with a high level of evidence in
oncology

include

TPMT

and

NUDT15

with

thiopurines,

DPYD

with

fluoropyrimidines, G6PD with rasburicase, UGT1A1 with irinotecan, and CYP2D6
with tamoxifen. At the same time, other associations with a lower level of evidence
are available. These include ABCB1 and CYP3A family members with several
chemotherapeutic agents, CYP2B6 with cyclophosphamide, and SLCO1B1 with
methotrexate [12].
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In this chapter, adverse effects encountered in two types of tumors are
discussed briefly with a summary of the germline pharmacogenomic research in both
types. The selected tumors are acute lymphoblastic leukemia (ALL) in children and
breast cancer in females. Pediatric ALL is considered a success story in the implication
of germline pharmacogenomics. In contrast, despite the success in utilizing tumor
tissue variants in developing new drugs, the host germline biomarkers of breast cancer
systematic treatment response are hardly used.
4.2 Pediatric Acute Lymphoblastic Leukemia
Acute lymphocytic leukemia (ALL) is the most common type of cancer in
children. It composes approximately 25% of tumors in patients younger than 15 years
old [218]. In the 2014 UAE’s cancer registry, leukemias were the most occurring
cancers in pediatrics, composing 43.5% of all tumors in patients younger than 14 years
old. Unfortunately, studies focusing specifically on ALL prevalence, burden, or
outcomes in the UAE are absent.
In the 1970s, and following the introduction of new cytotoxic modalities,
survival rates increased from 10% in the prior decade to 60%. In the following years,
protocols and dosing optimization resulted in a dramatic improvement in survival rates
to reach approximately 90% overall survival [218].
However, the same chemotherapeutic agents that made this advancement
possible were associated with severe adverse effects. The toxicity rates reported from
pediatric ALL therapy approached 75% of cases and interfered with their treatment.
The reported events were severe in many cases and resulted in a delay or withdrawal
from treatment. Nevertheless, delayed-onset adverse effects and long-term or life-long
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sequelae were reported [219, 220]. Sadly, 2% to 3% of pediatric ALL patients lose
their lives because of adverse treatment effects rather than the disease [218].
4.2.1 Adverse Drug Events and Pharmacogenetics in Pediatric ALL: Background
Treatment of pediatric ALL involves 2.5 to 3 years of therapy at different
phases. The used agents and protocols are updated continuously; however, the main
components are similar. Induction, the first phase of treatment, includes high doses of
chemotherapy given to eradicate tumor cells. Next, an intensification phase, also
known as consolidation, is used to ensure the elimination of the minimal residual
disease. The maintenance or continuation phase is the longest one spanning 2 to 2.5
years. Besides these three major phases, interim maintenance and delayed
intensification are usually given to maintain the achieved remission. The length and
frequency of these phases depend on the case severity. Figure 11 illustrates the major
phases and agents used in pediatric ALL therapy.

Figure 11: Phases and agents used in pediatric ALL treatment.
Source [221]
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4.2.1.1 Acute adverse events encountered during ALL treatment in children
Global data indicate that 75% of pediatric ALL patient encounter treatment
interrupting adverse drug effects [219]. Unfortunately, data about the frequencies or
outcomes of pediatric ALL treatment is lacking from UAE. In the following
paragraphs, the major adverse events and their global incidence rates will be described,
except for toxicities associated with oral chemotherapy in the maintenance phase,
described in a separate section.
1- Central or peripheral neurotoxicity: Central neurotoxicity is a severe adverse
effect that displays seizures, reduced consciousness, steroid psychosis, and other
symptoms, reported in 10% to 15% of ALL children [222]. Peripheral neurotoxicity is
a more frequent adverse event. It is estimated to occur in 100% of children treated with
vincristine. Fortunately, most cases of vincristine-induced peripheral neuropathies are
mild to moderate, and severe cases appear in around 10% of cases only. The common
sensory symptoms of neurotoxicity include abnormal sensation, numbness with
tingling, and diminishing vibratory or cutaneous sensations. Due to the limited
vocabulary expressions in younger children, there might be a delay or an absence in
neurotoxicity diagnosis [223].
2- Bone toxicities: Osteonecrosis is a disabling complication of high dose
steroids, particularly dexamethasone, in ALL [224]. Besides its high incidence,
osteonecrosis can compromise the long-term quality of life [225]. Due to its severity,
multiple research groups investigated steroid-induced bone toxicity pathogenesis, risk
factors, and pharmacogenomic predisposing factors [225, 226]. Pathogenesis is
hypothesized to result from vascular components affecting bone vasculature and bone
cell toxicity [225].
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3- Hyperglycemia: Multiple potential factors can result in hyperglycemia in
children with ALL, including corticosteroids treatment, dietary choices, stressmediated cortisol release, medicinal induced insulin secretion, and others. Steroidsinduced insulin resistance is the most well-established mechanism for hyperglycemia
[227]. Adding asparaginase to the treatment course will further interfere with insulin
production and secretion and increase the occurrence risk in pediatric ALL. In a recent
review of 44 studies, Grimes and colleagues found considerable different
chemotherapy-induced hyperglycemia incidence rates, from 3% to 63%. The lack of
consensus in the hyperglycemia definition might explain some of this variability [227].
Although chemotherapy-induced hyperglycemia is usually resolved with insulin
treatment, it might contribute to increase the metabolic syndrome and obesity rates in
pediatric cancer survivors [228].
4- Hypertension: 15% of pediatric ALL patients experience hypertension
during induction therapy. Despite its transient occurrence, steroids induced
hypertension is a well-recognized risk factor for acute, chronic, and late-onset
cardiomyopathy [229].
5- Oral mucositis: A rapid cell growth characterizes oral tissues, making them
vulnerable to cytotoxic effects. Mucositis manifests by inflammation or ulceration of
the mucosa that causes pain and bleeding. It is thought to occur in 65% to 90% of
chemotherapy-treated children. Oral mucositis can occur with high methotrexate
doses, vincristine, anthracyclines, and other chemotherapeutic agents. The severity of
oral mucositis usually reaches its peak between 7 and 14 days following the
chemotherapy, before it resolves slowly. The primary concern in dealing with this
adverse effect is that severe cases can lead to treatment cessation, which endangers the
overall outcomes [230, 231].
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6- Thromboembolism: cancer children are among the largest patients’ subsets
who experience venous thromboembolic events. Compared to children with solid
tumors, incidence rates are lower in leukemia patients, though they are estimated to
approach 5.2% in ALL pediatric patients. L-Asparaginase use is considered a risk
factor of thrombosis, besides steroids and other factors. The standard care for
thrombotic events includes warfarin and heparin use. However, treatment is
complicated by thrombocytopenia and increased bleeding tendency in leukemia
patients [232].
7- Asparaginase induced hypersensitivity: Asparaginase is clinically available
in three formulations; the first, and oldest one, is derived from Escherichia coli (E.
coli-asparaginase). The second is obtained from Erwinia chrysanthemi (Erwiniaasparaginase). Finally, the third one is E. coli derived but modified by conjugation
with mono-methoxy-polyethylene glycol (PEG-asparaginase), and it is believed to be
the best tolerated form [233]. Due to its distinct origin, Erwinia-asparaginase does not
exhibit cross-reactivity with the E. coli derived asparaginases, and it is given as a
replacement for patients experiencing hypersensitivity to the E. coli formulations.
Nevertheless, all formulas can provoke an immune response. PEG-asparaginase,
which is the most commonly used formula, is reported to induce hypersensitivity
reactions in 3%-24% of patients [234]. Moreover, 30% of patients can experience
silent hypersensitivity, in which their immune system responds by asparaginase inactivation without showing allergic symptoms [235]
Other rare adverse effects have been reported including, chemotherapyinduced nephrotoxicity, and Pancreatitis.
Several studies evaluated the most common adverse drug effects encountered
during pediatric ALL treatment, and some candidate pharmacogenetic biomarkers
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have been proposed. Although none of the studied biomarkers have sufficient evidence
yet, except for TPMT and NUDT15 for 6-MP toxicity, investigating pediatric ALL
adverse events is still a hot topic. Table 19 lists the most common acute adverse drug
effects, other than hematological toxicities, and their suggested pharmacogenomic
biomarkers.

Table 19: Non-hematological acute adverse effects in pediatric ALL treatment
Adverse Effect

Frequency

Risk factors [reference]

Mucositis

40%

Peripheral
neuropathy

4.2-25%

Bone toxicities

20%
(can reach
70% when
considering
nonsymptomatic
cases)
2-8%
70% if
asymptomatic
cases were
considered

Low body weight
Low neutrophil count
Elevated pretherapeutic
inflammatory mediators [222]
Vincristine doses intensity,
frequency, and intervals.
Concomitant use of CYP3A5
inhibitors [238].
Sex (Females have higher risk)
Age
Corticosteroids intensity
Albumin and cholesterol levels
Dexamethasone use (versus to
prednisolone)
[222, 240]
Age
Central line catheters
Immobilization
Infections
Combining asparaginase with
corticosteroids
[222, 241]
Concomitant use of asparaginase
Age, BMI, Down syndrome
CNS involvement at diagnosis
[222, 242]
Insufficient hydration and
alkalization [222]

Thromboembolism

Hyperglycemiacorticosteroids
induced

10-20%

Nephrotoxicityhigh dose
methotrexate
induced
Asparaginase
hypersensitivity
reactions /
intolerance

3%

20-25%

Asparaginase type, rout, and
duration [222]

Candidate PGx
biomarkers
[reference]
MTHFR (C677T)
[236]
XRCC1 (Arg399Gln)
[237]
CEP72 (rs924607)
[238]
CYP3A5*3 [239]
SH3YL1 (rs4241316
and rs10193882)
[240]
BMP7 (rs75161997)
PROX1-AS1
(rs1891059)
[226]
Prothrombotic genetic
defects (factor V
1691G>A mutation /
prothrombin
20210G>A / MTHFR
TT677)
[241]
-

Genes affecting
methotrexate
clearance (e.g.,
SLCO1B1) [222]
HLA-DRB1*07:01
[243]
GRIA1 [244]
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4.2.1.2 Oral 6-mercaptopurine and methotrexate, associated adverse effects, and
pharmacogenetics
The purine analog 6-mercaptopurine (6-MP) and the folate analog
methotrexate have been used in pediatric ALL for more than sixty years due to their
proven efficacy in inducing and conserving remission through the maintenance phase.
The mechanism of both drugs in the maintenance phase is still not well established. It
is thought to be due to nucleotide synthesis de novo pathways inhibition in stem cells,
apoptotic pathways modulation, or microenvironment manipulations [245].
Although both agents are used in earlier treatment phases and the continuation
phase, up to 2 to 3 years from diagnosis, the elongated use during maintenance is
challenging. Due to the high variability in 6-MP and methotrexate bioavailability and
pharmacokinetics, dosing does not follow body-size based rules, which is the golden
dosing standard in chemotherapy. The maintenance phase’s dosing protocol
recommends a starting dose ranging from 40 to 75 mg/m2/day for 6-MP and 10 to 20
mg/m2/week for methotrexate. Conventionally, later 6-MP and methotrexate doses are
adjusted depending on the Blood counts, from which the absolute neutrophil counts
(ANC) is considered the best indicator, besides liver enzymes [246].
At the end of treatment, a wide range of inter-patient variability in average 6MP and methotrexate doses can be noticed. Figure 12 illustrates the maintenance 6MP mean doses for 538 ALL children treated with the same protocol (NOPHO ALL92). The median 6-MP dose for all patients in that study was 59.4 mg/m2, while the
wide range of variability is noticeable [245].

Number of patients
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Time-weighted mean doses of 6-MP (mg/m2) during maintenance therapy

Figure 12: Variability in 6-MP mean doses in 538 pediatric ALL patients during
maintenance therapy.
Source [245].

The correlation between TPMT genotypes and the enzyme levels were reported
in the 1980s, followed by recognizing their effect on thiopurines. Because TPMT is
the major metabolizing enzyme of 6-MP, the complete enzyme deficiency can cause
severe, sometimes fatal, myelosuppression. Homozygous carriers and compound
heterozygous carriers of the alleles TPMT*2, TPMT*3C, and TPMT*3A will exhibit
enzyme deficiency. Simultaneously, the carriers of a single deficient allele will have
lower enzyme activity and an elevated risk of 6-MP toxicity [247]. As
such, TPMT genotyping before 6-MP administration has been recommended. CPIC
and all other pharmacogenomic consortia issued dosing recommendations guided by
TPMT genotypes [145].
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However, TPMT genotypes did not confer the same power in defining 6-MP
intolerance in different ethnicities. It was noticed that deficient TPMT alleles are rare
in Asian populations, despite the high toxicity rates of thiopurines. NUDT15 was
elucidated as a better predictor of thiopurine doses than TPMT in Asians.
Accumulating evidence of NUDT15 variants’ impact on 6-MP dose resulted in adding
these variants to the latest versions of 6-MP dosing CPIC recommendations [145, 247].
Despite the better understanding of 6-MP and methotrexate kinetics and
delineating the significance of 6-MP pharmacogenetics, monitoring of blood counts
and liver enzymes are still indispensable. Commonly, oral 6-MP and methotrexate
doses are adjusted to maintain WBC between 1.5-3x103/µl. Doses are reduced
whenever one of the following happens; WBC < 1.5x10 3/µl, ANC < 500/µl,
lymphocytes < 300/µl, or platelets < 50x103/µl [245]. Further reductions in blood
counts will lead to treatment interruption till counts get back to the previous thresholds.
Hospitalizations are usually required during the severe myelosuppression and febrile
neutropenia events [248, 249].
Treatment interruption can contribute to resistance and relapse. In 1991,
Schmeiglow and co-workers found that patients with a 6-MP treatment interruption
lasting more than 10% of their maintenance therapy span were at an increased risk of
relapse [250]. More recently, the same association between relapse rates and treatment
interruption was reported from the follow-up of 742 children from multiple ethnicities,
treated in 94 different institutions (87). Nevertheless, controversy still exists, whether
to increase the 6-MP dose until toxicity occurs or to maintain lower doses with small
increments and avoid toxicities. No studies yet have evaluated if achieving the full
protocol dose at the expense of treatment interruption is better than minimizing 6-MP
variation to avoid ANC drop and treatment interruption (87).
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Indeed, the myelosuppressive effect of 6-MP and methotrexate and the need
for hospitalization are acceptable, up to a certain level, during the initial phases of
treatment (i.e., induction and intensification phases), which last for six months. In
comparison, the maintenance phase, which lasts 2.5 to 3 years from the diagnosis, aims
to maintain antileukemic activity against lymphoblasts, with a minimal impact on the
quality of life [252]. Hence, hematological toxicities are mostly evaluated during the
maintenance phase. Adverse effects are monitored through their effect on the patient’s
quality of life. The selected endpoints usually include the need for treatment
interruption, the need for hospitalization, and associated adverse events like febrile
neutropenia [253, 254]. Febrile neutropenia, defined by a fever episode combined with
low neutrophil counts, is the most common reason for hospitalization in children with
cancer [249]. It is a leading cause of morbidity and mortality in cancer patients, with
a higher occurrence rate among pediatric ALL patients [255].
Hepatotoxicity is another 6-MP and methotrexate commonly induced adverse
effects. A two-fold increase in the liver enzymes is frequently reported with these
agents’ use. Severe or permanent liver damage are not frequent, and liver enzymes go
back to normal following the end of treatment [222].
4.2.1.3 Pharmacogenetic studies in pediatric ALL treatment adverse effects in
Arabs
Scant research to investigate pediatric ALL treatment adverse events
pharmacogenetics originate from Arab populations. From the Gulf region, one recent
study from Saudi Arabia found an association between rs1045642 in ABCB1 and lifethreatening infection in 70 pediatric ALL patients treated with corticosteroids [256].
The same variant besides another variant from the same gene, rs1128503, were found
associated with methotrexate induced neutropenia in 117 Lebanese ALL patients. In
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the same study, ABCC2-rs717620 and TYMS-28-bp tandem repeats were
significantly associated with the need to decrease weekly MTX doses [146]. There are
no published data regarding the frequencies of TPMT and NUDT15 alleles in
populations from the Gulf countries. Few studies covering allele frequencies of either
TPMT alone or with NUDT15 or ITPA have been conducted in Levantine and North
African Arab populations. All these studies used PCR-based genotyping to determine
Caucasians derived allele frequencies in healthy or pediatric ALL patients. The
selected alleles, study sample description, and allele frequencies of these studies are
summarized in Table 20.

Table 20: Studies of TPMT and NUDT15 from Arab Populations
Country
(year)
Lebanon
+
Kurdistan
(2019)
Tunisia
(2018)
Palestine
(2017)
Egypt
(2015)
Morocco
(2015)
Jordan
(2009)
Egypt
(2003)

Studied Alleles
TPMT*2, TPMT*3B
TPMT*3C,
NUDT15 rs116855232
TPMT*2, TPMT*3B,
TPMT*3C
TPMT*2, TPMT*3B
TPMT*3A, TPMT*3C
TPMT*2, TPMT*3B
TPMT*3A, TPMT*3C
TPMT*2, TPMT*3B,
TPMT*3C
TPMT*2, TPMT*3A
TPMT*3B, TPMT*3C
TPMT*2, TPMT*3A
TPMT*3C

Number and status
of participants
136 [L]
74 [K]
ALL children
300 healthy
56
ALL children
70
ALL children
103 healthy
200 healthy
200
healthy

Alternative allele
frequencies
TPMT*3 (0.02) [L]
and (0.014) [K]
NUDT15 (0.007)
[L]
TPMT*3A (0.008)
TPMT*3C (0.008)
TPMT*3 (0.089)

Reference

0

[259]

0

[139]

TPMT*3A (0.059)
TPMT*3C (0.03)
TPMT*3A (0.03)
TPMT*3C (0.13)

[260]

[257]

[138]
[258]

[137]

Three studies conducted on Arab pediatric ALL patients examined the
association between pharmacogenetic variants and treatment adverse events. In the
combined cohort (Lebanese, Arabs, and Kurds) of Moradveisi and colleagues work,
the minor alleles at TPMT*3A, NUDT15*3, and ITPA exhibited lower 6-MP median
dose intensity, although the few counts of alternative alleles banned establishing
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associations [257] Similarly, Ayesh and colleagues found only a single TPMT*3 allele
in patients from Palestine, while a similar cohort from Egypt did not present any of the
TPMT*3 alleles [258, 259].
To conclude, adverse events are a significant issue in pediatric ALL treatment
worldwide. Data regarding the frequency of these events in UAE are absent and scarce
from other Arab populations. Equally, allele frequencies of TPMT and NUDT15 are
not evaluated either in pediatric or healthy individuals from the UAE or the
neighboring Gulf countries.
4.2.2 Study Questions and Objectives
1- To determine the most frequent adverse drug events encountered during all
phases of pediatric ALL treatment, specifically with oral therapy during the
maintenance phase.
2- To examine the extent of applying pharmacogenetic tests in pediatric ALL
treatment in the main cancer center in UAE.
4.2.3 Study Hypothesis
Patients will be suffering from adverse drug event comparable to their
counterparts from other populations.
4.2.4 Primary and Secondary Outcomes
Primary outcomes: Frequencies of adverse effects, tolerated doses of 6Mercaptopurine and oral methotrexate, frequency of hospitalizations due to adverse
effects and febrile neutropenia events during maintenance phase.
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Secondary outcomes: Impact of TPMT and NUDT15 pharmacogenetic testing
on adverse events frequency.
4.2.5 Methods (Pediatric ALL)
4.2.5.1 Participants inclusion and exclusion criteria
Participants were recruited from the pediatric oncology and hematology ward
and clinic in Tawam hospital, Al-Ain city, Emirate of Abu Dhabi, UAE. All the
participants signed an informed consent form to participate in this study. This study
was conducted following the approval of the Tawam Human Research Ethics
Committee (THREC#552).
Inclusion criteria: Patients who received acute lymphoblastic leukemia
treatment for at least three consecutive months were eligible for inclusion. Other
inclusion criteria included the age at onset of leukemia (2-16 years) and being an
Emirati national or originating from one of the Arab countries.
Exclusion criteria: Down syndrome, receiving bone marrow transplantation
before recruitment, and being diagnosed with ALL as a secondary tumor.
Following parents’ consent, a whole blood sample (3 ml) was collected from
each patient, and the patient’s data was collected. Samples were kept for further
analysis following DNA extraction. No further wet laboratory tests were applied to
these samples.
4.2.5.2 Collected data
A retrospective review of the patients’ medical files was applied to collect the
following data:
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Demographic variables: Age (onset and recruitment), nationality (Emirate of
origin for Emiratis), family history of ALL or other types of cancer, parents’
consanguinity.
Clinical variables:
1- leukemia Immunophenotype
2- Risk grade
3- Treatment protocol
4- Drugs administered at each phase of treatment
5- Adverse events developed and their grade according to the common
terminology criteria for adverse events (CTCAE)-version 5 [261]. The
following data were collected to evaluate adverse events:
a. Developing oral mucositis, date of occurrence, and severity
b. Asparaginase intolerance: hypersensitivity reaction type and grade, time of
development, and the need to switch to another formula of asparaginase
c. Liver toxicity: evaluated by monitoring of liver enzymes (AST and ALT)
levels
d. Significant adverse events which caused treatment delay, dose adjustment,
or withdrawal of an agent.
e. Hospitalizations due to adverse events: date and reason of admission, blood
tests during the hospital stay, and hospitalization length.
4.2.5.3 Adverse events during the maintenance phase
Files of patients who received at least three cycles of maintenance treatment in
Tawam hospital were reviewed. The collected data included:
1- 6-Mercaptopurine (6-MP) and methotrexate doses during the follow-up period.
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2- White blood cells (WBC), Red blood cells (RBCs), platelets, and the absolute
neutrophil counts (ANC) were collected.
3- Febrile neutropenia events.
4- Hospitalizations for any reason during the maintenance phase.
4.2.5.4 Clinical pharmacogenetic tests data
The patients’ files were reviewed to explore if the patient had TPMT enzyme
activity test, TPMT or NUDT15 genotyping as part of their clinical care. The date of
test ordering, the technique used for testing, and the results were collected.
4.2.5.5 Statistical analysis
Descriptive statistical tests were applied to summarize data were continuous
variables (e.g., doses) were expressed by averages, means and standard deviation (SD),
while frequencies and percentages expressed categorical variables. Inferential
statistics for this group included Chi-square test to compare differences in means of
two groups.
4.2.6 Results (Pediatric ALL)
4.2.6.1 Sample Descriptive
Data were collected from the files of 66 children from the pediatric oncology
and hematology clinic at Tawam hospital, Al-Ain. The ALL study group was
composed of 42 males (63.6%) and 24 females (36.4%). The age range at recruitment
was 4 to 16 years. However, the age range at diagnosis was 2 to 12 years. The mean
age at diagnosis was 4.9±2.6 years. Thirty-six of the patients (54.5%) were Emiratis
(17 from Abu Dhabi, 7 from Sharjah, 5 from Ajman, 3 from Al Fujairah, 2 from Dubai,
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and 2 from RAK). Other patients (n=30) were Arabs from Syria (9), Palestine (5),
Egypt (6), Jordan (4), Oman (4), Yemen (2).
Notably, family history was positive for five patients. Two patients had a
sibling diagnosed with pediatric ALL, and two others had a cousin with the same
diagnosis. The fifth patient’s father was chronic myelogenous leukemia (CML)
patient, and two of the same patient’s cousins were cancer survivors.
4.2.6.2 Pediatric ALL patients’ clinical characteristics
All patients were diagnosed following blood film examination, bone marrow
aspiration, complete cell counts followed by flowcytometry, and cytogenetics testing
for further confirmation and classification. Immunophenotyping showed that seven
patients (10.6%) had T-cell ALL, while 59 patients (89.4%) had B-cell ALL. Patients
were assigned, by the treating clinicians, into risk groups according to the following
criteria: age at diagnosis, white blood cells count at diagnosis, cytogenetics findings,
CNS involvement, and the immunophenotype. Accordingly, 23 patients were
classified at diagnosis in the high-risk group in contrast to 43 in the standard-risk
group, from which two patients were later switched into the high-risk group due to
their inadequate response to induction.
4.2.6.3 Medical management of pediatric ALL patients in the study institute
For pediatric ALL patients, the treatment protocol followed at Tawam hospital
for most patients was CCG1991 for standard-risk patients and CCG1961 for the highrisk group. In general, management is composed of 3 main phases (induction,
consolidation, and maintenance). Delayed-induction and intermittent-maintenance
phases were applied in between the previous major phases to all patients. The
components of each phase were chosen according to the case severity, patients’
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responses, and tolerance to adverse events. Table 21 lists all the agents used in each
phase of treatment.

Table 21: Chemotherapeutic agents used for pediatric ALL group
Phase
Induction

Consolidation
(Intensification)

Interim Maintenance
Delayed Intensification

Maintenance

Drug
Cytosine Arabinoside (Ara-C), Vincristine
Steroids (prednisone), Daunomycin
Asparaginase (Pegylated, E. coli or Erwina)
Methotrexate (escalating dose/Capizzi and IT)
Methotrexate (IV and IT), Vincristine
Asparaginase (Pegylated, E. coli or Erwina)
6-Mercaptopurine
Steroids (prednisone)
Cyclophosphamide
Methotrexate (IV and IT), Vincristine
Asparaginase (Pegylated, E. coli or Erwina)
Vincristine, Doxorubicin
ARA-C, Thioguanine
Asparaginase (Pegylated, E. coli or Erwina)
Methotrexate
Cyclophosphamide
Steroids (Dexamethasone)
6-Mercaptopurine
Methotrexate (IT + oral)
Vincristine
Steroids (Dexamethasone)

IV; intravenous, IT; intrathecal

4.2.6.4 Pediatric ALL treatment associated adverse events
A. General Adverse Events
A retrospective review of patients’ medical charts illustrated that all patients
suffered from chemotherapy-induced adverse effects with varying severities.
Hematological adverse effects were analyzed separately. Other adverse effects are
listed in Table 22 with their prevalence and severity, according to the Common
Terminology Criteria for Adverse Events (CTCAE) Version 5.0. The definitions of the
detected toxicity grades are listed in Table 23.
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Table 22: Reported adverse events in pediatric ALL chemotherapy
Adverse Event

Number of
patients (%)
15 (22.7%)

Phase of first
occurrence (no.)
Ind (5) - Cons (4)
IM (5) - Main (1)

Associated
drug
Miscellaneous

Asparaginase
intolerance
Increased liver
enzymes
(ALT/AST)
(hepatotoxicity)
Hypertension

12 (18.2%)

Ind (2) - Cons (3)
IM (2)- DI (5)
Ind (3) - Cons (6)
DI (1) - Main (6)

Asparaginase

4 (6%)

Ind (4)

Steroids

Hyperglycemia

7 (10.6%)

Ind (7)

Steroids

Oral mucositis

16 (24.2%)

Neuropathic pain
6 (9%)
Ind (4) - Cons. (2)
Others
Avascular necrosis
3 (4.5%)
Ind
Testicular
2 (3%)
Ind
hydrocele
3 (4.5%)
Ind
Tumor lysis
2 (3%)
Cons.
syndrome
2 (3%)
Cons.
Constipation
Thrombosis
NA; not available, Ind; induction, Cons; consolidation, Main;
DI; Delayed intensification.

Methotrexate

Severity
(patients, no.)
Grade 2 (11)
Grade 3 (3)
Grade 4 (1)
Mild (11)
Severe (1)
Grade 2 (11)
Grade 3 (3)
Grade 4 (2)

Vincristine

Grade 2 (3)
Grade 3 (1)
Grade 2 (6)
Grade 3 (1)
NA$

Steroids
Steroids
Miscellaneous
Miscellaneous
Miscellaneous

Grade 3 (2) /4 (1)
NA
Grade 3 (2) /4 (1)
Grade 2 (2)
Grade 3

maintenance, IM; interim maintenance,

Table 23: Definitions of the reported toxicities grades in ALL group
Toxicity
Oral mucositis

High liver enzymes
(ALT/AST)
Hypertension

Reported
Grades
2
3
4
2
3
4
2
3

Hyperglycemia
Osteonecrosis

2
3
3
4

Definition according to CTCAE Version 5.0
moderate pain not interfering with oral intake
severe pain interfering with oral intake
life-threatening and urgent intervention is needed
levels increased by 3.5-5 X ULN
levels increased by 5-20 X ULN
levels increased by > 20 X ULN
stage 1 hypertension: recurrent or persistent high blood pressure
> 140/90 mmHg that is controlled by one antihypertensive
stage 2 hypertension: systolic blood pressure> 160 mmHg or
diastolic blood pressure >100 mmHg and more intensive therapy
is needed.
fasting glucose level >160-250 mg/dl*
fasting glucose level >250-500 mg/dl*
severe symptoms limiting self-care
life-threatening, urgent intervention needed**
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Table 23: Definitions of the reported toxicities grades in ALL group (continued)
Toxicity
Tumor lysis
syndrome

Reported
Grades
3
4

Definition according to CTCAE Version 5.0

Symptoms are present
severe life-threatening symptoms that required urgent
intervention (ICU admission)
Constipation
2
persistent symptoms
Thrombosis
3
Medical intervention needed
** Glucose level needed control by insulin *Steroids were canceled from maintenance phase for a
patient with grade 4 avascular necrosis. CTCAE; Common Terminology Criteria for Adverse Events
[261].

Other reported adverse effects that were significant but occurred in a single
patient were multifocal nephritis, methotrexate-induced severe dry eye and mouth,
hematuria, and multiple fractures following steroids induction treatment.
B. Hematological toxicity indicators during maintenance phase
The following data was collected from the maintenance phase, in which oral 6MP dose is adjusted according to the myelosuppression-induced adverse events. The
hematological toxicity manifestations collected were:
1. Treatment interruption for at least one week due to a decrease in the absolute
neutrophil count (ANC) below 1000/mm3
2. Febrile neutropenia events: defined as having ANC < 1000/mm 3 with a single
temperature >38.8˚ C, or a sustained temperature ≥ 38 for more than one hour.
The follow-up period ranged from 12 weeks to 100 weeks, and four patients
were excluded from this analysis because they were followed for less than 12 weeks.
Nine patients (14%) did not need any treatment interruption due to
myelosuppression during the follow-up period. Eleven patients (17%) had one event
of treatment cessation, six patients (10%) had two events, eight patients (13%) had
three events, nine patients (15%) had four events, and 19 patients (31%) had between
5-15 events of treatment cessations due to myelotoxicity.
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The percentage of oral treatment interruption was calculated by dividing the
number of days when oral treatment was held (off-treatment days) by the total number
of maintenance phase days (or the follow-up period). The off-treatment days ranged
from 0 to 25.4% of the maintenance period, where the median was 5.9% of the total
days. Out of the 62 patients followed for at least 12 weeks, 12 (19.35%) patients have
had treatment cessation for ≥ 10% of their maintenance period. Figure 13 illustrates
the percentage of treatment-hold for each patient, and the asterisks designate cases
where the hold was for 10% or more of the total period.

Figure 13: Percentage of off-treatment days from the maintenance phase.
Red asterisks designate patients whom the hold-treatment ≥ 10%.

Regarding the frequency of febrile neutropenia events, 24 patients (38%) did
not suffer from any event during their follow-up period. In contrast, 13 patients (21%)
suffered from 3 to 8 febrile neutropenia events during maintenance therapy. The rest
of the patients (41%) had between 1 to 2 episodes of febrile neutropenia.
C. Adverse events-related hospitalizations during the maintenance phase:
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Only two patients did not require any adverse event-related hospital admissions
during their maintenance treatment. The frequencies of hospital admission related to
adverse events for the rest of the patients ranged from 1 to 10 times. The admission
indication was febrile neutropenia in most cases, followed by severe viral or bacterial
infections. The frequencies of hospitalizations during the maintenance phase are
illustrated in Figure 14.
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Frequency of hospitalizations

10

8

6

4

2

0
Hospitalization due to FN

Hospitalization due to infections

Figure 14: Frequency of adverse events-related hospitalizations
FN; febrile neutropenia

4.2.6.5 Average 6-MP dose during maintenance phase of pediatric ALL treatment
The average 6-MP dose was calculated by dividing the daily prescribed dose
by the number of days from the maintenance phase in which data was collected. The
average doses mean (±SD) was 38.3 ± 16.1 mg/m2/day. Figure 15 illustrates a box plot
of average 6-MP doses during the maintenance phase for patients in which data was
available for at least 12 weeks.
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Figure 15: Box plot of average 6-mercaptopurine doses (mg/m2/day)

4.2.6.6 Comparison of average maintenance MP dose to other populations
Five studies from different populations were found to report the average 6-MP
dose (accumulated daily dose/number of days from the maintenance phase) in a
comparable group of pediatric ALL patients during maintenance phase treatment. The
analysis of variance (one way-ANOVA), illustrated in Table 24, revealed that the mean
of average doses was significantly lower than the mean reported in two studies from
Brazil and France. In contrast, no significant difference in the average doses was found
between the current and three groups from India, Japan, and Turkey.

Table 24: Comparison of average 6-MP dose to other populations
Country

Number
of
patients

Mean
Standard Difference
of
Deviation
average
doses
UAE
62
38.3
16.23
Brazil
115
45.6
14.1
7.3
France
78
62
24.25
23.7
India
69
41.5
6.575
3.2
Japan
51
31.6
10.7
-6.7
Turkey
48
37.8
12.1
0.5
CI; confidence interval, significant p-values are shaded.

95% CI

p-value

Reference

0.47-14.134
16.32-31.08
-4.39-10.79
-14.89-1.49
-9.003-8.003

0.0296
0.00
0.7766
0.1675
0.999

[262]
[263]
[264]
[265]
[253]
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4.2.6.7 Average oral methotrexate dose during the maintenance phase of pediatric
ALL treatment
The average dose of methotrexate was calculated by dividing the weekly
prescribed dose by the number of weeks from the maintenance phase in which data
was collected. The average dose (±SD) was 12.2 ± 4.9 mg/week. Figure 16 illustrates
a box plot of average methotrexate doses during the maintenance phase.

Figure 16: Box plot of average oral methotrexate dose (mg/m2/week)

4.2.6.8 Comparison of average methotrexate dose to other populations
A significant difference between the average methotrexate dose was seen
between the current group and groups from France and Japan, in contrast to Turkey's
group. Results of ANOVA test are listed in Table 25.

Table 25: Comparison of average oral methotrexate dose to other populations
Country

Number
of
patients

Mean
Standard Difference
95% CI
of
Deviation
average
doses
UAE
62
12.2
4.9
France
78
19
3.25
6.8
4.74-8.85
Japan
51
19
6.65
6.8
4.52-9.08
Turkey
48
11.3
3.63
-0.9
3.22-1.42
CI; confidence interval, cells with significant p-values are shaded.

p-value

Reference

0.00
0.00
0.75

[263]
[265]
[253]
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4.2.6.9 Clinical applied pharmacogenetic tests (TPMT enzyme activity, and
TPMT and NUDT15 genotyping) applied in the study institute
A retrospective review of patients’ files revealed that a limited number of
patients, specifically those diagnosed and treated within the last five years, had few
pharmacogenomic tests. These tests included TPMT enzyme activity, TPMT
genotyping, and NUDT15 genotyping.
1. TPMT enzyme activity: 26 patients had a TPMT enzyme activity test from
which only 2 (7%) had low TPMT activity.
2. TPMT genotyping: 23 patients have been genotyped for the most common
low/non-functional TPMT haplotypes (TPMT*2, *3A, *3B, *3C, *4, *8, and *12).
only one Emirati patient was found to carry one TPMT*3C allele (TPMT*1/*3C). The
same patient showed a low TPMT enzyme activity. The rest of the patients were not
carrying any of the examined low/non-functional alleles.
3. NUDT15 genotyping: 10 patients have been genotyped for the most common
low/non-functional NUDT15 haplotypes, and three of them were carriers of the
NUDT15*3 allele (NUDT15*1/*3), who were Emiratis.
The starting 6-MP doses were adjusted according to genotypes for the four
patients carrying the low function alleles. Revising the hospitalization and febrile
neutropenia data for the four patients revealed that three did not have any febrile
neutropenia event and did not need adverse event-related hospital admission during
the follow-up period of the maintenance phase. The fourth patient had one
hospitalization due to febrile neutropenia.
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4.2.7 Discussion (Pediatric ALL Group)
This study aimed to evaluate the reported adverse drug effects during ALL
treatment and examine the need for pharmacogenetic testing and its implication extent.
The results demonstrated the occurrence rates of adverse events, the tolerated doses of
6-MP, and the few, though significant, applied pharmacogenomic testing in the study
institute.
Clinically, patients in the pediatric ALL group were similar to their
counterparts from other populations regarding age at diagnosis, and leukemia subtypes
distribution, which made comparing the reported adverse events possible.
Notably, there was a high incidence of positive family history among
participants. Bener and co-workers reported increased consanguinity rates and tumor
positive family history in Emirati children with ALL and lymphomas compared to
matching controls from the same community [266]. Since then, no further reports have
been published regarding the prevalence or effect of family history and consanguinity
in pediatric cancer patients from the UAE. Recently, substantial evidence emerged
about the genetic basis and risk biomarkers of pediatric ALL inheritance [267].
Familial ALL is rare worldwide, but genetic analysis of kindreds is considered highly
informative in identifying molecular risk factors and creating a deeper understanding
of pathogenicity [268]. The high incidence of positive family history cases in the
current group suggests considering re-evaluating the familial cases and applying
family studies in UAE community.
In general, the reported adverse events occurrence rates were comparable to
other populations' rates. However, some severe adverse events should be underlined.
Peripheral neuropathy is a severe adverse event that is further complicated by
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assessment difficulty. Young children are usually not able to describe the sensations
clearly. Accordingly, peripheral neuropathy is generally under-reported in children
[223]. In the current group, 9% reported peripheral neuropathy symptoms, including
extremities pain, weakness, numbness, tingling, and balance disturbance. However, no
assessment tool was used, and the severity grade is not determined. In a recent
systematic review, Madsen and co-workers concluded that there are no chances to
elucidate peripheral neurotoxicity biomarkers in the absence of a reliable assessment
tool [239].
Bone toxicities commonly manifest as avascular necrosis resulting from the
high cumulative dose of steroids. Studies that consider self-reports from patients show
a low incidence of avascular necrosis compared to investigations that perform random
screening using magnetic resonance imaging (MRI). Accordingly, in the literature,
occurrence rates can vary from 1.1% to 17.6% [224, 269]. In the current group, the
three cases were symptomatic. As such, the occurrence rate of 4.5% is considerably
high compared to 1.1% symptomatic osteonecrosis reported from a large cohort of
1421 ALL children [224]. The three cases manifested as multiple fractures required
surgical intervention in two cases and resulted in canceling further steroid
administration during the continuation phase in one case.
Besides bone toxicity, steroids are known to induce hypertension and
hyperglycemia. Both were reported in 6% and 10.6%, respectively, in the current
group. The occurrence rate of steroid-induced metabolic adverse effects ranges from
10-45%. Although the benefits of high dose corticosteroids outweigh the temporary
toxicity risks, it was found that corticosteroid metabolic adverse effects can contribute
to an increased risk of metabolic syndrome among survivors [270]. The escalating
frequencies of obesity and metabolic syndrome in the UAE community, and their
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associated cardiovascular risks [72], highlight the need to evaluate these adverse
events with elongated studies in UAE community.
Hepatotoxicity, manifested by high transaminases, was reported in 24.2% of
patients, comparable to 27% incidence reported by Denton and co-workers. However,
and in contrast to Denton’s group, the least number of cases were reported in the
induction phase. Hepatotoxicity definition was similar in both groups regarding
transaminases levels, but hyperbilirubinemia was not considered in the current group
in contrast to Denton’s work, which might explain the un-similarities in the time of
onset [271].
Oral mucositis is a frequent temporary adverse event. Severe cases can lead to
treatment discontinuation, with a subsequent negative impact on the patient [231].
Four patients suffered from severe mucositis leading to treatment hold and
hospitalization for one of them. The current group's total rate was 22.7%, which is less
than the 40% rate reported by Figliolia and co-workers in a review of 169 ALL children
[272]. However, the current rate includes cases with grade ≥ 2 in which moderate to
severe pain is experienced, while less intense cases (grade 1) were not included.
One patient from the current group experienced sinus thrombosis, a severe
consequence associated with 10% mortality rates [273]. The reported case was wellcontrolled via low dose heparin, and no further complications occurred.
Hypersensitivity reactions to asparaginase occurred in 18.2% of patients from
the current group, which is within the reported range of PEG-asparaginase
hypersensitivity (3%-24%) [234]. Ten patients showed the symptoms at later treatment
phases, rather than during their first asparaginase encounter in induction. This
observation is not surprising as hypersensitivity reactions risk increases with multiple
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exposures, and most of these reactions frequently happen in the post-induction phases
[234].
Oral treatment interruption during the maintenance phase due to low blood
counts was analyzed as an indicator of hematological toxicity. There was a high
frequency of interruption days, which reached an average of 5.9% of the maintenance
duration. Notably, 19.35% of patients had therapy interruption that exceeded 10% of
their maintenance phase. Although interrupting oral therapy is the recommended
practice to avoid further counts deterioration, it was found to increase the recurrence
risk, specifically when it exceeds 10% of the maintenance phase duration [250].
Accordingly, it is essential to make these interruptions minimal. No long follow-up
studies have ever been conducted in the UAE for pediatric ALL survivors to validate
such associations.
Regarding febrile neutropenia events, 86% of patients from the current group
had at least one febrile neutropenic episode, which is significantly higher than the
global estimation of 50% occurrence rates in pediatric cancer patients [274]. However,
pediatric ALL is usually associated with the highest rates of febrile neutropenia events
[255]. In comparison to similar groups, the reported rates are not different [255].
Moreover, most of the emergency hospitalizations in the current group were due to
febrile neutropenic episodes. The high social and economic burden of febrile
neutropenia and hospitalizations are well-established [275], though understudied in
UAE population.
The average 6-MP dose is usually used to estimate the patient’s tolerance
during the maintenance phase. In the current group, the average 6-MP dose was
significantly lower than the average dose tolerated by patients from France [263], and
Brazil [262] but similar to other groups from Asia and the middle east [253, 264, 265].
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However, few studies reported an average 6-MP dose for pediatric ALL patients
regardless of their TPMT genotypes, which limited the current analysis. Similarly, the
average oral methotrexate dose reflects the patient’s tolerance to the cytotoxic effect
of methotrexate, and it was significantly lower in the current group than groups from
France [263] and Japan (191). The interpretation of these observations requires
pharmacogenetic testing of genes active in both drugs' metabolic pathways.
The pharmacogenetic testing for TPMT was adopted by Tawam hospital in
2015, and NUDT15 was available since 2018, which explains the few numbers of
patients who had these tests from the current group. Despite the low number of applied
tests, three patients were carrying a low function allele in NUDT15, representing 40%
of the applied tests. Although the few applied tests exclude making any statistical
comparisons, this observation emphasizes the importance of testing NUDT15 for
patients using thiopurines in the UAE population. Nevertheless, the same allele
(NUDT15*3) was also detected in the first group (targeted healthy individuals- study
subset 1). Furthermore, one ALL patient was a carrier of TPMT*3C, which is a low
activity allele. Again, the few numbers of applied tests exclude any statistical
comparison.
Notably, the four patients carrying the low function alleles in TPMT and
NUDT15 received adjusted 6-MP doses, which might explain the very low incidence
of neutropenia and its associated hospital admissions in these patients. These
observations highlight the potential gains from pharmacogenetic tests application in
pediatric ALL in the UAE.
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4.2.8 Pediatric ALL Group- Limitations
1- The follow-up period was not consistent for all patients. Some of the patients
were recruited after finishing their treatment, while others were still under treatment.
Accordingly, the frequencies of reported adverse events are subject to increase.
2- The documentation in the study center (Tawam hospital) has changed over
time; accordingly, there were inconsistencies in the method used for reporting adverse
events within the group. The reporting bias is usually common in retrospective studies
and should be considered while evaluating the outcomes [224].
3- Although most of the participants were Emirati (55%), other patients
originated from different Arab populations and are not expected to be genetically close
to Emiratis.
4- The TPMT test results were available for 23 patients, and NUDT15 results
were available for ten patients only. The low number of tests did not allow applying
inferential statistical analysis.
4.2.9 Projections from 100-Pharmacogenes Re-sequencing Group into Pediatric
ALL Subset
1. NUDT15: rs116855232 had a MAF=0.05 in the first subset and occurred in
three of the ALL patients. Any future study of 6-MP pharmacogenomics should
include this NUDT15 variant.
2. One novel variant in NUDT15 (Chr7: 2290503 T>C) with a CADD_phred
score=27.3 was detected in the first group. This is a potential target for future
functional studies. Indeed, sequencing the whole NUDT15 gene is recommended for
future studies.
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3. The common TPMT*2 and *3 alleles were not detected in the first group.
Instead, TPMT*8 and *16 were found. Future studies should consider whole gene
sequencing rather than genotyping alleles common in other populations.
4. Two probably damaging novel alleles in TPMT (Chr6: 18130982 T>A and
Chr6:18139240 A>G) were detected (CADD_phre scores =29.7, and 33, respectively).
The latter is a stop-gain variant. Both alleles are potential targets for functional studies.
This observation confirms the previous conclusion of the importance of sequencing
rather than genotyping in understudied populations.
5. In the 100 healthy individuals resequencing group two potentially important
varinats occurred significantly with higher frequencies in the UAE sample than
gnomAD populations. These are rs2306283 in SLCO1B1 (MAF=0.48) and rs1045642
in ABCB1 (MAF=0.45). The former has a possible association with methotrexate and
the latter with vincristine. Such associations are important candidates for future studies
in pediatric ALL in UAE as both drugs are cornerstone chemotherapies. These variants
were occurring with high allele frequencies in the UAE population, increasing the
opportunities of association studies feasibility.
4.3. Breast Cancer in Females
4.3.1 Adverse Drug Events and Germline Pharmacogenetics in Breast Cancer
Treatment
Breast cancer (BC) is the prominent cause of women cancer-related mortalities.
It impacts yearly the lives of 2.1 million women globally, according to the WHO. In
the UAE, breast cancer is the third cause of death following cardiovascular diseases
and injuries. In 2014’s national registry, breast cancer was the most common type of
cancer in the UAE, composing 21.27% of all diagnosed cancers in that year [276].
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Some studies have shown that females in the UAE tend to develop breast
cancer approximately one decade earlier than their western countries counterparts
[122, 154]. Figure 17 illustrates the age at diagnosis distribution of newly diagnosed
breast cancer cases in the UAE during 2014. The data, adapted from the national cancer
registry, shows that among the 768 new patients diagnosed in that year, 55.8% were
in women under the age of fifty [276].
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Figure 17: Distribution of breast cancer new cases across age in UAE.
Source: UAE Cancer registry report 2014.

The available management modalities are local, including surgery and
radiotherapy, and systemic, including different systemic medications. Systemic drugs
are commonly used in the adjuvant setting following the surgery, with or without
radiation. In other cases, systemic treatment can be beneficial before the surgical
intervention to downsize or downgrade the tumor, in an approach known as the neoadjuvant treatment. The third sitting of systemic therapy is palliative treatment in
advanced cases where no other options are feasible. The three broad classes of drugs
used in breast cancer are hormonal therapies, targeted therapies, and chemotherapies.
[277].
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The primary determinant of the selection between different systemic options is
the risk stratification, which is dictated by the burden of disease (lymph node
involvement and tumor size) and the biology of the disease (receptors status and the
results of newer genomic assays). Patient’s preferences and comorbidities are other
influencing factors [278].
Indeed, breast cancer is an umbrella term that covers multiple tumor entities
rather than a single disease. During the last century, identifying breast tumor subtypes
have made distinct strides. Hormonal receptors (estrogen and progesterone receptors)
were identified and targeted with hormonal therapy starting from the 1960s. Later,
human epidermal growth factor receptor homolog 2 (Her-2) was recognized, and antiHer-2 therapies were developed and used in the nineties of the last century. Since then,
it was clear that subtyping by biological features and other pathological features, like
the lobular versus ductal carcinomas, is central in the management and research of this
complex disease [279].

4.3.1.1 Adverse drug effects during breast cancer treatment:
Among the difficulties in identifying breast cancer treatment adverse effects is
their resemblance to the events occurring in older patients, like cardiovascular or
thrombotic events. On the other hand, studies collecting adverse events data are usually
conducted retrospectively, which subject them to bias. In comparison, clinical trials
report less adverse events than real-life practice and usually identify fewer drug
adverse effects than those encountered during practice [280].
In general, adverse drug effects experienced by breast cancer patients can be
classified into; 1. General acute chemotherapy-induced adverse effects, 2.
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Chemotherapeutic agent-specific adverse effects, 3. Adverse effects of hormonal and
targeted therapies, and, 4. Long-term adverse effects
1- General chemotherapy-induced acute adverse effects:
Nausea and vomiting are among the most dreaded events for patients starting
chemotherapy. Nearly 25% of patients suffer severe or very severe nausea and
vomiting, despite the availability of prophylaxis anti-emetic measures [281]. Delayed
nausea and vomiting are usually more difficult to manage and control [282].
The most common adverse event encountered with almost all cytotoxic agents
is hematological toxicity. Anemia, neutropenia, thrombocytopenia, and with lesser
prevalence, lymphopenia, are all dose-limiting events during chemotherapy courses
[283]. Neutropenia is the most common form affecting about 50% of patients during
breast cancer adjuvant chemotherapy [284]. In practice, strategies to control
chemotherapy-induced

neutropenia

include

reducing

chemotherapy

dose,

postponement of treatment, and administering colony-stimulating factors (G-CSF).
While the former two can contribute to an inferior treatment outcome, the latter
approach of administering G-CSF was blamed for increasing the incidence rates of
secondary leukemias [216, 285]. Anemia is another common adverse effect that is
rarely studied, though 31% of patients experience at least one anemic event during
adjuvant chemotherapy [286]. Thrombocytopenia is less common than anemia, though
is associated with an increased bleeding risk, which gives its management a priority
among chemotherapy-induced adverse effects [287]. In a broad review that included
4075 breast cancer patients, Hasset and coworkers stated that hospital admissions due
to severe neutropenia occurred in 5.5% of patients following chemotherapy. The
reported rate was lower than preceding studies due to the use of prophylactic growth
factors, albeit was substantial [288].
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Febrile neutropenia and severe infections are other adverse effects closely
related to and affected by hematological toxicity. It is believed that around 15% of
breast cancer patients will suffer from at least one febrile neutropenic episode during
cytotoxic therapy. In comparison, severe infections are less common, but they have an
inferior effect on treatment outcomes [289].
Several groups attempted to explore chemotherapy-induced general toxicity
pharmacogenomic predictors, without any significant success. The different
chemotherapeutic agents used, variable biological and factors among participant
groups, and inconsistencies in toxicity definitions, were among the reasons for this
failure [290]. Table 26 lists some large studies (sample size >200) conducted to
evaluate hematological toxicity during breast cancer chemotherapy.

Table 26: Large pharmacogenetic studies of acute toxicity in breast cancer
Regimen
AC

No. of BC patients
(Country or region)
311 (China)

AC

822 (North America)

FAC/
FEC

207 (India)

CAF/
CMF

458 (North America)

Toxicity1
grade IV
neutropenia
ANC<500/µl
Grade III or IV
hematological
toxicity
Grade II-IV
hematological
toxicity
Grade III or IV
neutropenia
and leucopenia
Grade II-IV
hematological
toxicity
CBC at days 8
& 15 of T dose

Significant genetic associations3
(p value) [Reference]
CYP3A5*3 (rs776746)
G allele has protective effect
(p=0.023) [291]
Haplotype of the minor alleles at
ALDH1A1
(rs3764435, rs168351) with increased
risk of toxicity (p=0.03) [292]
ABCB1 (rs1128503)
with increased risk (p=0.049) [293]

SOD2 (rs4880) CC associated with half
toxicity risk compared to TT
(p=0.03) [294]
FEC/
243 (India)
NQO1 (rs1800566) has protective effect
FAC/
from toxicity
FMC
(p=0.027) [295]
AC-T
218 BC patients with
ABCB1 (rs1045642)
operable lymph nodeT/T was significantly associated with
positive BC from Korea
neutropenia.
(P = 0.015) [296]
AC; anthracycline and cyclophosphamide, CP; cyclophosphamide, Dox; Doxorubicin, Epi; epirubicin,
FAC/FEC; fluorouracil, anthracycline/epirubicn, cyclophosphamide, T; Docetaxel, FN; febrile
neutropenia, 5-FU; 5-fluorouracil, CMF; cyclophosphamide, methotrexate, fluorouracil
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2- Chemotherapeutic agent-specific adverse effects
I. Anthracyclines induced cardiotoxicity (AIC): Cardiotoxicity is a significant
anthracycline-induced adverse effect. Anthracycline-induced cardiomyopathy is
usually chronic, progressive, and dose-dependent. The occurrence rates of
symptomatic heart failure increase from 5% to 48%, with the increase in doxorubicin
cumulative dose from 400 to 700 mg/m2 [297].
Few studies explored genetic biomarkers for anthracycline-induced
cardiotoxicity in the breast cancer setting. One of the biggest of these studies included
877 early breast cancer patients treated with epirubicin. Ten pharmacogenetic variants
with previous supporting evidence to be associated with AIC were genotyped from
which rs246221 in ABCC1 showed a significant association with cardiotoxicity
(defined as left ventricular ejaculation fraction (LVEF) decline more than 10%)
(p=0.02) [298].
Schneider and colleagues conducted a GWAS to identify potential biomarkers
for anthracycline-Induced congestive heart failure in a group of 3,431 breast cancer
patients. rs28714259 was one of the nine SNPs identified with a significant association
with AIC risk and remained significant in two other validating cohorts (total validating
cohort > 3000 patients) [299].
II- Taxanes-induced neurotoxicity (TIN): The mechanism of taxanes, also
known as anti-microtubules, induced neurotoxicity is thought to be by inhibiting
tubulin depolymerization in the neuronal axons [300]. This effect, commonly
manifested as sensory neuropathy, is more often associated with paclitaxel than
docetaxel. Severe disabling symptoms might progress if treatment was not correctly
adjusted [301].
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Two large studies that included 411 and 1303 breast cancer patients receiving
paclitaxel highlighted CYP2C8 variants as significant biomarkers for grade 2 or more
TIN [302, 303]. CYP2C8*3 was also a significant TIN biomarker in a third study the
explored 564 genetic markers in 412 paclitaxel treated patients [304]. Currently,
CYP2C8*3 and paclitaxel-toxicity association is classified a 3-level clinical
annotation in PharmGKB.
III- Palmar-plantar syndrome and other fluoropyrimidines-induced toxicities:
palmar-planter syndrome (also known as hand-foot syndrome) is a severe skin reaction
associated with docetaxel, and the fluoropyrimidines; 5-fluorouracil, and capecitabine.
Even though it is not life-threatening, this syndrome is painful and can interfere with
daily activities and compromise patients’ quality of life. The incidence rates vary
according to the causative agent, with higher incidences reported with capecitabine
[305].
Dihydropyrimidine dehydrogenase (DPD) s the rate-limiting enzyme in
fluoropyrimidines catabolism. DPYD variants that impair the enzyme activity have a
well-established association with fluoropyrimidines' toxicity [306]. Ten DPYD SNPs
are annotated with a level-1 significant clinical association in PharmGKB. However,
the frequency of actionable DPYD variants and phenotypes vary significantly between
ethnicities. Almost 3-5% and 0.1–0.2% of Caucasian populations exhibit a partial to
complete DPD enzyme deficiency, respectively. In contrast, almost 8% of African
Americans have a partial DPD enzyme deficiency [133].
Prospective DPYD genotyping is not yet routinely implemented in clinical
practice. Two large prospective multicenter studies evaluated the safety and costeffectiveness of prospective DPYD in different types of solid tumors. Both studies
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concluded that applying this pharmacogenetic test was feasible, contributed to
reducing toxicity rates, and increased fluoropyrimidine treatment safety [307, 308].
IV- Platinum compounds toxicities: Due to their high toxicity profile, cisplatin
and carboplatin are less commonly used in breast cancer. However, they proved better
outcomes with triple-negative breast cancer patients, especially those carrying
mutations in the breast cancer genes BRCA1 and BRA2 [309]. The typical platinum
salts-induced toxicities include neurotoxicity, hematological toxicities, and
nephrotoxicity [310].
The most common adverse events associated with breast cancer are illustrated
in Figure 18 with their most probable causative agent(s).

Figure 18: Common adverse drug effects in breast cancer chemotherapy.
Source [290]
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3- Adverse effects of hormonal and targeted therapies:
Endocrine therapy, including tamoxifen and aromatase inhibitors, is
considered the most effective targeted breast cancer therapies. The adverse events
associated with hormone therapy are less than those associated with chemotherapy.
Tamoxifen, the selective estrogen receptor modulator, increases the risk of endometrial
carcinoma, pulmonary embolism, and stroke. On the other hand, aromatase inhibitors,
which are the preferred hormone treatments for postmenopausal females compared to
tamoxifen, are associated with musculoskeletal adverse effects [311].
Trastuzumab, the humanized monoclonal antibody targeting HER-2, is
associated with cardiotoxic effects in up to 9% of cases if used with non-anthracycline
regimens. These rates can double if trastuzumab is used sequentially after
anthracyclines [297].
4- Chronic chemotherapy-induced adverse effects:
Chronic side effects can substantially reduce the long-term quality of life for
breast cancer survivors. A large study included 1,506 breast cancer survivors; fatigue,
depression, pain, mucosal changes, and peripheral neuropathy were among the most
reported long-term effects [312]. More severe effects like cardiac toxicity and
secondary cancers are also reported. Pharmacogenomic contribution in delayed
adverse effects has not been investigated except for a few studies conducted on
anthracyclines and trastuzumab induced cardiac toxicity [297].
4.3.1.2 Breast cancer treatment adverse effects and pharmacogenetic studies in
UAE and other Arab populations
Due to the high prevalence of breast cancer, numerous studies were conducted
in the Arab population regarding different disease aspects, like epidemiology,
management, patient’s quality of life, and susceptibility genetics [313-315].
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In contrast, scarce studies have been carried on germline pharmacogenetics in
Arab breast cancer patients. One study from Saudi Arabia evaluated the effect of
ABCB1 variants on multicomponent chemotherapy regimen response in 100 breast
cancer patients [316]. A smaller study from Jordan included 40 patients, genotyped
DPYD in cancer patients on fluorouracil [317]. In Lebanon, 145 female breast cancer
patients receiving cyclophosphamide were genotyped for three common alleles of
CYP2B6. The authors reported the allele frequencies and an observed significant
association with time to recurrence [318].
A single study utilized a high-throughput microarray platform for germline
pharmacogenetic analysis in breast cancer. In this study, Awada and coworkers used
the drug-metabolizing enzymes and transporters (DMETPlus) microarray to
characterize 1936 SNPs in 100 Lebanese breast cancer patients receiving docetaxel.
12 SNPs were significantly associated with docetaxel toxicity indicators, however, the
detected biomarkers were not further validated in the same population [319].
Apart from the previous few studies, no more germline pharmacogenetic
studies in breast cancer were carried out in Arab countries. One review of genetics and
genomics conducted in the Middle East and North Africa (MENA) region, with a focus
on diabetes and breast cancer, reported a “distinct lack of pharmacogenetic and
pharmacogenomic studies”. The authors concluded that genetic and genomic research
in the surveyed countries, including UAE, is of suboptimal translational value.
Similarly, adverse drug events during breast cancer treatment in the UAE are
lacking. Hence, the adverse effects that are potential targets for future germline
pharmacogenetics are vague.
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4.3.2 Study Questions and Objectives
To determine the most frequent adverse drug events during systemic therapy
in breast cancer in the UAE's leading oncology clinic.
4.3.3 Study Hypothesis
Patients will be suffering from adverse drug events comparable to their
counterparts from other populations. One or more adverse drug effects will be
recognized as a target for future pharmacogenetic studies.
4.3.4 Primary and Secondary Outcomes
Primary outcomes: To document clinical data and collect blood samples from
patients
Secondary outcomes: To infer the potential germline pharmacogenetic targets
for future studies
4.3.5 Methods (Breast cancer group)
4.3.5.1 Participants inclusion and exclusion criteria
Participants were recruited from the Oncology unit, Tawam hospital, Al-Ain
city, Emirate of Abu Dhabi, UAE. All the participants signed an informed consent
form to participate in this study. This study was conducted following the approval of
the Tawam Human Research Ethics Committee (THREC#552).
Inclusion Criteria: Female breast cancer, who received their oncology care for
at least three months in the study center, were eligible for inclusion. Emirati breast
cancer patients who visited the oncology outpatient clinic from March 2018 to March
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2020 were invited were invited to participate. Other inclusion criteria included
receiving most of the chemotherapy sessions in the same facility (Tawam Hospital).
Exclusion criteria: Receiving the breast cancer diagnosis as a secondary tumor.
Following patient consent, a whole blood sample (5 ml) was collected from
each patient, and the patient’s data was collected. Samples were kept for further
analysis following DNA extraction.
4.3.5.2 Collected data
A retrospective review of the patients’ medical charts was applied to collect
the following data:
1- Date and age at diagnosis
2- Menopausal status
3- Histological class of tumor
4- Receptors status
5- Treatment plan
6- Drugs administered at each phase of treatment
7- Metastasis date and site
8- Recurrence or progression if any.
9- Adverse events associated with any used drug during all phases of treatment,
with their severity grade according to (CTCAE)-version 5 [261].
10- Genetic tests applied to the patients related to their tumor management.
Data was collected using a data collection sheet and entered into an excel
spread sheet prepared for this purpose.

132
4.3.6 Results (Breast Cancer Group)
4.3.6.1 Sample descriptive
77 Emirati females diagnosed with primary breast cancer were recruited. Age
at recruitment ranged between 30 and 80 years. However, age at diagnosis (onset)
ranged between 27 and 77 years, where the mean age at diagnosis was 47.7±12.1 years.
The distribution of the age at diagnosis on five years intervals is depicted in figure 19.
Out of the 77 patients, 48 (62.3%) were diagnosed while premenopausal, while 29
patients (37.7%) were diagnosed postmenopausal.

Figure 19: Age at diagnosis for breast cancer patients

4.3.6.2 Clinical characteristics
The retrospectively collected clinical data are summarized in Table 27.
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Table 27: Clinical characteristics of breast cancer patients’ group
Clinical Characteristics

Count of patients (%)
Total=77
Histological type
DCIS
6 (7.8%)
IDC
63 (81.8%)
DCIS+IDC
2 (2.6%)
ILC
6 (7.8%)
Receptor status
Triple-positive
18 (23.4%)
ER+ /PR+ /Her225 (32.5%)
ER+/PR-/Her24 (5.2%)
ER+/PR-/Her2+
7 (9.1%)
ER-/PR+/Her20
ER-/PR+/Her2+
3 (3.9%)
ER-/PR-/Her2+
14 (18.2%)
Triple-negative
6 (7.8%)
Other tumor sites at diagnosis
None
64 (83.1%)
Lymph node(s)
7 (9.1%)
Bone
3 (3.9%)
2 other sites
3 (3.9%)
Metastasis sites
None
50 (64.9%)
(during the follow-up period)
Bone
5 (6.4%)
Bone + another site
6 (7.8%)
Lung
3 (3.9%)
Lung + another site
2 (2.6%)
Liver
2 (2.6%)
Skin
1 (1.3%)
Ovaries
1 (1.3%)
Adenocarcinoma
1 (1.3%)
3+ sites
6 (7.8%)
DCIS; ductal carcinoma in situ, IDC; invasive ductal carcinoma, ILC; invasive lobular carcinoma, ER;
estrogen receptor, PR; progesterone receptor, Her2; human epidermal growth factor receptor 2 .

4.3.6.3 Chemotherapy protocols
Out of the 77 recruited patients, eight were excluded from chemotherapy
analysis because of few data (n=4) or refusing chemotherapy (n=4). The rest (n=69)
patients had different chemotherapeutic regimens in different settings (adjuvant,
neoadjuvant, or palliative). Table 28 lists the regimens used for the primary tumor, and
Table 29 lists agents used when tumor recurrence or progression occurs.
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Table 28: Primary chemotherapy protocols used for breast cancer patients
Regimen
CEF-T

Setting
Count of patients
Adjuvant
10
Neoadjuvant
4
AC/EC-T
Adjuvant
15
Neoadjuvant
26
TCHP
Neoadjuvant
8
Taxane
Neoadjuvant
2
Palliative
3
TC
Adjuvant
1
CEF; cyclophosphamide & epirubicin & 5-fluorouracil, T; paclitaxel or docetaxel (taxane), AC;
doxorubicin (Adriamycin) and cyclophosphamide, EC; epirubicin and cyclophosphamide, TC;
docetaxel and cyclophosphamide, TCHP; Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab),
and Pertuzumab.

Table 29: Chemotherapy agents used for breast cancer recurrence/progression
Agent
Capecitabin
Eribulin
Carboplatin

Setting
Palliative
Palliative
Palliative

Count of patients
8
4
4

4.3.6.4 Chemotherapy-induced adverse events in breast cancer group
Adverse events reported during chemotherapy and their grades are listed in
Table 30. The definitions of each reported toxicity grade, according to the CTCAE
Version 5.0. are listed in Table 31.

Table 30: Chemotherapy-induced adverse events in breast cancer group
Adverse Event
Hematological toxicity
(low blood counts)

Count of
patients
17 (24.6%)

Associated drug

Neuropathy

8 (11.6%)

AC (10)
Taxol (4)
Carboplatin (1),
Capecitabin (2)
Taxol (8)

Mucositis

14 (20.2%)

Miscellaneous (14)

Febrile Neutropenia
High liver enzymes

5 (7.2%)
3 (4.3%)

EC (1) AC (4)
AC-T (3)

Severity*
(patients’ count)
Grade 2 (5)
Grade 3 (9)
Grade 4 (3)
Grade 2 (5)
Grade 3 (2)
Grade 4 (1)
Grade 2 (13)
Grade 3 (2)
Grade 3 (5)
Grade 2 (2)
Grade 3 (1)
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Table 30: Chemotherapy-induced adverse events in breast cancer group (continued)
Adverse Event

Count of
patients
3 (4.3%)

Gastrointestinal
(Constipation/ diarrhea/
abdominal discomfort)

Associated drug
TCHP (1)
AC (1)
EC (1)
Paclitaxel (1)
Capecitabin (2)

Severity*
(patients’ count)
Grade 2 (3)
Grade 3 (1)

Palmar-plantar
2 (2.9%)
Grade 2 (2)
syndrome
GERD
1 (1.4%)
EC (1)
Grade 2 (1)
AC; Adriamycin and cyclophosphamide, EC; epirubicin and cyclophosphamide, GERD;
gastroesophageal reflux disease, TCHP; Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab),
and Pertuzumab

Table 31: Toxicity grades definitions in the breast cancer group
Toxicity
Hematological
toxicity

Reported
Grades
2
3
4

Neuropathy

Oral mucositis
Febrile
Neutropenia
High liver enzymes
(ALT/AST)

2
3
4
2
3
3
2
3
4
2
3
2

Definition according to CTCAE Version 5.0*
A decrease in neutrophil count<1500-1000 /mm3/or platelets
count<75,000-50,000/mm3/or hemoglobin <10-8 g/dl.
A decrease in neutrophil count<1000-500 /mm3/or hemoglobin
<8 g/dl or platelets count<50,000-25,000/mm3
A decrease in neutrophil count<500/mm3/or platelets
count<25,000-25/mm3/or life-threatening decrease in
hemoglobin
moderate symptoms
severe symptoms limiting self-care
life-threatening and urgent intervention is needed
moderate pain not interfering with oral intake
severe pain interfering with oral intake
absolute neutrophil count < 1000/mm3 with a single temperature
>38.3˚C or sustained temperature ≥ 38˚C for >1hour.
levels increased by 3.5-5 X ULN
levels increased by 5-20 X ULN
levels increased by > 20 X ULN
moderate symptoms responsive to treatment
moderate symptoms indicating medical intervention
Painful erythema and swelling that affects daily activities.

Gastrointestinal
toxicity
Palmar-planter
syndrome
CTCAE; Common terminology criteria for adverse events, ULN; upper limit of normal, ALT; alanine
transaminase, AST; aspartate aminotransferase. Reference [261].
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4.3.6.5 Other agents used in breast cancer patients’ management
All patients received other agents based on their receptor status. The list of
agents used for the current group and their classes are listed in Table 32.

Table 32: Agents used for breast cancer management other than chemotherapy
Drug

Class

Tamoxifen
Letrozole
Anastrozole
Fulvestrant
Goserelin
Exemestane
Trastuzumab
Pertuzumab
Palbociclib
Lapatinib

Hormonal
Hormonal
Hormonal
Hormonal
Hormonal
Hormonal
Targeted therapy
Targeted therapy
Targeted therapy
Targeted therapy

Count of patients used the drug
(%)
36 (47%)
21 (27%)
5 (6.5%)
7 (9%)
13 (17%)
2 (2.6%)
35 (45.5%)
27 (35%)
7 (9%)
2 (2.6%)

4.3.6.6 Reported adverse events from treatments other than chemotherapies
The most reported adverse event was letrozole induced arthralgia in 7 patients
(total number of patients used letrozole=35), leading to treatment discontinuation in 5
of them and replacing it with tamoxifen.
The second most reported adverse event was hematological toxicity induced
by Palbociclib in 4 patients (total number of patients used Palbociclib=7), leading to
treatment discontinuation in two of them.
Other adverse events included Herceptin induced pruritis (n=1) and tamoxifeninduced heavy vaginal bleeding (n=1), which both lead to treatment discontinuation.
4.3.6.7 Hospital applied genetic tests for breast cancer patients
No pharmacogenetic tests were carried for any of the breast cancer patients.
The available genetic tests for breast cancer patients in the study health care
facility (Tawam Hospital) include testing genes involved in susceptibility and
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heritability of cancer. Patients with positive family history, or young age at diagnosis
are ordered these tests.
4.3.7 Discussion (Breast Cancer Group)
In this study group, the adverse events encountered by breast cancer females
treated with chemotherapy have been demonstrated. There are no germline
pharmacogenomic tests recommended for any of the chemotherapies in breast cancer,
except for DPYD before capecitabine or fluorouracil use. However, this test is not
available or offered for patients in the study center (Tawam hospital). CYP2D6
genotyping is another candidate that is recommended before using tamoxifen as an
indicator of its response. Again, this recommendation is not followed in the study
oncology unit.
In the current group, 63.6% of the participating females had the onset of breast
cancer below 50 years of age. The early onset of breast cancer has been repeatedly
reported in the UAE [122, 276]. Recently, the national screening program is discussing
lowering the breast cancer screening age, which is set now at 40 years, into the age of
30 years, due to these reports [320].
The fear of adverse effects is one primary reason for patients' treatment refusal
[321, 322]. In the current group, four patients refused to commence chemotherapy or
refused to complete it following the first chemo session. Refusal of treatment is
postulated to decrease survival rates from 84.7% to 46.2% [323]. Accordingly, there
is an immense need to evaluate the occurrence rates, the reporting system, and the
controlling measures of adverse effects.
Despite nausea and vomiting are the most encountered chemotherapy adverse
effects, they were not reported uniformly in patients’ charts. Accordingly, including
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this data was not possible. The same problem was faced with alopecia and early
menopause other common and troublesome adverse effects.
Different forms of cytopenia were reported in 24.6% of the patients during
chemotherapy. It is important to emphasize that prophylactic measures, including
administering G-CSF, have been followed for all patients before the first
chemotherapy course or following the first episode of neutropenia. Nevertheless, three
patients had grade 4 neutropenia and needed emergency hospitalization. In general,
the current group's cytopenia rates are less than 50% estimations from previous
international studies [284]. However, the impact of prophylactic measures should not
be excluded.
A severe form of palmar-plantar syndrome was reported in two patients. The
occurrence was associated with capecitabin use. Eight patients in the current group had
capecitabin in their treatment plan as part of palliative therapy, making this adverse
effect’s occurrence rate of 25%, which is considerably high. Capecitabin-induced
palmar-plantar syndrome occurs in 31% of patients treated with capecitabine as
monotherapy [324]. Moreover, 14 other patients were treated with fluorouracil,
another fluoropyrimidine. However, capecitabine, a fluorouracil prodrug, is the most
associated drug to the palmar-planer syndrome, specifically in breast cancer patients
[325]. The latest CPIC guidelines recommend reducing fluoropyrimidine doses by
50% for DPYD intermediate metabolizers and avoiding using these drugs for poor
metabolizers [326]. There is no pharmacogenetic testing applied in the study center.
Hence, DPYD can be considered as an important candidate for future research and
implementation plans.
In the current group, 20% of patients suffered from moderate to severe oral
mucositis. Oral mucositis is usually encountered by 20% to 40% of patients treated
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with chemotherapy. Besides its associated discomfort and its impact on lowering oral
intake, oral mucositis increases the risk of local and systemic infections [327].
Moreover, several reports concluded that oral mucositis is usually inadequately
reported and treated in cancer patients [328].
Letrozole-induced arthralgia is reported in up to 50% of patients using this
potent aromatase inhibitor and leads to treatment discontinuation in 20% of cases
[329]. In the current group, arthralgia was reported in 20% of the patients using
letrozole and lead to treatment discontinuation in 14%. However, inconsistencies in
defining induced arthralgia and the ambiguity surrounding this syndrome usually
affects its reporting rates [329]. Aromatase inhibitors are associated with improved
disease-free and overall survival in postmenopausal breast cancer patients. They are
an indispensable standard of care, and better predictors of discontinuation factors are
crucially needed [330]. Although no pharmacogenetic biomarkers are available for
letrozole associated adverse effects, CYP2A6 is a pharmacokinetic biomarker of
intermediate evidence. Further studies can consider this gene in relation to toxicity.
In general, the frequencies of reported adverse events in the current group are
low. Nevertheless, this is the first investigation of breast cancer adverse events in the
UAE. Due to its high burden on the health care system, breast cancer safe treatment
should attract more research attention at the national level.
4.3.8 Breast Cancer Group-Limitations
1- Few patients have been recruited to this group due to several reasons: nonEmirati breast cancer patients were excluded, and a considerable number of Emirati
patients were not recruited because they traveled to complete their treatment abroad,
and they spent a short period in the study center.
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2- The reported adverse events frequencies might be underestimating the actual
frequencies. The adverse events reporting system has been changed in the oncology
clinic, which affected reported adverse events' uniformity. Some patients treated in the
clinic were living in other cities, so they received part of their health care, especially
emergency hospital admissions, in another city. Data from other hospitals were not
shared or documented for those patients.
3- This study group lacks a specific and measurable outcome, other than
adverse events frequencies. The absence of previous national data about used regimens
and the most common adverse events contributed to this limitation.
4.3.9 Projections of 100-Pharmacogenes Re-sequencing Results into Breast
Cancer Subset
1. DPYD: rs115232898 was detected in the first group (MAF=0.05) is a rare
allele not detected in European populations. Moreover, one probably damaging novel
allele was detected in the same gene (Chr1: 97771744 G>C). Accordingly, future
research in breast cancer or other tumors where fluoropyrimidines are used should
consider DPYD sequencing rather than genotyping the common alleles. Rare DPYD
alleles in the UAE population could explain the capecitabine-induced toxicity
observed in the breast cancer group.
2. As illustrated in the literature review of paclitaxel-induced neuropathy,
CYP2C8 is a strong candidate pharmacogenetic biomarker. In the 100 healthy
individuals’ sequences, rs11572080 in CYP2C8 presented with MAF=0.14. Moreover,
one novel and the probably damaging variant was detected in the same gene (Chr10:
96797037C>T). Future studies are recommended on CYP2C8 and paclitaxel-induced
neuropathy in the current population. Taxanes are heavily employed in breast cancer
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chemotherapy in UAE, as demonstrated in the breast cancer subset, and sequencing
will be the preferable technique.
3. Anthracyclines are used in almost 90% of breast cancer chemotherapy in
UAE, as demonstrated in the breast cancer subset. Two variants interacting with
epirubicin were detected from healthy individuals' sequencing; Rs1690 in GSTP1 and
Rs4244285 in CYP2C19, and both occurred in relatively high frequencies (MAF=0.31,
and 0.15, respectively). Both variants might have contributed to anthracycline-induced
toxicities in the breast cancer group. Due to the lack of supporting evidence for any
germline pharmacogenetic biomarker for anthracyclines toxicity, both alleles and
genes are potential candidates for future UAE studies.
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Chapter 5: Conclusions

Interindividual drug response differences are major challenges in medical
practice. Pharmacogenomic studies contribute to delineating the genomic bases of
these differences and exploring biomarkers that can be utilized in practice. The high
variability in pharmacogenes is well-documented and it surpasses the variation extent
in other genes in the human genome [10].
The timeline of pharmacogenomics, which was briefly reviewed here,
witnessed different achievements and disappointments. A long time elapsed between
recognizing any gene-drug association and utilizing it and numerous associations
discovered in candidate gene studies failed to be reproduced, ending to the clinical
implementation dilemma. However, in the current precision medicine era,
pharmacogenomics is gaining momentum.
The results of the resequencing of 100 pharmacogenes in healthy Emirati
individuals illustrated how underrepresented populations could exhibit rare variants
and allele frequencies that are distinct from the globally available genomic data.
Indeed, UAE population and the Arab populations are poorly represented in the human
genome databases [68], and the current study sheds light on one side of this gap. Rare
variants are hypothesized to contribute to up to 40% of drug response variation [7].
Population-specific association studies would clarify the actual contribution of the
detected rare variants to drug response.
Many dosing guidelines are issued for specific star alleles rather than single
variants, making inferring haplotypes and star alleles crucial, though complex. In the
laboratory settings, several genotyping methods are used for star allele detection, such
as multiplex PCR. However, these methods are usually biased toward detecting the
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known alleles. In contrast, inferring haplotypes from sequencing data can retrieve the
common and rare haplotypes [88]. A list of actionable haplotypes and diplotypes was
compiled, in the current study, despite the design limitations.
Moreover, a panel of candidate genes and variants for future studies was
curated. Genes were considered probable candidates when they showed a significantly
high frequency of actionable variants, like ABCB1, CES1, NAT2, and GSTP1. Other
genes were postulated to be suitable for further investigation when they have been
scarcely studied before in Arabs, despite their significant functions, like SULT1A1,
FMO, TPMT, NUDT15, and DPYD. Finally, genes active in pathways of drugs used
in population-significant health issues were also classified as probable candidates, like
SLCO1B1, VKORC1, CYP2C9, CYP4F2, and CYP2C19.
In the current group of healthy individuals, 93% would receive a dosing
guideline affecting 34 drugs used for several indications. Essential drugs like
antiepileptics, antidepressants, anti-infections, and anti-cancer agents were among the
affected agents. The power of detecting an actionable variant in a healthy individual
was comparable to other studies [48, 49]. These findings prompt future research in the
feasibility of pre-emptive pharmacogenomic testing in the UAE.
Notably, the highest frequencies of the detected actionable variation in
healthy individuals were annotated with cardiovascular drugs. These include
SLCO1B1 variants interacting with statins, CYP2C9, CYP4F2, and VKORC1 variants
with warfarin, CYP2C19 with clopidogrel, and ABCB1 with simvastatin and digoxin.
Cardiovascular diseases are the leading cause of mortality in the UAE, and their rates
are among the highest in the world [71]. Pharmacogenomic testing cost-effectiveness
is proved for warfarin and clopidogrel in other communities, which promotes
validating these tests implementation in UAE community.
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In the warfarin users’ group, the predictability of VKORC1 genotypes on
warfarin dose in Emiratis was demonstrated. Two genetic variants, rs9923231 and
rs61742245, and age were associated with warfarin dose variability in the tested group.
The effect of a rare variant that has been scarcely studied were documented.
Notably, haplotype analysis of VKORC1 variants based on the star system did
not give a significant association with warfarin dose, in contrast to the haplotypes built
from the population-specific variants. Herein, the importance of population studies and
the advantages in considering rare and unique variants are illustrated.
In the current study, the cancer subsets compose the first attempt to evaluate
adverse drug effects encountered in oncology clinics in the UAE. In the pediatrics
group, the reported adverse events rates were comparable to their counterparts from
other populations. However, some severe events were emphasized like peripheral
neuropathy, oral mucositis, and steroid-induced osteoporosis, hyperglycemia, and
hypertension. Given that they are indispensable in pediatric ALL, steroids and their
induced adverse effects are vital research subject. Strikingly, steroid-induced effects
were found to increase the risk of metabolic syndrome among survivors [270]. With
the increasing survival rates of pediatric ALL, the long-term effects of treatment
should be considered.
High rates of oral treatment interruption during the maintenance phase was
reported. There is an immense need to evaluate these interruptions' long-term effects,
especially with the accumulating evidence on their association with relapse (8,9).
A wide range of variability in 6-MP and methotrexate doses was shown in the
pediatrics ALL group. However, it was not possible to evaluate the factors contributing
to this variability due to the scarce genetic information collected. Applying TPMT and
NUDT15 testing for the whole group is a main future plan for this study. Despite the
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few genetic tests applied in the hospital, the correlation between pharmacogenomicbased dosing and better outcomes was noticeable.
Deficiencies in adverse-events documentation were demonstrated in the breast
cancer group. The fear of encountering adverse chemotherapy effects is a primary
reason in chemotherapy refusal (8). Due to the high burden of breast cancer in UAE
community, more robust measures to document and control adverse drug effects in
chemotherapy are needed.
Pharmacogenomic associations in the germline genome are limited in breast
cancer. Significant associations with approved guidelines include DPYD with
fluoropyrimidines toxicity and CYP2D6 with tamoxifen response, which were both not
applied in the current group. Moreover, many candidate genes are suggested for the
different toxicities associated with breast cancer systemic therapy. Herein, a
collaborative approach between different health institutes is suggested to improve the
current practice of adverse events reporting and examine future pharmacogenomic
research opportunities.
Pharmacogenomic research is a promising area of research in UAE
community. The current study can be considered as a field exploration designed to
accommodate the UAE population's specificities. Hopefully, the outcomes have
opened wide doors for further investigation and clarified some of the discrepancies
hindering pharmacogenomics research in the region.
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